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Abstract 
The nervous system of schistosomes has been successfully targeted by anthelmintic drugs but 
the use of many of these has discontinued because of toxic side effects and so there is a need to 
better understand key neuronal processes at a molecular level to develop safer and more effec-
tive intervention strategies that target this vital system. Cholinesterases - acetylcholinesterases 
(AChE)s and butyrylcholinesterases (BChE)s - are key enzymes that play a pivotal role in the 
nervous system of schistosomes by regulating neurotransmission through acetylcholine 
hydrolysis and, accordingly, are an example of such an intervention target.  
 
The first results chapter (chapter two) of this thesis investigated the anti-schistosome efficacy of 
polypyridylruthenium (II) complexes and showed they were active against all intra-mammalian 
stages of S. mansoni. Two compounds, Rubb12-tri and Rubb7-tnl, which were among the most 
potent in their ability to kill schistosomula and adult worms and inhibit egg hatching in vitro, were 
assessed for their efficacy in a mouse model of schistosomiasis using 5 consecutive daily i.v. doses 
of 2 mg/kg (Rubb12-tri) and 10 mg/kg (Rubb7-tnl). Mice treated with Rubb12-tri showed an 
average 42% reduction (P = 0.009), over two independent trials, in adult worm burden. Liver egg 
burdens were not significantly decreased in either drug-treated group but ova from both of these 
groups showed significant decreases in hatching ability (Rubb12-tri - 68%, Rubb7-tnl - 56%) and 
were significantly morphologically altered (Rubb12-tri - 62% abnormal, Rubb7-tnl - 35% 
abnormal). I hypothesize that the drugs exerted their activity, at least partially, through inhibition 
of both neuronal and tegumental acetylcholinesterases (AChEs), as worms treated in vitro 
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showed significant decreases in activity of these enzymes. Further, treated parasites exhibited a 
significantly decreased ability to uptake glucose, significantly depleted glycogen stores and 
withered tubercules (a site of glycogen storage), implying drug-mediated interference in this 
nutrient acquisition pathway. 
 
Chapter three of this thesis provided the first comprehensive molecular characterization of three 
S. mansoni cholinesterases (SmChEs), designated as SmAChE1, SmBChE1 and SmAChE3, which 
were identified from the interrogation of the now wholly annotated S. mansoni genome. Anti-
SmChE antibodies localized the proteins to the tegument and neuromusculature of adults and 
schistosomula and developmental expression profiling differed among the molecules, suggestive 
of functions extending beyond traditional cholinergic signaling for each of them. I also reported 
the presence of ChE activity in parasite ES products for the first time and proteomically identified 
the molecules responsible (SmAChE1 and SmBChE1). Functional recombinant versions of the 
three SmChEs were produced in Pichia pastoris and enzyme nomenclature (AChE or BChE) was 
verified based on substrate preference. Lastly, in the first characterization study of a BChE from 
helminths, evidence is provided that SmBChE1 may act as a bio-scavenger of AChE inhibitors as 
the addition of recombinant SmBChE1 to parasite cultures mitigated the effect of the anti-
schistosomal AChE inhibitor dichlorvos whereas SmBChE1-silenced parasites displayed increased 
sensitivity to dichlorvos. 
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SmChEs were further characterized by RNAi-based experiments in chapter four of this thesis. 
RNAi-mediated silencing of individual SmChEs, or simultaneous silencing of all three SmChEs, 
significantly suppressed transcript and protein expression levels and AChE activity in parasites. In 
a dissection of the hypothesis that tegumental AChE mediates exogenous glucose scavenging by 
the parasite, I showed that RNAi-mediated knockdown of SmAChE1 and SmAChE3, but not 
SmBChE1, significantly reduced glucose uptake by schistosomes. Parasite survivability in vitro and 
in vivo was significantly impaired with the silencing of SmChEs, either individually or in 
combination, attesting to the essentiality of these molecules. 
 
Chapter five of this thesis explored the vaccine potential of SmChEs. When treated in vitro with 
anti-SmChE IgG, parasites displayed significantly decreased ChE activity, which eventually 
resulted in death. Vaccination with individual SmChEs, or a combination of all three SmChEs, 
significantly reduced worm burdens (28% - 38%, averaged across two independent trials) 
compared to controls. Liver egg burdens were significantly decreased for all mice across both 
trials (13% - 46%) except those vaccinated with SmAChE1 in trial 1. Egg viability, as determined 
by egg hatching from liver homogenates, was significantly reduced in the groups vaccinated with 
the SmChE cocktail (40%) and SmAChE3 (46%). Surviving worms from each vaccinated group were 
significantly stunted and depleted of glycogen stores, compared to controls. 
 
In conclusion, this thesis has identified the burgeoning potential of a new class of anti-
schistosome drugs that, at least in part, target the nervous system of the parasite and provided 
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a comprehensive characterization of a family of ChEs from S. mansoni, giving compelling evidence 
for the essentiality of the proteins and their utility as intervention targets against schistosomiasis. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table of Contents 
 
x 
 
Table of contents 
Statement on the contributions of others .......................................................................................ii 
Acknowledgements ......................................................................................................................... iii 
Publications by the candidate relevant to the thesis ...................................................................... v 
Abstract ........................................................................................................................................... vi 
Table of contents ............................................................................................................................. x 
List of Figures ................................................................................................................................. xv 
List of Tables ................................................................................................................................ xvii 
List of Abbreviations ................................................................................................................... xviii 
CHAPTER 1 - Introduction and Literature review .......................................................................... 1 
1.1 Introduction ......................................................................................................................... 2 
1.1.1 Schistosomiasis ................................................................................................................. 2 
1.1.2 Epidemiology and geographic distribution ...................................................................... 2 
1.1.3 Transmission ..................................................................................................................... 4 
1.1.4 Lifecycle ............................................................................................................................ 5 
1.1.5 Pathology and clinical manifestation ............................................................................... 7 
1.1.6 Chemotherapeutic intervention and challenges ............................................................. 8 
1.1.7 A vaccine for schistosomiasis? ....................................................................................... 10 
1.1.8 Acetylcholine, acetylcholinesterase and butyrylcholinesterase .................................... 14 
1.1.9 Molecular diversity of AChE ........................................................................................... 17 
1.1.10 The nervous system of schistosomes ............................................................................. 18 
1.1.11 Acetylcholine in schistosomes ....................................................................................... 19 
1.1.12 Acetylcholinesterase in schistosomes ............................................................................ 20 
1.1.13 Non-neuronal functions of helminth acetylcholinesterase ........................................... 22 
1.1.13.1 Helminth AChE and glucose uptake ................................................................................ 22 
1.1.13.2 Helminth AChE and adhesion.......................................................................................... 23 
1.1.13.3 Helminth AChE and immune responses .......................................................................... 24 
1.1.13.4 Helminth AChE and host pathogenicity .......................................................................... 25 
1.1.13.5 Helminth AChE and apoptosis ......................................................................................... 25 
Table of Contents 
 
xi 
 
1.1.14 Schistosoma AChE as a vaccine target? ......................................................................... 25 
1.1.15 AChE inhibitors ............................................................................................................... 27 
1.1.15.1 AChE inhibitors as anti-schistosomal  ............................................................................. 28 
1.1.16 Metal-based drugs in medicine ...................................................................................... 29 
1.1.16.1 The use of metal-based drugs to combat infectious disease ......................................... 30 
1.1.16.2 Ruthenium complexes as antimicrobials ........................................................................ 31 
CHAPTER 2 - Polypyridylruthenium (II) complexes as anti-schistosomals ................................. 33 
2.1 Introduction ....................................................................................................................... 34 
2.2 Methods ............................................................................................................................. 37 
2.2.1 Ethics Statement ............................................................................................................ 37 
2.2.2 Nomenclature and preparation of ruthenium complexes ............................................. 37 
2.2.3 Parasite extract preparation .......................................................................................... 39 
2.2.4 Enzyme activity in parasite extracts and inhibition assays ............................................ 39 
2.2.5 Effect of ruthenium complexes against larval S. mansoni parasites ............................. 41 
2.2.6 Effect of ruthenium complexes against adult S. mansoni parasites .............................. 41 
2.2.7 Effect of ruthenium complexes on S. mansoni egg hatching and development ........... 42 
2.2.8 Assessment of enzyme inhibitory effects induced by treatment of worms with 
ruthenium complexes ................................................................................................................... 42 
2.2.9 Effect of glucose uptake and glycogen storage on worms treated with ruthenium 
complexes ..................................................................................................................................... 43 
2.2.10 Scanning electron microscopy ....................................................................................... 44 
2.2.11 Cytotoxicity assays ......................................................................................................... 45 
2.2.12 Tolerability study ............................................................................................................ 45 
2.2.2. In vivo efficacy of ruthenium complexes ....................................................................... 46 
2.2.13 Statistical analyses ......................................................................................................... 47 
2.3 Results ................................................................................................................................ 48 
2.3.1 Inhibition of AChE in schistosome extracts by ruthenium complexes ........................... 48 
2.3.2 In vitro effect of ruthenium complexes on larval S. mansoni parasites......................... 52 
2.3.3 In vitro effect of ruthenium complexes on adult S. mansoni parasites ......................... 52 
2.3.4 In vitro effect of ruthenium complexes on S. mansoni egg hatching and development54 
2.3.5 Mechanism of anti-schistosome action of Rubb12-tri and Rubb16-tnl ........................... 56 
Table of Contents 
 
xii 
 
2.3.6 Toxicity of Rubb12-tri and Rubb7-tnl ............................................................................... 59 
2.3.7 In vivo efficacy of Rubb12-tri and Rubb7-tnl ................................................................... 60 
2.4 Discussion........................................................................................................................... 63 
CHAPTER 3 - Characterization of novel cholinesterases ............................................................. 70 
3.1 Introduction ....................................................................................................................... 71 
3.2 Material and Methods ....................................................................................................... 73 
3.2.1 Ethics statement ............................................................................................................. 73 
3.2.2 Parasite maintenance, culture and ES collection ........................................................... 73 
3.2.3 Parasite extract preparation .......................................................................................... 74 
3.2.4 Bioinformatics studies .................................................................................................... 75 
3.2.5 Developmental expression analysis of SmChE genes by real-time qPCR ...................... 76 
3.2.6 Cloning and expression of SmChE gene fragments in E. coli ......................................... 77 
3.2.7 Purification of pSmChEs ................................................................................................. 78 
3.2.8 Generation of anti-SmChE antisera and purification of IgG .......................................... 79 
3.2.9 Immunolocalization using anti-SmChE antisera ............................................................. 79 
3.2.10 Cloning and expression of full-length SmChEs in P. pastoris ......................................... 81 
3.2.11 SmChE Enzyme Assays .................................................................................................... 83 
3.2.12 Purification of secreted SmChEs from adult S. mansoni ES products ............................ 84 
3.2.13 Mass spectrometric analysis of purified, secretory SmChE ........................................... 85 
3.2.14 Bio-scavenging of organophosphorus esters by SmBChE1 ............................................ 87 
3.3 Results ................................................................................................................................ 89 
3.3.1 Identification of novel genes encoding ChE proteins in S. mansoni .............................. 89 
3.3.2 Developmental expression analysis of SmChE genes .................................................... 98 
3.3.3 Cloning and protein expression of SmChEs in bacteria ............................................... 100 
3.3.4 Immunolocalization of SmChEs .................................................................................... 100 
3.3.5 Expression and ChE activity of fSmChEs ....................................................................... 102 
3.3.6 BChE and secretory AChE activity in schistosomes ...................................................... 104 
3.3.7 Bio-scavenging of organophosphorus esters by SmBChE1 .......................................... 106 
3.4 Discussion......................................................................................................................... 108 
CHAPTER 4 - RNAi-mediated silencing of SmChEs .................................................................... 115 
Table of Contents 
 
xiii 
 
4.1 Introduction ..................................................................................................................... 116 
4.2 Materials and Methods .................................................................................................... 117 
4.2.1 Ethics statement ........................................................................................................... 117 
4.2.2 Parasite maintenance ................................................................................................... 117 
4.2.3 siRNA Design and Synthesis ......................................................................................... 118 
4.2.4 Electroporation of schistosomula with siRNA .............................................................. 118 
4.2.5 Total RNA isolation, cDNA synthesis, and real-time qPCR ........................................... 119 
4.2.6 Parasite extract preparation ........................................................................................ 119 
4.2.7 AChE and BChE activity assay ....................................................................................... 120 
4.2.8 Determination of schistosomula viability .................................................................... 120 
4.2.9 Evaluation of protein expression ................................................................................. 120 
4.2.10 Glucose uptake of schistosomula treated with siRNA ................................................. 120 
4.2.11 Infection of mice with SmChE siRNA-treated schistosomula ...................................... 121 
4.2.12 Statistical analyses ....................................................................................................... 121 
4.3 Results .............................................................................................................................. 122 
4.2.13 SmChE transcript reduction and protein suppression ................................................. 122 
4.2.14 Suppression of SmChE activity ..................................................................................... 124 
4.2.15 Suppression of parasite viability .................................................................................. 125 
4.2.16 RNAi-mediated suppression of glucose uptake ........................................................... 127 
4.2.17 SmChEs are essential for parasite development and survival in mammalian host ..... 129 
4.4 Discussion......................................................................................................................... 130 
CHAPTER 5 - Vaccine efficacy of recombinant S. mansoni cholinesterases ............................ 137 
5.1. Introduction ..................................................................................................................... 138 
5.2. Material and Methods ..................................................................................................... 139 
5.2.1. Ethics statement ........................................................................................................... 139 
5.2.2. Parasites ....................................................................................................................... 139 
5.2.3. Recombinant protein expression and purification ...................................................... 140 
5.2.4. Effect of polyclonal anti-SmChE IgG on larval worms .................................................. 140 
5.2.5. Effect of polyclonal anti-SmChE IgG on adult worms .................................................. 141 
Table of Contents 
 
xiv 
 
5.2.6. Anti-SmChE IgG responses in S. mansoni-infected mice during infection and before and 
after PZQ treatment .................................................................................................................... 141 
5.2.7. Vaccine trials ................................................................................................................ 142 
5.2.7.1 Mouse necropsy and estimation of worm and egg burden: .................................... 142 
5.2.7.2 Egg viability assays .................................................................................................... 143 
5.2.7.3 Glucose consumption and glycogen storage assays ................................................ 143 
5.2.7.4 Immune responses in vaccinated mice .................................................................... 144 
5.2.8. Statistical analyses ....................................................................................................... 144 
5.3. Results .............................................................................................................................. 145 
5.3.1. Anti-SmChE polyclonal antibodies block enzyme activity and decrease viability of larval 
S. mansoni in vitro ....................................................................................................................... 145 
5.3.2. Effects of anti-SmChE antibodies on adult worms ....................................................... 146 
5.3.3. Antibody responses to SmChEs during the course of infection and following PZQ 
treatment in mice ....................................................................................................................... 149 
5.3.4. Vaccine efficacy of recombinant SmChEs in a mouse model of schistosomiasis ..... 149 
5.4. Discussion......................................................................................................................... 152 
CHAPTER 6 - General discussion and future directions ............................................................ 158 
References .................................................................................................................................. 166 
Appendices .................................................................................................................................. 204 
 
 
 
 
 
 
 
 
List of Figures 
 
xv 
 
List of Figures 
Chapter 1 
Fig 1. 1. Geographic distribution of the common schistosome species infecting humans ............ 4 
Fig 1. 2. The life cycle of the schistosome parasite ........................................................................ 7 
Fig 1. 3.  The neurotransmission routes at the neuromuscular junction. .................................... 16 
Fig 1. 4. AChE inhibition by organophosphates. ........................................................................... 27 
 
Chapter 2 
Fig 2. 1. The kinetically inert tri-nuclear (Rubbn-tri), linear tetra-nuclear Rubbn-tl and non-linear 
tetra-nuclear Rubbn-tnl) ................................................................................................................ 38 
Fig 2. 2. Effect of ruthenium complexes on SmAChE activity in adult S. mansoni extracts. ............ 50 
Fig 2.3. Activity of ruthenium complexes against adult S. mansoni worms. ................................ 53 
Fig 2.4. Inhibition of S. mansoni egg hatching and effect on egg development by ruthenium 
complexes. .................................................................................................................................... 55 
Fig 2.5. Action of Rubb12-tri and Rubb16-tnl on adult SmAChE and SmAP activity.   .................... 56 
Fig 2.6. Effect of Rubb12-tri and Rubb16-tnl on adult S. mansoni glucose uptake and storage 
ability. ............................................................................................................................................ 58 
Fig 2. 7. Cytotoxicity of ruthenium complexes. ............................................................................ 60 
Fig 2. 8. In vivo effect of Rubb12-tri and Rubb7-tnl on S. mansoni-infected mice. ........................ 62 
 
 
Chapter 3 
Fig 3. 1. The amino acid sequence alignment of ChEs from S. mansoni and other species. ........ 91 
Fig 3. 2. Phylogenetic of AChEs. .................................................................................................... 96 
Fig 3. 3. Magnified view of 3D models showing the catalytic triads of SmAChE1, SmBChE1, and 
SmAChE3.. ..................................................................................................................................... 98 
List of Figures 
 
xvi 
 
Fig 3. 4. Expression profiles of SmAChE1, SmBChE1, and SmAChE3. ........................................... 99 
Fig 3. 5. Immunofluorescent localization of SmChEs. ................................................................. 101 
Fig 3. 6. Enzymatic activity of fSmChEs.. ..................................................................................... 103 
Fig 3. 7. BChE and secretory AChE activity in schistosomes. 1. .................................................. 105 
Fig 3. 8. SmBChE1 bio-scavenges DDVP and protects parasites against DDVP-induced effects..
..................................................................................................................................................... 107 
 
Chapter 4 
Fig 4. 1. Suppression of SmChE mRNA transcript and protein expression in schistosomula by 
RNAi............................................................................................................................................. 123 
Fig 4. 2. Effects of SmChE knockdown on cholinesterase activity.  ............................................. 125 
Fig 4. 3. Effects of SmChE silencing on schistosomula viability.. ................................................ 126 
Fig 4. 4.  Schistosome glucose uptake is affected by SmChE suppression.. ................................ 128 
Fig 4. 5. Silencing of SmChEs suppresses parasite establishment in vivo.. ................................. 130 
 
 
Chapter 5 
Fig 5. 1. Anti-SmChE antibodies inhibit ChE activity in schistosomula which leads to decreased 
parasite viability. ......................................................................................................................... 146 
Fig 5. 2.  Effects of anti-SmChE antibodies on adult S. mansoni worms. .................................... 148 
Fig 5. 3. Antibody responses to SmChEs during the course of infection and following PZQ 
treatment in mice. ...................................................................................................................... 149 
Fig 5. 4. Vaccine efficacy of recombinant SmChEs in a mouse model of schistosomiasis. ........ 151 
Fig 5. 5. Effect of pSmChEs vaccination on glycogen storage in, and size of, S. mansoni adults. 152 
 
 
 
List of Tables 
 
xvii 
 
List of Tables 
Chapter 1 
Table 1. 1. Current lead vaccine candidates for schistosomiasis ................................................. 12 
 
Chapter 2 
Table 2. 1. Inhibition of acetylcholinesterase (AChE) activity in adult S. mansoni and S. 
haematobium Triton X-100-soluble extracts ................................................................................ 49 
Table 2.2. Inhibition of SmNPP-5 and alkaline phosphatase activity in adult S. mansoni Triton X-
100-soluble extracts by a series of ruthenium complexes. .......................................................... 51 
Table 2.3. Potency of selected ruthenium complexes against S. mansoni schistosomula after 48 
h treatment. .................................................................................................................................. 52 
 
Chapter 3 
Table 3. 1. Km and Vmax fSmChEs as estimated by Michaelis-Menten equation ..................... 102 
 
 
 
 
 
 
 
 
List of Abbreviations 
 
xviii 
 
List of Abbreviations 
°C degrees Celsius 
2YT 2X YT (two times yeast and tryptone) 
AA Antibiotic/Antimycotic 
ABTS 2,2'-Azino-Bis (3-Ethylbenziazoline-6-Sulfonic Acid) 
ACh acetylcholine 
AChE acetylcholinesterase 
AcSCh acetylthiocholine 
ADCC antibody-dependent cellular cytotoxicity 
Alum aluminium hydroxide 
AOX Alcohol Oxidase 
AP Alkaline phosphatase 
bbn bis[4(4'-methyl-2,2'-bipyridyl)]-1,n-alkane (n = number) 
BCA Bicinchoninic acid 
BCh butrylcholine 
BcSCh butyrylthiocholine 
BLAST Basic Local Alignment Search Tool 
BMGY Buffered Glycerol-complex medium 
BMMY Buffered Methanol-complex medium 
BSA Bovine serum albumin 
cDNA complementary Deoxyribonucleic acid 
List of Abbreviations 
 
xix 
 
ChE cholinesterase 
CNS central nervous system 
CO
2
 carbon dioxide 
DALYs Disability Adjusted Life Years 
DDVP Dichlorvos 
DEPC Diethyl pyrocarbonate 
DIR drug-induced resistance 
DMEM Dulbecco's modified eagle medium 
DNA Deoxyribonucleic acid 
DTNB 5′-dithiobis(2-nitrobenzoic acid) 
DTT Dithiothreitol 
EC50 Concentration required to kill 50% of parasites 
EDTA Ethylenediaminetetraacetic acid 
ELISA enzyme linked immunosorbent assay 
ES Excretory-secretory 
FCS Fetal calf serum 
g relative centrifugal force 
g gram 
HRP horseradish peroxidase 
i.v. Intravenous 
IC50 Concentration required to inhibit 50% of enzyme activity 
List of Abbreviations 
 
xx 
 
IgG Immunoglobulin class G 
IPTG isopropyl β-D-1-thiogalactopyranoside 
kDa kilodalton 
L litre 
m milli 
M molar 
mAChRs muscarinic acetylcholine receptors 
MALDI-TOF MS Matrix-Assisted Laser Desorption/Ionisation-Time Of Flight Mass 
Spectrometry 
MDA mass drug administration 
MTT 3-(3,4-Dimethylthiazol-2yl)-5-diphenyl  tetrazolium  bromide 
n nano 
nAChRs nicotinic acetylcholine receptors 
NCBI National Centre for Biotechnology Information 
OD optical density 
ORF open reading frame 
OXA Oxamniquine 
PAGE polyacrylamide gel electrophoresis 
PAS peripheral anionic site 
PBS phosphate buffered saline 
PBST phosphate buffered saline with 0.05% Tween 20 
List of Abbreviations 
 
xxi 
 
PCR Polymerase chain reaction 
PDE Phosphodiesterase 
pH power of hydrogen 
pNPP p-Nitrophenyl phosphate 
PNS peripheral nervous system 
PRiMA Proline-Rich Membrane Anchor 
PZQ Praziquantel 
RNA Ribonucleic acid 
RNAi RNA interference 
rpm revolution per minute 
RT-PCR Reverse transcription polymerase chain reaction 
SDS sodium dodecyl sulphate 
SEM Scanning electron microscopy 
SGTP schistosome glucose transporters 
siRNA small interfering RNA 
TAC tris (p-aminophenyl) carbonium salts 
WHO World Health Organization 
YPD Yeast extract/Peptone/Dextrose 
YPDS Yeast extract/Peptone/Dextrose/sorbitol 
μ micro 
Chapter 1. Introduction and Lit Review 
 
1 
 
CHAPTER 1 
 
 
Introduction and Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction and Lit Review 
 
2 
 
1.1 Introduction  
1.1.1 Schistosomiasis 
Schistosomiasis, also known as Bilharzia, is one of the neglected tropical diseases caused by 
trematodes of the genus Schistosoma (Webster et al. 2006).  Schistosomes, a digenetic 
trematode (flatworm) are blood-dwelling flukes which inhabit the host vasculature, producing 
eggs which cause the majority of disease manifestations resulting from infection (McManus et 
al. 2008). While there are over twenty species of Schistosoma, the three species of most public 
health importance are Schistosoma mansoni, which causes hepatic schistosomiasis; Schistosoma 
haematobium, causing urogenital schistosomiasis; and Schistosoma japonicum, which is the 
causative agent of hepato-intestinal schistosomiasis. Although less common and geographically 
restricted to a few areas, Schistosoma intercalatum, and Schistosoma mekongi are also medically 
important (Olveda et al. 2013). 
 
1.1.2 Epidemiology and geographic distribution 
Schistosomiasis is a common cause of morbidity and mortality worldwide and described 
as second only to malaria in its debilitating effects when disease burden is measured with 
reference to Disability Adjusted Life Years (DALYs). For this reason, the World Health Organization 
(WHO) prioritized schistosomiasis for focused global intervention (Hotez et al. 2007). 
 
Schistosomes infect approximately 200 million people in over 78 countries, and more than 750 
million people are at risk of acquiring the infection in endemic areas (Gryseels et al. 2006; Hotez 
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et al. 2010). The majority of cases (90%) occur in Africa (Utzinger et al. 2009). Globally, it is 
estimated that 120 million infected people are clinically symptomatic, with 20 million manifesting 
severe symptoms from the disease (Colley et al. 2014). Schistosomiasis contributes to more than 
200, 000 deaths annually, with DALYs, lost to the disease potentially as high as 70 million (King et 
al. 2008). Infection with schistosomes can also inflict massive health and socio-economic burden 
on endemic areas with illness leading to disability and sluggish physical and mental development 
in children (Hotez et al. 2007). 
 
The geographic distribution of the three dominant Schistosoma species in humans is attributed 
to the presence of a suitable intermediate host – the freshwater snail.  S. mansoni and S. 
haematobium are endemic in Sub-Saharan Africa and the Arabian Peninsula, with the former also 
present in South America. S. japonicum is endemic in the swampland and lake regions of China, 
the Philippines, and Indonesia (Fig 1.1) (Gryseels et al. 2006).  
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Fig 1.1. Geographic distribution of the common schistosome species infecting humans 
 (Gryseels et al. 2006). 
 
1.1.3 Transmission 
Endemic schistosomiasis transmissions have been reported in 52 countries of three continents 
with moderate to high transmission rates (Colley et al.). This highlights the need for preventative 
measures that improve the lives of millions of people living in these regions. The disease is highly 
prevalent in poor rural communities where there is poor access to safe drinking water and 
adequate sanitation as transmission usually occurs when water sources are contaminated with 
feces containing parasite eggs, which hatch in stagnant or slow-moving fresh water. Schistosoma 
transmission is highest among individuals that have frequent contact with stagnant water 
(fishers, farmers using irrigation, women fetching water), with the most vulnerable members of 
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the population being pregnant women and children, who if not treated, suffer chronic health 
consequences into later life (Hotez et al. 2007; McManus et al. 2008). 
 
1.1.4 Lifecycle 
It is notoriously difficult to study Schistosoma biology as the parasite has a complex life cycle 
involving two host; a definitive vertebrate host in which adult male and female worms grow and 
sexual reproduction follows, and a species-specific intermediate host, freshwater snails of the 
genus Bulinus (S. haematobium), Biomphalaria (S. mansoni), Oncomelania (S. japonicum) in 
which they multiply asexually (Utzinger et al. 2009). This multi-stage lifecycle is tightly regulated, 
apparently by strict control of stage-specific gene expression (Anderson et al. 2016). However, 
the mechanisms regulating vital gene expression in schistosomes are still poorly understood.  
 
Eggs are excreted in feces or urine of the definitive hosts. Upon reaching fresh water, the 
deposited eggs hatch into free-swimming miracidia in response to changes in osmotic pressure, 
light and a decrease in temperature, reviewed elsewhere  (Xu et al. 1990). Miracidia demonstrate 
host-seeking behaviors in response to chemosensory cues. It then penetrates the intermediate 
host, a process which is initiated by signals from macromolecular glycol-fatty acid conjugates 
found on the snail surface (Kalbe et al. 2004). Parasites within the snail develop into sporocysts 
and then cercariae (Collins et al. 2011). Sporocysts of S. mansoni possess a birth pore with 
acetylcholinesterase (AChE) activity and nervous and muscular structures that could enable 
release of the cercariae by actively opening and closing the pore activity (Driguez et al. 2016). 
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AChE activity in sporocysts has also been hypothesized to be involved in chronobiological 
mechanisms (Driguez et al. 2016). It is worth mentioning that the nervous system of Schistosoma 
larvae was primarily  revealed using AChE staining (Bruckner et al. 1974)  
 
Snails shed cercariae into their aqueous environment that penetrate the skin of a definitive host, 
causing them to undertake transformation into schistosomula. These larvae migrate through the 
dermal layers of the skin and then lung capillaries over a number of days to eventually reside in 
the vasculature of the liver, intestines or bladder, depending on the species (Ross et al. 2002). In 
these sites, mature worms pair at 5-6 weeks post-infection and spend the rest of their life (an 
average of 3-5 years) inside the host in the cupola. Female worms produce eggs, which enter the 
intestinal lumen or bladder to be voided in the feces or urine. Excreted eggs are fully 
embryonated and hatch only when they come in contact with bodies of fresh water to continue 
the cycle (Ross et al. 2002) 
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Fig 1.2. The life cycle of the schistosome parasite  
(http://www.cdc.gov/parasites/schistosomiasis/biology.html).  
 
1.1.5  Pathology and clinical manifestation 
Schistosoma infection can be acute or chronic. Typically, parasites inside human tissues induce 
an immunological response that causes local and systemic pathological effects ranging from 
anemia, delayed growth and cognitive development, and malnutrition to organ-specific effects 
such as fibrosis of the liver and urogenital cancer (Gray et al. 2011). 
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Cercarial dermatitis (swimmer's itch) is the first stage of Schistosoma infection and is 
characterized by fever and a maculopapular rash at the site of skin penetration (Ross et al. 2001; 
Ross et al. 2002). The second stage of disease – acute schistosomiasis (Katayama fever) - is due 
to a host inflammatory response against the release of highly antigenic eggs. Acute infection 
usually occurs in children or young adults with no past exposure to the disease (Gryseels et al. 
2006). It occurs within a couple of months after cercarial penetration with common symptoms 
including, fever, generalized myalgia, bloody diarrhea, and hepatosplenomegaly. The final stage 
- chronic schistosomiasis - arises mostly because of the host’s unregulated immune response to 
entrapped eggs in tissues. It can present months to years after exposure, making diagnosis 
difficult. Excretory-secretory (ES) products released from the eggs deposited in different host 
tissues induce a localized inflammatory reaction arising from a T-helper 2 (Th2) type immune 
response, characterized by the formation of granuloma around the egg (Ashton et al. 2001). 
Prolonged years of granuloma formation due to massive infection results in extensive hepatic 
and intestinal fibrosis and collagen deposition that is the primary pathology of chronic 
schistosomiasis (Pearce et al. 2002; Sandor et al. 2003).  
 
1.1.6 Chemotherapeutic intervention and challenges 
Currently, safe and effective treatment of human schistosomiasis relies on the administration of 
a single drug, Praziquantel (PZQ) at an oral dose of 40 mg/kg (Trainor-Moss et al. 2016). It has 
comparatively few side effects and is effective against the adult stage of all common species of 
schistosomes pathogenic to humans, thus advantageous for the control of mixed infections 
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(Tchuem Tchuenté et al. 2013), but it does not affect eggs or juvenile stages (Gryseels et al. 2006) 
and does not provide absolute protection from reinfection. The precise mechanism of action of 
the drug remains unclear. However, experimental work in mice has demonstrated 
that PZQ treatment disrupts the tegument (worm surface), exposing tegumental antigens to the 
host immune system (Mehlhorn et al. 1981) which results in quantitative alteration of host-
parasite-specific immune responses (Mutapi et al. 2007). Interestingly, in a subset of the 
population, PZQ-mediated modification of the immune response confers a degree of resistance 
to re-infection – drug-induced resistance (DIR) (Pearson et al. 2015). 
 
Overall, in endemic areas where the risk of re-infection is high, preventive chemotherapy, 
or mass drug administration (MDA) using PZQ is the mainstay of control (Mduluza et al. 2001). 
This periodic MDA is however unsustainable as a stand-alone control measure and ideally, should 
be integrated with additional intervention strategies. Besides, there is considerable concern 
about the development of PZQ resistance (Botros et al. 2005). This scenario underscores the 
increasing need for the development of novel and inexpensive drugs against schistosomiasis.  
 
Yet another obstacle to early intervention is the lack of accurate diagnostic tools that can 
distinguish between active and late infections. Current diagnosis of Schistosoma infection relies 
upon microscopic detection of species-characteristic eggs in stool samples, or urine (in the case 
of S. haematobium). When prevalence and intensity of infection are decreased after 
chemotherapy, however, microscopic methods become less sensitive (van der Werf et al. 2003). 
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Immunological approaches for the detection of Schistosoma antibodies or antigens (e.g., 
circulating cathodic and anodic antigen) (Kremsner et al. 1994) offer increased sensitivity but 
decreased specificity and difficulties in obtaining a genuinely quantitative diagnosis are inherent 
problems. PCR-based diagnostics have been developed to overcome these issues, but the need 
for specialized equipment and training to conduct these tests in endemic settings is a 
disadvantage (Utzinger et al. 2015).  
 
1.1.7 A vaccine for schistosomiasis? 
The current schistosomiasis control strategy that relies on periodic MDA of PZQ, is logistically 
difficult, expensive and difficult to achieve in our lifetime (Fenwick et al. 2016 ). The development 
of an anti-schistosome vaccine and its integrated use with sustainable MDA strategies, therefore, 
is an essential tool for the global fight against schistosomiasis.  
 
The feasibility of a schistosomiasis vaccine has been demonstrated in a series of proof-of-concept 
studies where laboratory animals - initially mice (Dean et al. 1983) and, later, non-human 
primates (Kariuki et al. 2004) - were immunized with radiation-attenuated cercariae and found 
to be >80% resistant to a subsequent experimental schistosomal challenge. While the acquisition 
of protective immunity to human schistosomiasis, either naturally occurring or drug-induced, is 
well documented (Correa-Oliveira et al. 2000; Black et al. 2010), it can be slow in maturing and is 
not widespread throughout endemic populations. In order to augment this resistance and 
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stimulate anti-schistosomal immunity, it is crucial that an antigen threshold is reached (Wilson et 
al. 2014) to perturb parasite pathogenesis through immune intervention. 
 
Currently, vaccination strategies are focused on targeting the intra-mammalian stages of the 
parasite, particularly, the migrating schistosomula (widely considered most susceptible to 
immune attack) and adult female (to prevent the release of tissue-destructive and pathology-
inducing eggs). Further, proteins of the tegument and ES fraction of these parasitic stages are 
arguably the most important groups of molecules to target for vaccine antigen identification due 
to their role in numerous fundamental interactions with the host and accessibility to the host 
immune system (Loukas et al. 2007).  Most approaches have concentrated on identifying 
protective antigens from these stages and delivering these recombinant constructs or purified 
extracts in various formulations (McManus et al. 2008). The availability of comprehensively 
annotated genomes for all human schistosome species (Berriman et al. 2009; Young et al. 2012) 
and the publication of juvenile and adult tegumental and ES proteomic studies (Gaze et al. 2014; 
Pearson et al. 2015; Sotillo et al. 2015; Driguez et al. 2016) have provided researchers with a 
goldmine of bioinformatic and evidence-based information regarding the protein composition of 
these “sites of vaccine potential”, significantly facilitating the rational selection of vaccine 
candidate antigens.  
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Table 1. 1. Current lead vaccine candidates for schistosomiasis 
 Feature 
 
Candidate antigen 
 
 SmTSP-2  Sm-p80 Sh28GST Sm14 Sm29 
Known function of the 
antigen 
Molecular organization  
of membranes (Tran et 
al. 2010) 
Renewal/recycling of 
the parasite surface 
(Siddiqui et al. 1993)  
Detoxification of 
ROI (Vibanco-
Perez et al. 1998)  
FABP for lipid 
uptake from the 
host (Moser et al. 
1991)  
ND    
Expressed by all human 
stage 
Yes (Smyth et al. 2003) Yes (Siddiqui et al. 
1993) 
Yes (Walker et al. 
1993)  
Yes (Brito et al. 
2002)    
Adults and 
schistosomula 
(Cardoso et al. 2008) 
 
Essential for survival Yes§ (Tran et al. 2010)  ND* ND Yes§§ (Furlong 
1991) 
 
ND 
Cross-species protection ND 
 
Yes(Karmakar et al. 
2014)  
Yes (Boulanger et 
al. 1995) 
Yes (Tendler et al. 
1996)  
ND  
Located on tegument Yes (Braschi et al. 
2006; Tran et al. 2006) 
 
Yes (Siddiqui et al. 
1993) 
 
Yes (Porchet et 
al. 1994)  
Yes (Brito et al. 
2002)  
 
Yes (Cardoso et al. 
2008) 
 
antigenic polymorphism  Conserved (Cupit et al. 
2011) 
ND  Conserved 
(Trottein et al. 
1992)  
Polymorphic(Ramos 
et al. 2003)  
ND  
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Antibodies inhibit parasite 
growth in vitro 
ND  Yes, ADCC** (Torben et 
al. 2012)  
Yes, ADCC 
(Riveau et al. 
1998)  
ND 
  
ND  
Evidence of protection in 
animal models 
Mice (Tran et al. 2006)  Primates  (Ahmad et al. 
2011)  
Primates  
(Boulanger et al. 
1999)  
Mice (Tendler et al. 
1996) 
Mice (Cardoso et al. 
2008; Alves et al. 
2015)  
 Cross-reactivity with 
vertebrate proteins 
ND No (Siddiqui et al. 
1993) 
No (Trottein et 
al. 1992; Hughes 
1993)  
ND  ND  
Antibody recognition by 
resistant humans 
Yes (Gaze et al. 2014) Yes (Gaze et al. 2014; 
Pearson et al. 2015) 
ND  Yes (Gaze et al. 
2014)  
Yes (Gaze et al. 
2014) 
Clinical trial status Phase I (Merrifield et 
al. 2016) 
Preclinical (Merrifield 
et al. 2016) 
Phase III (Mo et 
al. 2014)  
Phase I (Merrifield 
et al. 2016) 
Preclinical 
(Merrifield et al. 
2016) 
**antibody-dependent cell cytotoxicity, *not determined, § determined by RNAi,   §§ determined from biochemical studies 
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The upsurge in the availability of “omics-based” information has recently paved the way for the 
use of protein array technology as a vaccine antigen discovery tool. This technology permits the 
profiling of an individual’s immune response to the entire immunome (the protein subset of an 
organism that is capable of inducing an immune response in a natural infection) of a pathogen 
and comparing the differences in antibody profiles between susceptible and resistant endemic 
populations allows the identification of antigens involved in a protective immune response 
(Driguez et al. 2015). In schistosome research, protein array studies have contributed significantly 
to our understanding of the human immune responses to schistosomiasis and allowed the 
identification of numerous vaccine candidate antigens, both previously documented (validating 
protein arrays as a vaccine antigen discovery tool) and novel (Gaze et al. 2014; Pearson et al. 
2015; Driguez et al. 2016). Indeed, one of the antigens identified from two independent 
schistosome protein array was acetylcholinesterase (AChE) (Pearson et al. 2015; Driguez et al. 
2016), which has provided the impetus for the study herein.  
 
1.1.8 Acetylcholine, acetylcholinesterase and butyrylcholinesterase 
Signaling in the nervous system is mediated through the interaction of neurotransmitters (for 
example, biogenic amines, neuroactive amino acids and gasses and acetylcholine (ACh)) with 
their cognate receptors located at the neuromuscular junction (Hu et al. 2011). In the synapse of 
the axon terminal of a motor neuron and the motor end plate, for instance, ACh is loaded into 
vesicles and transported across the synapse via a pH gradient. Following synaptic vesicle fusion 
and neurotransmitter release, the ACh disperses within the synaptic cleft and activates 
Chapter 1. Introduction and Lit Review 
 
15 
 
muscarinic (mAChRs) or nicotinic acetylcholine receptors (nAChRs), located on post-synaptic cells 
(Albuquerque et al. 2009). Stimulation of nicotinic receptors produces a rapid, excitatory effect 
and the result of muscarinic receptor stimulation is slower and can be excitatory or inhibitory, 
depending on the stimuli. Once the appropriate effector function of the AChR has been achieved, 
unbound ACh must be regulated or controlled in order to avoid prolonged contraction or 
relaxation (Nishimura et al. 2010). 
 
The action of unbound ACh is terminated by single step enzymatic hydrolysis of the 
neurotransmitter into acetate and choline by acetylcholinesterase (AChE). The hydrolysis of ACh 
is initiated when the acyl group of ACh is initially transferred to the active-site serine of AChE, 
after which a water nucleophile attacks this ester, removing acetate and completing the 
hydrolysis.  AChE is an efficient enzyme, capable of hydrolyzing ACh within 100 milliseconds of 
reaching the active site and catalyzing the breakdown of up to 10,000 ACh molecules per second 
(Dvir et al. 2010). After hydrolysis, most of the choline is transported back into the presynaptic 
nerve ending by high-affinity choline transporter and is then available for the synthesis of 
additional ACh (Day et al. 1996; Pax et al. 1996; Halton 1997) (Fig 1.3). 
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Fig 1.3.  The neurotransmission routes at the neuromuscular junction.  
Modified from http://neuroscience.uth.tmc.edu/s1/chapter11.html#synthesis    
   
Butyrylcholinesterase (BChE) is also a cholinesterase (ChE) domain-containing protein with 
features similar to AChE (Barker et al. 1966; Rumjanek 1987; Camacho et al. 1995; Bentley et al. 
2004) and is present in extra-neuronal tissues such as liver, lung and plasma. Enzymatically, BChE 
is also known as a pseudocholinesterase as it is less substrate specific for ACh than AChE and 
preferentially hydrolyzes butyrylcholine BCh (Mack et al. 2000), however, its physiological 
function is not known since humans lacking BChE activity do not show any pathology (Massoulie 
2002). Since BChE presents as a soluble form in the circulation of mammals, is suggested to serve 
as a safeguard against the diffusion of excess ACh and orally ingested toxins into the bloodstream 
because of its broad specificity to different substrates (Allon et al. 1998; Huang et al. 2007; 
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Lockridge 2015). In addition, it could also serve as a competitive inhibitor of orally ingested 
compounds toxic to AChE, including plant alkaloids such as cocaine (Massoulie 2002; Zhan et al. 
2003). Previous studies, in schistosomes, demonstrated the presence of pseudocholinesterase 
(nonspecific cholinesterase activity) (Bueding 1952; Fripp 1967; Bruckner et al. 1974; Camacho 
et al. 1994); however, there is no evidence so far to support the existence of BChE in 
schistosomes.  
 
1.1.9 Molecular diversity of AChE 
Based on studies in vertebrates, AChE exists in multiple molecular forms based on differences in 
the carboxy-terminal region that define oligomerization state and membrane anchoring 
(Massoulie 2002). Catalytic subunits may be assembled into asymmetric collagen-tailed or 
globular molecules or remain as monomers (Massoulie 2002). The C-termini of AChEH isoforms 
are hydrophobic and glycophosphotidyl (GPI) anchored to cell membranes and the cysteine in 
this region forms an intramolecular disulfide bond between monomers to form a dimer. The 
AChES form of AChE has a truncated C-terminus and remains soluble and monomeric. Thirdly, 
AChET (tailed) proteins are collagen-tailed forms that associate with the Proline-Rich Membrane 
Anchor (PRiMA) protein on cell membranes which operate to organize AChET into tetramers 
(Pezzementi et al. 2012).  
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1.1.10 The nervous system of schistosomes  
The Platyhelminthes (flatworms), to which Schistosoma belong, are the most primitive organisms 
on earth to have developed a bilateral nervous system (Baguñà et al. 1978).  Schistosomes are 
acoelomate parasites that have no circulatory system or endocrine glands and so, in the absence 
of a body cavity and circulating body fluid, lack the capacity for classical endocrine cellular 
communication. Thus, the only mechanism for long distance signal transduction in schistosomes 
for the coordination of such critical processes as movement, metabolism and reproduction, is 
performed by the nervous system (Halton et al. 1996; Ribeiro et al. 2010).  
 
The schistosome nervous system is comprised of two main interconnected components: the 
central nervous system (CNS) and peripheral nervous system (PNS). The CNS consists of a bi-
lobed cephalic ganglion and several pairs of longitudinal nerve cords that run along the entire 
length of the worm (Reuter et al. 1996).  The longitudinal nerve cords are connected via a network 
of circular regularly spaced connecting bands of nerve tissue (Reuter et al. 1996; Ribeiro et al. 
2010). The PNS consists of smaller nerve cords and nerve plexuses (large meshed networks of 
neurons) that supply the worm’s body structure, muscles and organs (Halton et al. 1996; Ribeiro 
et al. 2005).  
 
There are two distinct nerve plexuses in schistosomes: the sub-muscular plexus, which innervates 
the body wall musculature and the oral and 9 ventral suckers (Mair et al. 2000); and the sub-
tegumental plexus, which is associated with the innervation of sensory structures, such as 
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papillae (Gobert et al. 2003) in the male gynocophoric canal and on the tegument of the worm 
(Mair et al. 2004). Cholinergic neurons, nerve cells responsible for the neurotransmission of ACh, 
are found throughout the entire schistosome nervous system, as evidenced by histochemical 
staining for AChE (Fripp 1967). Further, nAChRs have been identified on the tegument of S. 
mansoni (Camacho et al. 1995) and both the body wall muscles and the surface of S. 
haematobium (Bentley et al. 2004). 
  
1.1.11 Acetylcholine in schistosomes 
While ACh has an excitatory effect on muscle contraction and motility for most flatworms (Pax 
et al. 1996), it acts as an inhibitory neurotransmitter in schistosomes. This fact is documented by 
studies showing the dose-dependent induction of flaccid paralysis of extracted muscle fiber and 
whole worms when they are treated with ACh (Barker et al. 1966). The exact mechanism by which 
this neurotransmitter inhibits muscle contraction in flatworm, however, remains unknown (Day 
et al. 1996). 
  
In addition to the neuromuscular function of ACh, the neurotransmitter has a role in the uptake 
of exogenous glucose; an idea first postulated with the finding that nAChRs were concentrated 
on the male dorsal tegument (Camacho et al. 1995), a major nutrient absorptive surface for the 
worm pair (Rumjanek 1987).  Evidence for this relationship was provided with the discovery that 
glucose uptake was increased in schistosomes in vitro with the addition of blood-equivalent 
concentrations of ACh and ablated with specific agonists of nAChRs   (Camacho et al. 1995). The 
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proposed mechanism behind this uptake system is that binding of ACh to tegumental nAChRs 
influences glucose transport through the modulation of tegumental schistosome glucose 
transporters (SGTP), such as SGTP1 and SGTP4 (Skelly et al. 1996) which are also present on the 
surface of this parasite (Jones et al. 2002). 
 
1.1.12 Acetylcholinesterase in schistosomes  
AChE activity was first demonstrated in adult schistosomes in 1952 (Bueding 1952) and later 
confirmed in other stages of the schistosome lifecycle (Espinoza et al. 1991; Espinoza et al. 1991; 
Tarrab-Hazdai et al. 1991; Camacho et al. 1994), both biochemically and using schistosome AChE-
specific antibodies. Initially the enzyme was characterized by biochemical purification from worm 
extracts using affinity chromatography methods employing competitive inhibitors of ACh 
(Goldlust et al. 1986) and, more recently, recombinant  AChEs have been expressed from 
different schistosome species (Jones et al. 2002; Bentley et al. 2003; Bentley et al. 2005; You et 
al. 2016). The involvement of AChE in controlling the motor activity of schistosomes was shown 
by demonstrating that AChE induced paralysis in worms while the administration of eserine, an 
AChE inhibitor, caused a concentration-dependent longitudinal muscle relaxation in the parasite 
(Pax et al. 1981). 
 
Schistosome AChE is associated with the neuro-musculature, and tegument of the parasite (Levi-
Schaffer et al. 1984). In S. mansoni schistosomula, AChE was found to be highly enriched in the 
tegument (350 fold) compared to the rest of the worm (Arnon et al. 1987). The enzyme 
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predominantly exists in a dimeric globular form (Camacho et al. 1994) and is reportedly attached 
to the tegument and muscle via a covalently linked GPI anchor (Arnon et al. 1987). More recent 
sequence comparison of schistosome AChE with the vertebrate enzyme, however, has revealed 
unique C-terminii and it has been suggested that schistosome AChE may associate with another 
protein which is GPI-anchored itself (Bentley et al. 2003).  Different levels of AChE activity has 
been reported among different species of Schistosoma and this is due to the differing amounts 
of the enzyme in their teguments (S. haematobium and S. bovis, respectively, have 20 and 6.9 
times the amount of tegumental AChE activity than S. mansoni) (Camacho et al. 1994). 
 
It should be noted that only one AChE-encoding gene from Schistosoma has been described over 
a decade ago (Bentley et al. 2003; Bentley et al. 2005). However, interrogation of the S. mansoni 
and S. haematobium genomes (Berriman et al. 2009; Young et al. 2012) has revealed multiple 
separate genes. In S. mansoni, three paralogs (SmAChE1 (Smp_154600), SmBChE1 (Smp_125350) 
and SmAChE3 (Smp_136690)) have been identified (http://www.geneDB.org) of comparable 
length encoding AChEs. Previous studies on the biochemically purified material, therefore, would 
have been unable to attribute enzyme characteristics to anyone AChE protein. Accordingly, it is 
the aim of the studies proposed herein to explore the function and interplay of all three SmChEs 
from S. mansoni. 
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1.1.13  Non-neuronal functions of helminth acetylcholinesterase  
It is now widely accepted that AChE can perform multiple biological functions due to its presence 
in multiple cell types and sub-cellular locations (Santos et al. 2007). In helminths, neuronal AChE 
appears to perform a “traditional” cholinergic activity while surface-associated or secreted AChE 
has roles in non-neuronal functions such as nutrient acquisition, parasite adhesion to host tissue 
and immune modulation (Arnon et al. 1999; Selkirk et al. 2005).  
 
1.1.13.1 Helminth AChE and glucose uptake   
Glucose is a primary and essential nutritional source used by schistosomes to fuel their growth 
and fecundity and, while the parasite is capable of glycolysis and glycogenesis, the intra-
mammalian stages of the worm rely heavily on the consumption of exogenous glucose (You et 
al. 2014).  The role of AChE in host glucose uptake by schistosomes is suggested to limit the 
interaction of host ACh with tegumental nAChR (Camacho et al. 1995), presumably decreasing 
the amount of glucose uptake through surface glucose transporters (Jones et al. 2002). The 
contribution of tegumental AChE to this system is evidenced by the ablation of glucose uptake 
with a membrane-impermeable inhibitor of AChE, which has the same result as the 
administration of an excess of ACh (Jones et al. 2002). The specific mechanism by which nAChRs 
mediate glucose transport remains unknown.  
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1.1.13.2 Helminth AChE and adhesion 
Further to the observation that some adhesion proteins shared significant sequence homology 
with ChE domains (Scholl et al. 2003), there is now a growing body of evidence that AChE plays a 
non-classical role as an adhesion protein (Soreq et al. 2001; Silman et al. 2005). Examples of these 
ChE-like adhesion molecules include glutactin, neurotactin, gliotactin from Drosophila and the 
mammalian neuroligins (Botti et al. 1998). These proteins are absent of hydrolase activity as they 
lack a complete catalytic triad, but their ChE-like domain has high sequence similarity with AChE 
and acts as a protein-protein interaction motif, suggesting that AChE itself may function in a 
similar manner (Darboux et al. 1996). Further, cholinesterase-like adhesion molecules possess a 
typical electrostatic motif of negative potential around a zone that is homologous to the active-
site gorge (Peripheral anionic site) of AChE (Felder et al. 1997). Electrostatic interactions can 
facilitate target recognition through a protein-complex formation, further lending support to an 
adhesive function for AChE (Botti et al. 1998). 
 
The possible role of schistosomal AChE in facilitating adhesion has not been explored. Two 
hypotheses are that the tegumental AChE of schistosomes may aid in adsorption of host 
molecules onto the outer surface of the parasite, one of many immune-evasive strategies 
employed by the worm (Clegg et al. 1971) or assist in a vascular attachment via an adhesive 
interaction (Wyszomirska et al. 2005). In vivo treatment with anti-schistosomal compounds and 
AChE inhibitors such as tris (p-aminophenyl) carbonium salts (TAC) (Bueding et al. 1967), results 
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in a shift of the worms from the mesenteries to the liver which may occur due to an inability of 
the parasite to attach to the vasculature. 
 
1.1.13.3 Helminth AChE and immune responses  
Acetylcholinesterase secreted by some nematodes are reported to inhibit local ulceration in the 
stomach by hydrolyzing ACh, which is known to stimulate gastric acid secretion (Pritchard 1993), 
but this was not corroborated by experimental evidences and It has been indirectly shown that 
the nematode N. brasiliensis employs parasite-derived AChE to alter the host cytokine 
environment to inhibit M2 macrophage recruitment, a condition favorable to worm survival 
(Vaux et al. 2016). Also, lysosomes are secreted by phagocytic cells during phagocytosis and the 
circulating ACh is suggested to enhance the release of lysosomal enzymes by selectively 
increasing of intracellular levels of cGMP (Ignarro et al. 1973; Ignarro et al. 1974).  It is, therefore, 
possible that AChE secreted by helminths may interfere with the process by hydrolyzing ACh 
before it reaches its target immunological cells, thus reducing inflammation in the surroundings 
where the parasites reside and preventing efficient expulsion. Circulating ACh also plays a role in 
the upregulation of intestinal helminth killing by antibody-dependent cellular cytotoxicity (ADCC) 
through the mediation of leukocyte cGMP levels (Gale et al. 1974) and so helminth-derived AChE 
may interfere with this process through the hydrolysis of ACh. 
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1.1.13.4 Helminth AChE and host pathogenicity 
Several studies on nematodes have implicated parasite-derived AChE in the pathogenesis of 
helminth infection. It has been suggested that AChE may provide acetate and choline precursors 
for helminth metabolism (Pritchard 1993). It was also suggested that AChE is involved in 
controlling the permeability of parasites as observed in the presence of AChE inhibitors (Schwabe 
et al. 1961).  
 
1.1.13.5 Helminth AChE and apoptosis  
There is data to strongly suggest that AChE is a vital component in the common pathway leading 
to apoptosis as more than 40 different types of cells have demonstrated AChE expression during 
and after the induction of apoptosis by different stimuli (Zhang et al. 2012).  It is proposed that 
AChE play a key role in the formation of the apoptosome as silencing of the enzyme ablated the 
interaction between apoptotic protease-activating factor-1 and cytochrome c (Park et al. 2004). 
While there is no research showing the involvement of parasite-derived AChE in the apoptosis of 
helminth cells, the schistosome apoptosis pathway, which is active throughout the parasite’s life 
cycle, is similar to that in mammals (Lee et al. 2011; Han et al. 2013). 
 
1.1.14  Schistosoma AChE as a vaccine target? 
There are several indications to support the usefulness of schistosomal AChE as a vaccine target, 
in line with the criteria used for Table 1.1. Firstly, AChE has been immunolocalized to the 
tegument of schistosomula and adult worms (Camacho et al. 1995; Espinoza et al. 1995), a result 
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consistent with the detection of AChE activity in these membranes (Camacho et al. 1994), 
suggesting that the enzyme is accessible to immune attack. Secondly, a panel of monoclonal 
(Espinoza et al. 1995) and polyclonal (Espinoza et al. 1991; Espinoza et al. 1991; Tarrab-Hazdai et 
al. 1991) anti-schistosomal antibodies were able to interact with the surface localized enzyme on 
intact schistosomula and produce almost total complement-dependent killing of the parasite. 
Thirdly, some of the same monoclonal antibodies and polyclonal anti-schistosomal  AChE 
antibodies showed no cross-reactivity against human AChE (Espinoza et al. 1991; Espinoza et al. 
1991; Tarrab-Hazdai et al. 1991; Espinoza et al. 1995), indicating that a vaccine safe for human 
use could possibly be designed. Lastly, recent protein array studies have detected considerably 
high levels of circulating antibodies to schistosomal AChE in humans exhibiting resistance and 
low pathology to schistosomiasis, suggesting an involvement of these antibodies in a protective 
anti-schistosomal response (Pearson et al. 2015; Driguez et al. 2016). Recently, a study in S. 
japonicum has shown that a recombinant AChE is capable of generating a protective immune 
response that resulted in 33% male worm burden and 73% mature intestinal egg reduction, 
respectively, in a mice model of schistosomiasis (You et al. 2018).   
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1.1.15  AChE inhibitors 
Acetylcholinesterase is expressed in all vertebrate and invertebrate animals as a key enzyme of  ACh-
mediated neurotransmission (Lang et al. 2012) and, owing to its critical role in organism survival; AChE 
is a sensitive target for both natural and synthetic inhibitors, including organophosphates (Fig 1.4). 
AChE inhibitors are present in the venom of many animals and have been employed in a variety of 
uses including insecticides and as chemical weapons (Silman I 2000).  
 
In clinical medicine, certain medical disorders such as dementia, myasthenia gravis, and glaucoma 
can be directly related to a dysfunction of the cholinergic system and thus treated through 
modulation of the cholinergic function using AChE inhibitors (Čolović et al. 2013).  
 
 Fig 1.4. AChE inhibition by organophosphates. Depicted is the interaction of AChE with sarin nerve 
gas. The phosphate group of the inhibitor binds to the carboxyl-ester group of the active site serine 
and, in this form, the enzyme is no longer available for its next physiological function.  
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1.1.15.1  AChE inhibitors as anti-schistosomals 
Schistosoma AChE is the target of several anti-parasitic drugs, including hycanthone (Hillman et al. 
1975) metrifonate (Bueding et al. 1972; Feldmeier et al. 1982), phosphonium salts and phosphoranes 
(Levi-Schaffer et al. 1984) and TAC (Bueding et al. 1967). Historically, some of these drugs were widely 
used for the treatment of schistosomiasis but have either been withdrawn from the market or are 
restricted in their use due to medical, operational, and economic criteria (Reich et al. 2001). 
 
Metrifonate is an organophosphate compound initially used as an insecticide (Lorenz et al. 1955). It 
has been shown to be effective against S. mansoni and S. haematobium in vitro (Bueding et al. 1972) 
but is more effective against S. haematobium (Davis et al. 1969; Feldmeier et al. 1982). It has been 
suggested that S. haematobium may be more susceptible to metrifonate than S. mansoni because of 
approximately 20 times much higher levels of AChE activity in its tegument (Camacho et al. 1994; 
Abdi 1995). Metrifonate was withdrawn from the market and further development in 1998 because 
of issues with toxicity (Lopez-Arrieta et al. 2006) and it is no longer on the WHO model list of essential 
drugs  (Kramer et al. 2014). 
 
Hycanthone (a metabolite of the anti-schistosomal compound lucanthone) was also one of the most 
widely used drugs both S. mansoni and S. haematobium (Rosi et al. 1965) and has been shown to 
stimulate the motor activity of the parasite through the inhibition of AChE. The drug is commercially 
discontinued because of toxicity to the host (Roquis et al. 2014) and the development of drug 
resistance (Cioli et al. 1989).     
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Oxamniquine (OXA) is structurally similar to hycanthone. In addition to possessing AChE inhibitory 
activity which increases parasite motility upon treatment (Hillman et al. 1975), it is closely associated 
with inhibition of the nucleic acid metabolism of the worm (Abdi 1995). Resistance to OXA has limited 
it use (Cioli et al. 1989) and, while this has been attributed to a mutation in a sulfotransferase, no link 
between resistance and AChE mutation was reported (Valentim et al. 2013). Although highly 
effective, albeit only against S. mansoni (Organization 1993), OXA has more side-effects and is more 
expensive than PZQ and so is being phased out of the world market (Beck et al. 2001). Studies aimed 
at creating safer and cheaper OXA derivatives are currently underway (Valentim et al. 2013). 
 
Another group of anticholinergic drugs studied for their efficacy against Schistosoma was 
phosphonium salts and TAC (Bueding et al. 1967; Levi-Schaffer et al. 1984). The effect of these 
compounds and their derivatives were described to have substantial effects on the catalytic activity 
of AChE and the viability of the various life stages of S. mansoni worms (Bueding et al. 1967; Levi-
Schaffer et al. 1984). 
  
1.1.16 Metal-based drugs in medicine  
Traditionally, the use of organic compounds in the field of medicinal chemistry and pharmaceutics 
has been the primary choice of any medical research (Guo et al. 1999). More recently, metal-based 
complexes have gained great interest as potential therapeutic agents, particularly following the 
remarkable accidental success of the anti-cancer drug cisplatin (Cohen 2007). The principle is that 
inert transition metal complexes, such as ruthenium can replace organic compounds in the targeting 
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of the active sites of enzymes (Debreczeni et al. 2006). One of the main advantages of these metal 
complexes is that they can be more readily prepared because they can be constructed from smaller, 
simpler, and more synthetically accessible components (Bregman et al. 2006). 
 
1.1.16.1 The use of metal-based drugs to combat infectious disease  
Encouraged by the success of many metal-based compounds as anti-tumor and anti-arthritic agents, 
researchers began to investigate their activity against protozoan parasites (Navarro et al. 2010) and 
bacteria (Li et al. 2015).  Some transition metal ions have been used to form coordination complexes 
with the anti-malarial drug chloroquine (Navarro et al. 2010).  Treatment of experimental rodent 
malaria with ruthenium complexes of chloroquine was demonstrated to be more effective than the 
parent drug, reducing the parasitemia levels by 94% compared to 55% at an equivalent concentration 
without producing acute toxicity (Sanchez-Delgado et al. 1996).  
 
There are limited examples of metal complexes that have activity against helminths. The gold complex 
auranofin has been shown to have anti-schistosomal  properties, killing parasites in vitro at a 
concentration of 5 μM and reducing worm burdens by 60% upon treatment of S. mansoni-infected 
mice with 6mg/kg doses of auranofin (twice daily for 9 days beginning at seven weeks post-infection) 
(Kuntz et al. 2007). Auranofin is also documented to kill Taenia crassiceps metacestodes in the culture 
at an LD50 of 3.8 μM. In the case of both flatworms, there is evidence that the gold complex exerts its 
activity by inhibiting the unique platyhelminth redox enzyme thioredoxin-glutathione reductase 
(Kuntz et al. 2007; Bonilla et al. 2008; Angelucci et al. 2009; Martinez-Gonzalez et al. 2010).   
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1.1.16.2 Ruthenium complexes as antimicrobials 
From all the transition metals, ruthenium (Ru) is at the forefront of several critical areas of science, 
including chemotherapy, and some ruthenium (II) polypyridyl complexes have shown significant 
biological activity (Keene et al. 2009; Li et al. 2015) in this regard. This is partly due to the fact that Ru 
complexes have relatively low toxicity, are cost-effective compared to other transition metals, and 
have established synthetic chemistry for establishing octahedral coordination geometries (Meggers 
2009). Also, they exert their biological effect by strongly binding to biological ligands with similar 
exchange kinetics to platinum complexes (Li et al. 2015). Further, the photophysical properties of Ru 
complexes facilitate the cellular accumulation and localization studies by the use of conventional 
techniques such as confocal microscopy and flow cytometry (Keene et al. 2009; Gill et al. 2012). 
 
The antibacterial potential of Ru complexes was documented some six decades ago by Dwyer and co-
workers (Dwyer et al. 1952) and there have been numerous recent studies documenting the efficacy 
of Ru complexes against a variety of different microbial pathogens (Li et al. 2011; Pandrala et al. 2013; 
Gorle et al. 2014).  
 
One of the advantages of using Ru complexes as antimicrobial is that they are significantly less toxic 
to human cells compared to prokaryotic cells. The positively charged Ru complexes are suggested to 
selectively target bacterial cells over eukaryotic cells due to the presence of predominantly negative 
charges on the surface of the bacterial membrane and cell wall (Silhavy et al. 2010). Further, the 
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overall neutral charge in the outer membrane leaflet of eukaryotic cells (Mason et al. 2007) creates a 
significantly reduced capacity for electrostatic interaction with the Ru complexes (Gorle et al. 2016).  
 
In eukaryotes, Ru complexes have been shown to target and inhibit enzymes such as AChE (Vyas et 
al. 2014). These cationic Ru complexes are speculated to bind through a combination of electrostatic 
and hydrophobic interactions at the peripheral anionic (PAS) site of AChE which is located at the gate 
of the enzyme’s catalytic gorge (Bourne et al. 2005; Meggers 2009) and increasing level of AChE 
inhibition have been achieved by making modifications at the periphery of the Ru polypyridine 
scaffold (Mulcahy et al. 2008). 
 
In this project, I will be evaluating the inhibition of schistosome AChE by Ru complexes and exploring 
the anti-parasitic effects of this interaction with a view to developing new chemotherapeutics to 
combat schistosomiasis. 
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CHAPTER 2 
 
Polypyridylruthenium (II) complexes exert anti-schistosome activity through  
inhibition of parasite acetylcholinesterases. 
 
 
 
This chapter has been published in its entirety as: 
(Sundaraneedi et al. 2017) 
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2.1 Introduction 
More than half a billion people are at risk of contracting schistosomiasis (bilharzia), a neglected 
tropical parasitic disease that is endemic in more than 75 countries in Africa, Asia, and South 
America, where over 200 million individuals are infected and approximately 280,000 die every 
year (Gryseels et al. 2006; Hotez et al. 2010; Hotez et al. 2014). Schistosomiasis is caused by 
infection with blood flukes of the genus Schistosoma, and disease results from the deposition of 
eggs in host tissues, leading to granuloma formation that can cause fibrosis, portal hypertension, 
and even death (Hams et al. 2013).  
 
Despite this considerable disease burden, to date, there are no vaccines against schistosomiasis 
(Molehin et al. 2016).  Praziquantel (PZQ) remains the only effective frontline drug to treat the 
parasite despite its shortcomings, which include ineffectiveness against juvenile stages of the 
worm (Vale et al. 2017), poor efficacy in treating pre-patent infections (Seto et al. 2011), reports 
of reduced efficacy in field studies (Wang et al. 2012) and the inevitable risk of the development 
of resistant strains in response to periodic mass drug administration (Bergquist et al. 2017).  Since 
there are no alternative effective drug treatments for these parasites, new therapies are urgently 
required.  
 
Among potential targets for chemotherapy are acetylcholinesterases (AChEs). These enzymes 
catalyze the rapid breakdown of the neurotransmitter acetylcholine (ACh) in both central and 
peripheral nervous systems of eukaryotic organisms, and so control neuronal function (Massoulie 
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et al. 1993).  In addition to controlling cholinergic synapses, the enzyme is present in large 
amounts on the tegument of schistosomes (Tarrab-Hazdai et al. 1984), where it has been 
implicated to play a role in the regulation of host glucose uptake by the parasite by limiting the 
interaction of host ACh with tegumental nicotinic ACh receptors (nAChRs) (Camacho et al. 1995). 
These receptors are associated both spatially and temporally with surface AChE expression and 
are concentrated on the tegument (Camacho et al. 1995), the primary site of glucose uptake 
(Skelly et al. 2014). Evidence for this relationship is shown by the ablation of glucose uptake with 
a membrane-impermeable inhibitor of AChE (which has the same result as the administration of 
an excess of ACh) or specific agonists of nAChRs.  The interaction of ACh with tegumental nAChRs 
is thought to decrease the amount of glucose uptake through surface glucose transporters but 
the specific mechanism for this is not known (Camacho et al. 1995; Camacho et al. 1995). 
 
Concerning its termination of synaptic transmission, inhibition of AChE produces an excess 
accumulation of ACh and overstimulation of its receptors, causing uncoordinated neuromuscular 
function that often results in death due to respiratory paralysis (Thapa et al. 2017). As such, AChE 
inhibitors are widely used as pesticides (Kwong 2002) and anthelmintics (Orhan 2013). Indeed, 
metrifonate, an organophosphate AChE inhibitor initially used as an insecticide has also been 
used for the treatment of schistosomiasis until it was withdrawn from the market and further 
development because of off-target toxicity (Kramer et al. 2014). 
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In addition to organophosphates, mono-nucleated chemical complexes of the transition metal 
ruthenium have been shown to target and inhibit enzymes such as AChE (Vyas et al. 2014), and 
there are numerous recent studies documenting the efficacy of polypyridylruthenium(II) 
complexes against a variety of different microbial pathogens (Li et al. 2011; Pandrala et al. 2013; 
Gorle et al. 2014). Unlike their organophosphate counterparts, ruthenium complexes are 
speculated to exert their inhibitory effects through a combination of electrostatic and 
hydrophobic interactions at the peripheral anionic (PAS) site of AChE, which is located at the gate 
of the enzyme’s catalytic gorge (Bourne et al. 2005), and not through direct interaction with the 
active site. Ruthenium complexes are thought to be less toxic to human cells than small-molecule 
inhibitors because of this mode of inhibition and also because the overall neutral charge in the 
outer membrane leaflet of eukaryotic cells (Mason et al. 2007) creates a greatly reduced capacity 
for electrostatic interaction with the metal compounds (Gorle et al. 2016). 
 
Results of this study demonstrate the AChE-inhibitory action of two mononuclear and a series of 
di-, tri- and tetra-nuclear polypyridylruthenium(II) complexes linked by the bis[4(4'-methyl-2,2'-
bipyridyl)]-1,n-alkane ligand (“bbn”; n = 7, 10, 12 and 16) against extracts of Schistosoma mansoni 
(SmAChE) and Schistosoma haematobium (ShAChE) and both adult and juvenile S. mansoni 
parasites in vitro. Results also provide evidence consistent with the capacity of these complexes 
to disrupt the parasite’s glucose uptake ability through the inhibition of tegumental AChE, a 
cholinergic pathway unique to schistosomes (Camacho et al. 1995; Camacho et al. 1995). Finally, 
experimental results show the in vivo efficacy of two ruthenium complexes in a mouse model of 
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schistosomiasis, providing evidence that drugs based on these compounds could be a valuable 
addition to the chemotherapeutic arsenal against this debilitating disease. 
 
2.2 Methods 
2.2.1 Ethics Statement  
The James Cook University (JCU), animal ethics committee, approved all experimental work 
involving animals (ethics approval number A2271). Mice were raised in cages in the JCU 
quarantine facility for the duration of the experiments in compliance with the 2007 Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes and the 2001 Queensland 
Animal Care and Protection Act. All reasonable efforts were made to minimize animal suffering. 
 
2.2.2 Nomenclature and preparation of ruthenium complexes 
[Ru(phen)2(Me2bpy)]2+ and the mononuclear (Rubbn-mono), dinuclear (Rubbn-di),  
trinuclear (Rubbn-tri), tetranuclear linear (Rubbn-tl) and tetranuclear non-linear (Rubbn-tnl) 
polypyridylruthenium(II) complexes (Fig 8) were synthesized using the appropriate bis[4′-(4-
methyl-2,2′-bipyridyl)]-1,n-alkane bridging ligand (bbn) as previously described (Gorle et al. 
2014). Compounds were dissolved in H2O at stock concentrations of 1 mM.  
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Fig 2.1. The kinetically inert tri-nuclear (Rubbn-tri), linear tetra-nuclear Rubbn-tl and non-linear tetra-nuclear Rubbn-tnl)  
ruthenium (II) complexes. 
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2.2.3 Parasite extract preparation  
S. mansoni cercariae were shed from infected Biomphalaria glabrata snails (Biomedical Research 
Facility, MD, USA) by exposure to light at 28°C for 2 hours. Cercariae were used to infect 6-8 week 
old male BALB/c mice (Animal Resources Centre, WA, Australia) by tail penetration (180 S. 
mansoni cercariae/mouse) and adults were harvested by vascular perfusion at 7 weeks post-
infection (Lewis et al. 1986). S. mansoni eggs were purified from infected mouse livers as 
previously described (Dalton et al. 1997) and were used in the xWORM egg hatching assay or to 
make soluble egg antigen (SEA) (Tucker et al. 2013). For experiments involving schistosomula, S. 
mansoni cercariae were mechanically transformed as previously described (Tucker et al. 2013).  
To make PBS-soluble extracts, S. mansoni adult worms were homogenized in PBS (50 µl/worm 
pair) at 4°C using a TissueLyser II (Qiagen) and the supernatant collected by centrifugation at 
15,000 xg for 60 min at 4°C. Triton X-100-soluble extracts of S. mansoni and S. haematobium 
were made in the same way except worms were lysed in buffer containing 1% Triton X-100, 40 
mM Tris-HCl, pH 7.4. Protein concentration was determined using the Pierce BCA Protein Assay 
kit (Thermofisher), aliquoted and stored at -80°C until use. 
 
2.2.4 Enzyme activity in parasite extracts and inhibition assays  
SmAChE or ShAChE, S. mansoni nucleotide pyrophosphatase-phosphodiesterase 5 (SmNPP5) and 
S. mansoni alkaline phosphatase (SmAP) activity in Triton X-100-soluble adult worm extracts and 
SmAChE activity in SEA were determined in a Polarstar Omega microplate reader (200 µl final 
volume in 96-well plates).  SmAChE and ShAChE activity was determined using the Ellman method 
Chapter 2. Polypyridylruthenium (II) complexes as anti-schistosomals 
 
40 
 
(Ellman et al. 1961); extracts were serially diluted (20 - 5 µg) in AChE assay buffer (0.1 M sodium 
phosphate, pH 7.4), 2 mM acetylthiocholine (ACh) and 0.5 mM 5,5’-dithio-bis(2-nitrobenzoic 
acid) (DTNB) were added and absorbance was measured at 405 nm every 10 min for 5 h at 37°C. 
For SmAChE and ShAChE inhibition assays, parasite extracts equal to a specific activity of 0.55 
nmol/min/well were diluted in AChE assay buffer to a final volume of 170 µl and pre-incubated 
with ruthenium complexes (10 nM – 100 µM) for 20 min at RT.  ACh and DTNB were added at 2 
mM and 0.5 mM, respectively and absorbance was measured at 405 nm every 10 min for 5 h at 
37°C.  SmNPP5 activity (Rofatto et al. 2009) was measured by serially diluting extracts in SmNPP5 
assay buffer (50 mM Tris-HCl, pH 8.9, 120 mM NaCl, 5 mM KCl, 60 mM glucose), adding 0.5 mM 
p-nitrophenyl thymidine 5′-monophosphate (p-Nph-5’-TMP) and reading the absorbance (405 
nm) every 10 min for 5 h at 37°C. For SmNPP5 inhibition assays, parasite extract equal to 32 
nmol/min/well was diluted in SmNPP5 assay buffer to a final volume of 180 µl and pre-incubated 
with ruthenium complexes (10 nM – 100 µM) for 20 min at RT. A substrate (p-Nph-5’-TMP) was 
added to 0.5 mM and absorbance was measured at 405 nm every 10 min for 5 h at 37°C.  SmAP 
activity (Cesari et al. 1981) was measured by serially diluting extracts in AP assay buffer (0.1 M 
glycine, pH 10.4, 1 mM MgCl2, 1 mM ZnCl2), adding 2 mM p-nitrophenyl phosphate (pNPP) and 
measuring absorbance at 405 nm every 2 min for 1 h at 37°C.  For SmAP inhibition assays, parasite 
extract equal to 1 nmol/min/well was diluted in AP assay buffer to a final volume of 180 µl and 
pre-incubated with ruthenium complexes (10 nM – 100 µM) for 20 min at RT. A substrate (pNPP) 
was added to 2 mM and absorbance was measured at 405 nm every 2 min for 1 h at 37°C. For all 
kinetic enzyme assays, specific activity was calculated using the initial velocity of the reaction. 
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For all assays, inhibition for each sample was calculated relative to the negative control (reactions 
without ruthenium complexes) and reactions were performed in duplicate with data presented 
as the average ± SEM. 
 
2.2.5 Effect of ruthenium complexes against larval S. mansoni parasites 
Newly-transformed schistosomula (100 parasites) were cultured (37°C, 5% CO2) in 200 µl of 
Basch medium supplemented with 4× antibiotic/antimycotic (AA - 200 units/ml penicillin, 200 
µg/ml streptomycin and 0.5 µg/ml amphotericin B) in a 96 well plate in the presence of a series 
of serially-diluted ruthenium complexes (100 µM – 10 nM). After 48 h, parasite viability was 
assessed microscopically by Trypan Blue exclusion staining as previously described (Wangchuk et 
al. 2016).  Six of the most effective compounds were tested again for their larvacidal efficacy (100 
schistosomula per treatment); this time at concentrations of 200, 100, 50, 25, 12.5 and 6.25 μM. 
Experiments were performed in duplicate with IC50 data presented as the average ± SEM.  
 
2.2.6 Effect of ruthenium complexes against adult S. mansoni parasites 
Five pairs of adult worms were cultured in 2 ml of Basch medium supplemented with 4x AA in a 
24 well plate in the presence of ruthenium complexes (50 µM). Control worms were treated with 
an equal amount of H2O. Worms were cultured at 37°C and 5% CO2 for 7 days, monitored every 
24 h for motility by microscopic examination and considered dead if no movement was seen. The 
most effective ruthenium complexes (5 compounds) were tested in duplicate (five pairs of worms 
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each) at 10, 50 and 100 µM. Data are presented as the average of each duplicate experiment ± 
SEM. 
 
2.2.7 Effect of ruthenium complexes on S. mansoni egg hatching and development 
Egg hatching was evaluated by the xWORM egg hatching assay (Rinaldi et al. 2015). Ova (5,000 
per well, 200 µl reaction volume) were incubated in 0.1x PBS, pH 7.2, containing ruthenium 
complexes (50 µM) and induced to hatch under bright light at RT for 16 h. The motility of the 
miracidia released from the hatched eggs was monitored every 15 s and the motility index was 
calculated as described (Rinaldi et al. 2015). Experiments were performed in triplicate with 
control reactions containing no ruthenium compounds. To investigate the effects of ruthenium 
complexes on egg development, triplicate sets of five pairs of adult S. mansoni worms were 
cultured in Basch media with or without 5 µM Rubb12-tri, for 72 h. The eggs released into the 
media were counted and misshapen, malformed or immature eggs (Pellegrino et al. 1962) were 
scored as “abnormally developed”.  Egg hatching and morphology data is presented as the 
average of each triplicate experiment ± SEM. 
 
2.2.8 Assessment of enzyme inhibitory effects induced by treatment of worms with ruthenium 
complexes 
Freshly perfused worms were cultured in the presence of sub-lethal concentrations (5 µM) of 
Rubb12-tri or Rubb16-tnl - two ruthenium compounds determined to be most effective in terms 
of their combined activity against schistosomula, adult worms and eggs – in Basch medium at 
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37°C and 5% CO2. To measure surface SmAChE or SmAP activity, 5 pairs of worms (preliminary 
experiments by us showed this number of parasites was sufficient to accurately measure surface 
enzyme activity) were transferred to either AChE assay buffer (0.1 M sodium phosphate, pH 7.4, 
2 mM ACh, 0.5 mM DTNB) or AP assay buffer (0.1 M glycine, pH 10.4, 1 mM MgCl2, 1 mM ZnCl2, 
2mM p-nitrophenyl phosphate). Surface enzyme activities were quantified by measuring the 
absorbance at 405 nm after incubation for 60 min (SmAChE) or 30 min (SmAP).  Activity was 
measured from triplicate sets of parasites (5 pairs of worms) and each assay was technically 
replicated three times. For each enzyme assay, activities of drug-treated parasites were 
expressed relative to worms cultured without ruthenium complexes (negative controls). To 
measure somatic SmAChE activity, PBS-soluble extracts were made from worms used for surface 
SmAChE activity (triplicate sets of five pairs of worms) and then assayed in triplicate as described 
above. Data are presented as the average of each triplicate biological and technical experiment 
± SEM. 
 
2.2.9 Effect of glucose uptake and glycogen storage on worms treated with ruthenium 
complexes 
Five pairs of freshly-perfused worms were cultured in the presence of sub-lethal concentrations 
(5 µM) of Rubb12-tri or Rubb16-tnl in DMEM (1 mg/ml glucose). Media (50 µl) from each 
experiment was collected after 24 h and the amount of glucose was quantified using a 
colorimetric glucose assay kit (Sigma) according to the manufacturer’s instructions. Media was 
collected from triplicate sets of parasites (five pairs of worms) and each assay was replicated 3 
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times. Glucose levels were expressed relative to media collected from worms which received no 
drug (negative control). Data is presented as the average of each triplicate biological and 
technical experiment ± SEM.  To measure the glycogen content of worms treated with ruthenium 
drugs, Triton X-100-soluble extracts were made and assayed for glycogen in a modified procedure 
described by Gomez- Lechon et al. (Gómez-Lechón et al. 1996). Briefly, 0.2 M sodium acetate, pH 
4.8, was added to 30 μg parasite extract and 50 μl glucoamylase (10 U/ml) to make a reaction 
volume of 150 μl. The mixture was incubated at 40°C for 2 h with shaking at 100 rpm, 40 μl added 
to a new microplate with 10 μl 0.25 M NaOH and the amount of glucose quantified using the 
colorimetric glucose assay kit. Extracts were made from triplicate sets of parasites (five pairs of 
worms) and assays were performed three times.  Data is presented as the average of each 
triplicate biological and technical experiment ± SEM.   
 
2.2.10 Scanning electron microscopy 
Control parasites and worms treated with 5 µM Rubb12-tri were prepared for scanning electron 
microscopy by fixation in 3% glutaraldehyde followed by successive dehydration for  15 min each 
in a graded ethanol series (100%, 90%, 80%, 70%, 60%, 50%), 1:1 ethanol:hexamethyldisilizane 
(HMDS) and, finally, 100% HMDS. Dehydrated worms were covered and left overnight in a fume 
hood to allow the HMDS to evaporate then mounted on an aluminum stub, sputtered with gold 
and visualized using a JEOL JSM scanning electron microscope operating at 10 kV. Images were 
acquired digitally using Semaphore software. 
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2.2.11 Cytotoxicity assays 
Cytotoxicity assays were performed using the mitochondrial-dependent reduction of 3-(3,4-
dimethylthiazol-2yl)-5-diphenyl tetrazolium bromide (MTT) to formazan as described by Pandrala   
(Pandrala et al. 2015).  The human bile duct cell line H69 was cultured in 96-well microtiter plates 
containing 0.1 ml of growth factor-supplemented media (DMEM/F12 with high glucose (4 
mg/ml), 10% FCS, 1×AA, 25 μg/ml adenine, 5 μg/ml insulin, 1 μg/ml epinephrine, 8.3 μg/ml holo-
transferrin, 0.62 μg/ml hydrocortisone, 13.6 ng/ml triiodo-1-thyronine (T3) and 10 ng/ml 
epithelial growth factor (EGF)) (Smout et al. 2015) to a cell density of 5,000 per well at 37°C in 5% 
CO2.  Cell viability was assessed after continuous exposure to a concentration series (50, 25, 10, 
5, 1, 0.5 and 0.1 μM) of Rubb12-tri, Rubb16-tnl, PZQ or Dichlorvos (DDVP) – a metabolite of the 
anti-schistosome AChE inhibitor metrifonate - for 72 h. The amount of reduced MTT to formazan 
within the cells was quantified by measuring the absorbance at 550 nm. Data are the average of 
six replicate experiments ± SEM. 
 
2.2.12 Tolerability study 
In order to determine the maximum tolerated dose of Rubb12-tri and Rubb7-tnl to be 
administered to mice infected with S. mansoni, five intravenous (i.v.) doses (tail vein) of Rubb12-
tri and Rubb7-tnl were given to groups of three male BALB/c mice (6-8 weeks) daily for five 
consecutive days. The doses ranged from 0.25 to 10 mg/kg in PBS and were administered in a 
volume of 30 μl. Animals were closely monitored for adverse clinical signs throughout the study 
and mice showing adverse effects were euthanized using CO2 asphyxiation. The highest dose that 
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did not cause any adverse clinical signs was considered to be the maximum tolerated dose (MTD) 
for five consecutive daily doses. 
 
2.2.13 In vivo efficacy of ruthenium complexes 
Groups of 8 male BALB/c mice (6-8 weeks) were infected with S. mansoni cercariae as described 
above. At 35 days post-infection, groups were given five consecutive daily i.v. doses (tail vein - 30 
μl) of the MTD of either Rubb12-tri (2 mg/kg in PBS) or Rubb7-tnl (10 mg/kg in PBS). PBS was 
similarly administered to the control group. Two independent trials were performed.  Parasites 
were harvested by vascular perfusion at 49 days post-infection and the average worm burden 
per mouse for each group of mice (trial 1 PBS control – n = 8 mice, trial 1 Rubb12-tri-treated – n = 
8 mice, trial 1 Rubb7-tnl-treated – n = 6 mice, trial 2 PBS control – n = 7 mice, trial 2 Rubb12-tri-
treated – n = 7 mice, trial 2 Rubb7-tnl-treated – n = 8 mice) was calculated.  Data is presented as 
a combination of the two independent trials ± SE.  Livers from each group (trial 1 PBS control – n 
= 8 mice, trial 1 Rubb12-tri-treated – n = 8 mice, trial 1 Rubb7-tnl-treated – n = 6 mice,  trial 2 PBS 
control – n = 7 mice, trial 2 Rubb12-tri-treated – n = 7 mice, trial 2 Rubb7-tnl-treated – n = 8 mice) 
were collected, halved and weighed, with one half digested with 5% KOH to determine liver eggs 
per gram of tissue (EPG) as previously described (Tran et al. 2006). The other half of each liver 
was pooled according to group, homogenized in H2O and placed in identical foil-covered 
volumetric flasks under bright light to hatch eggs released from the livers. After 1 h, the number 
of miracidia in 10 x 50 μl aliquots of H2O (sampled from the extreme top of each flask) were 
counted.  The amount of eggs in each flask at the start of the hatching experiment was 
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determined by liver EPG calculations, allowing the egg hatching index of each group to be 
calculated by expressing the hatched eggs (miracidia) as a percentage of the total eggs. Data 
presented is for trial 1 only and represents the average of ten counts ± SEM.  To assess fitness of 
parasites recovered from mice treated with ruthenium complexes compared to controls, worms 
recovered from each group were pooled and five pairs were assayed for surface enzyme activity 
(SmAChE, SmNPP5 and SmAP) or glucose uptake ability as described above.  Somatic SmAChE 
activity was determined from homogenates made from the worms assayed for surface SmAChE 
activity, also as described above. Each assay was technically replicated three times and data is 
presented as the average of triplicate technical replicates of both trials combined ± SEM. To 
compare eggs released from parasites recovered from mice treated with ruthenium complexes 
and controls, triplicate sets of worms (five pairs) from each pool were incubated in Basch media 
at 37°C in 5% CO2 for 72 h.  The number of eggs released were counted and scored on the basis 
of development and morphology (Pellegrino et al. 1962) by visualization under a FITC filter on a 
Zeiss AxioImager-M1 fluorescent microscope.  Data presented is for trial 2 and is the average of 
triplicate experiments ± SEM. 
 
2.2.14 Statistical analyses 
Statistical analyses were performed using GraphPad Prism 7.  Inhibition curves and IC50 values 
were generated using sigmoidal dose-response (variable slope) with a non-linear fit model. One-
way ANOVA with Dunn’s multiple comparisons was used to determine significance (p), which was 
set at 0.05. In the case where only two groups were compared, student’s t test was used.  
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2.3 Results 
2.3.1 Inhibition of AChE in schistosome extracts by ruthenium complexes 
A series of ruthenium complexes of different nuclearity (mono-, di-, tri- and tetra-linear and tetra-
nonlinear) and with different chain lengths in the linking ligand (bb7, bb10, bb12, bb16) were 
screened (1 µM) for AChE inhibitory activity in Triton X-100-soluble extracts from adult S. 
mansoni and S. haematobium and S. mansoni soluble egg antigen (SEA) (Table 2.1). In S. mansoni 
extracts, all tri- and tetra-nuclear complexes inhibited AChE activity by 70-90% and 7 of the 13 
compounds had IC50 values ≤ 1 µM. A dose-response curve and Lineweaver-Burk plot is shown 
for the most potent of these complexes (Rubb12-tri, IC50 = 0.3 µM) (Fig 2.2). 
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Table 2. 1. Inhibition of acetylcholinesterase (AChE) activity in adult S. mansoni and S. haematobium Triton X-100-soluble extracts 
 and S. mansoni soluble egg extract (SEA) by a series of ruthenium complexes.  
Compound  S. mansoni extract S. haematobium extract S. mansoni SEA 
AChE  Inhibition 
(%)a, b 
IC50 (µM)b AChE  Inhibition 
(%)a, b 
IC50 (µM)b AChE  Inhibition 
(%)a, b 
IC50 (µM)b 
Ru(phen)2(Me2bpy) 9.3 ± 1.8 67.0 ± 11.6 13.3 ± 1.8 90.2 ± 1.2 66.5 ± 5.8 ND 
Rubb12-mono 11.1 ± 0.8 18.9 ± 2.8 52.2 ± 0.5 1.1 ± 0.1 73.5 ± 4.9 ND 
Rubb12-di 73.9 ± 0.5 1.6 ± 0.3 20.9 ± 0.2 16.8 ± 0.4 94.2 ± 0.8 ND 
Rubb7-tri 84.3 ± 4.5 0.4 ± 0.0 37.2 ± 0.3 0.4 ± 0.0 77.5 ± 0.6 ND 
Rubb10-tri 78.7 ± 0.7 0.5 ± 0.0 73.6 ± 2.0 3.0 ± 0.0 91.3 ± 0.3 ND 
Rubb12-tri 89.4 ± 0.4 0.3 ± 0.0 87.6 ± 0.4 0.7 ± 0.0 96.3 ± 1.4 0.2 ± 0.0 
Rubb16-tri 46.8 ± 1.1 1.9 ± 0.0 31.6 ± 0.5 18.0 ± 0.1 89.7 ± 0.1 ND 
Rubb7-tl 73.4 ± 1.5 1.0 ± 0.0 24.8 ± 0.3 36.4 ± 4.4 78.7 ± 8.0 ND 
Rubb12-tl 89.9 ± 1.6 0.3 ± 0.0 55.4 ± 2.6 1.0 ± 0.1 97.2 ± 0.6 0.2 ± 0.0 
Rubb16-tl 76.3 ± 1.6 2.4 ± 0.1 59.3 ± 0.1 1.9 ± 0.1 90.8 ± 0.2 ND 
Rubb7-tnl 84.0 ± 0.6 0.9 ± 0.1 19.5 ± 0.3 ND 98.1 ± 0.3 ND 
Rubb12-tnl 80.0 ± 0.1 0.4 ± 0.0 75.9 ± 2.5 3.2 ± 0.0 92.7 ± 0.3 0.3 ± 0.0 
Rubb16-tnl 73.0 ± 0.8 2.3 ± 0.1 51.1 ± 6.0 ND 89.6 ± 0.1 ND 
ainhibition of Sm-AChE activity assessed at 1µM. 
bdata represents the mean of duplicate experiments ± SEM
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Fig 2.2. Effect of ruthenium complexes on SmAChE activity in adult S. mansoni extracts.  
Concentration-dependent inhibition of SmAChE activity in S. mansoni adult extracts when treated 
with Rubb12-tri, a representative member of the ruthenium complexes tested, as determined by 
Ellman assay. (A) Dose-response curve of Rubb12-tri. (B) Lineweaver-Burk inhibition plot of SmAChE 
activity in S. mansoni adult extracts in the presence of Rubb12-tri. Data represent the average of 
triplicate experiments ± SEM. 
 
Interestingly, a different pattern of inhibition by the ruthenium complexes was observed against 
ShAChE activity with the IC50 values being considerably more varied than was observed for 
SmAChE activity, and not all compounds showed correlated potency between the two species. In 
addition, there was more variability among the tri- and tetra-nuclear complexes with the more 
lipophilic complexes (e.g. Rubb10-tri and Rubb12-tri) having stronger inhibitory activity. Rubb12-
mono, Rubb12-tri and Rubb12-tnl showed greater activity and the IC50 values of these complexes 
were less than 1 µM.  Overall, ruthenium compounds displayed a similar pattern of inhibition 
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against SmAChE activity in S. mansoni egg versus adult extracts, although most complexes 
showed a stronger inhibitory capacity towards SmAChE activity in SEA with three compounds 
(Rubb12-tri, Rubb12-tl and Rubb7-tnl) achieving >95% inhibition. 
 
In order to examine the selectivity for SmAChE, the series of ruthenium complexes was screened 
(10 µM) against S. mansoni extract for inhibition of two major tegumental enzymes –SmNPP5 
and SmAP. None of the compounds strongly inhibited activity of either enzyme at 10 µM, a 
tenfold higher concentration than was used for the SmAChE inhibition assays (Table 2.2). 
 
Table 2.2. Inhibition of SmNPP-5 and alkaline phosphatase activity in adult S. mansoni Triton X-
100-soluble extracts by a series of ruthenium complexes.  
Compound SmNPP-5 Inhibition (%)a AP Inhibition (%)a 
Ru(phen)2(Me2bpy) 2 3 
Rubb12-mono 15 2 
Rubb12-di 1 1 
Rubb7-tri 9 1 
Rubb10-tri 12 8 
Rubb12-tri 2 4 
Rubb16-tri 15 6 
Rubb7-tl 13 2 
Rubb12-tl 3 2 
Rubb16-tl 26 1 
Rubb7-tnl 13 1 
Rubb12-tnl 24 1 
ainhibition of enzyme activities assessed at 10 µM. 
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2.3.2 In vitro effect of ruthenium complexes on larval S. mansoni parasites 
The entire series of Ru complexes were screened for their larvacidal activity against S. mansoni 
schistosomula with IC50 values calculated for the most effective compounds in a separate 
experiment. (Table 2.3).   
  
Table 2.3. Potency of selected ruthenium complexes against S. mansoni schistosomula after 48 h 
treatment. 
                 
 
 
 
 
 
 
1data represents the mean of duplicate experiments ± SEM 
 
2.3.3  In vitro effect of ruthenium complexes on adult S. mansoni parasites 
S. mansoni worms were cultured in the presence of 50 µM of each ruthenium complex to 
investigate their effectiveness in killing adult parasites, which was assessed by lack of motility. 
The effects of selected compounds on worm survival is shown in Fig 2.3A. Similar to the enzyme 
inhibition in parasite extracts, the tri-and tetra-nuclear complexes were the most effective 
Compound  IC50 (µM)1 
Rubb12-tri 45.1 ± 4.8 
Rubb12-tl 68.5 ± 3.6 
Rubb12-tnl 42.8 ± 1.2 
Rubb7-tl 81.3 ± 0.6 
Rubb7-tnl 30.3 ± 2.0 
Rubb16-tnl 27.3 ± 0.4 
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compared to the mono- and di-nuclear complexes. The killing ability increased with the increasing 
number of ruthenium centers in the complex, and the tetra-nonlinear complexes were more 
active in comparison with their linear counterparts. As with the schistosomula killing experiment, 
the most effective compounds (five) were tested again, this time at concentrations of 100 µM, 
50 µM and 10 µM (Fig 2.3B). All tri-and tetra-nuclear complexes (10 µM) killed 100% of the 
parasites in six days. Treatment with the ruthenium complexes induced significant changes in the 
gross morphology of the parasites (Fig 2.3C).  In particular, a tight coiling of the treated worms 
was observed. 
 
Fig 2.3. Activity of ruthenium complexes against adult S. mansoni worms. (A) Selective 
representation of survival of parasites (cultured in Basch media) after treatment with Ru complexes 
(50 µM).  Data represents the average of duplicate experiments ± SEM.  (B) Survival of parasites 
(cultured in Basch media) after treatment with various concentrations of the most potent 
ruthenium complexes determined from the screening experiment. Data represents the average of 
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duplicate experiments ± SEM. (C) Alteration in general morphology of adult S. mansoni worms 
caused by ruthenium complexes. I: control parasites; II:  parasites treated with Rubb12-tri. 
 
2.3.4  In vitro effect of ruthenium complexes on S. mansoni egg hatching and development 
S. mansoni egg hatching in the presence (50 µM) of ruthenium complexes was investigated by 
measuring the motility index of hatched miracidia from eggs using the xWORM assay (Fig 2.4A). 
Significant reduction in hatching/motility was observed for 9/13 compounds tested.  Rubb12-tnl 
was the most effective, reducing the motility index by 67% (P < 0.0001).  To analyze the effect of 
ruthenium complexes on egg development, the eggs released from worms incubated for 3 days 
in the presence of 5 µM Rubb12-tri were scored for morphology.  Eggs released from treated 
worms were abnormally developed (immature or misshapen) compared to controls (Fig 2.4B; P 
< 0.01). 
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Fig 2.4. Inhibition of S. mansoni egg hatching and effect on egg development by ruthenium 
complexes.  (A) Graph representing the percentage of S. mansoni eggs hatched (motility index) in 
the presence of various ruthenium complexes (50 µM) as determined by the x-WORM motility 
assay.  Data represents the average of triplicate experiments ± SEM. (B) Triplicate sets of five pairs 
of adult S. mansoni worms were cultured in Basch media with or without 5 µM Rubb12-tri for 72 h. 
The eggs released into the media were counted and those that were misshapen or immature were 
scored as “abnormally developed”. Graph shows the difference in percentage of normally 
developed eggs between treated and control groups and data represents the average of triplicate 
experiments ± SEM. Differences in egg hatching were measured by ANOVA and differences in egg 
development by t test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001,****P ≤ 0.0001. 
Chapter 2. Polypyridylruthenium (II) complexes as anti-schistosomals 
 
56 
 
2.3.5  Mechanism of anti-schistosome action of Rubb12-tri and Rubb16-tnl 
Adult worms were cultured in the presence of sub-lethal concentrations (5 µM) of Rubb12-tri or 
Rubb16-tnl - the two ruthenium compounds deemed to be most effective at killing adult parasites 
– for 24 h and then examined for changes in surface and somatic SmAChE activity and glucose 
uptake (given this pathway can be ablated by an organophosphorus AChE inhibitor). Treated 
worms showed significantly decreased levels of surface and somatic SmAChE activity in the 
presence of each complex (Fig 2.5A and 2.5B) however, consistent with enzyme inhibition 
experiments using parasite extracts, AP activity was not significantly affected (Fig 2.5C).  
 
Fig 2.5. Action of Rubb12-tri and Rubb16-tnl on adult SmAChE and SmAP activity.  
Five pairs of worms were cultured in Basch media for 24 h in the presence of a sub-lethal dose (5 
µM) of Rubb12-tri or Rubb16-tnl and then incubated in AChE assay buffer or AP assay buffer. PBS 
extracts were then made from equal amounts of control and treated worms and 30 µg of each 
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extract was used to determine somatic SmAChE activity by the Ellman method. (A) Surface SmAChE 
(B) somatic SmAChE and (C) surface SmAP activity of control worms and worms treated with 
Rubb12-tri or Rubb16-tnl. For all assays, data are the average of triplicate biological and technical 
experiments ± SEM. Differences were measured by ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
**** P ≤ 0.0001. 
 
The amount of glucose in the media of parasites treated with either complex was significantly 
higher than control worms (Fig 2.6A), suggestive of impaired glucose uptake in the presence of 
ruthenium compounds. Consistent with these results, extracts of treated parasites had a 
significantly lower glycogen content compared to controls (Fig 2.6B).  Moreover, scanning 
electron micrographs of the tegument of male parasites treated with Rubb12-tri or Rubb16-tnl 
showed the dorsal tubercules (a site of glycogen storage (Bueding et al. 1967)) to be withered 
and flattened (Fig 2.6C). 
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Fig 2.6. Effect of Rubb12-tri and Rubb16-tnl on adult S. mansoni glucose uptake and storage ability.  
Worms were cultured in Basch media for 24 h in the presence of a sub-lethal dose (5 µM) of Rubb12-
tri or Rubb16-tnl. Worms were then incubated for 24 h in DMEM containing 1 mg/ml glucose. PBS 
extracts were then made from equal amounts of control and treated worms and 30 µg of each 
extract was used to determine the glycogen content of the worms using a modified glucose oxidase 
assay. (A) Amount of glucose in media collected from control and treated S. mansoni worms.  (B) 
Levels of glycogen in extracts made from control and treated S. mansoni worms. For all assays, data 
are the average of triplicate biological and technical experiments ± SEM. Differences were 
measured by ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. (C) Scanning electron 
micrographs of adult male S. mansoni worm tegument after incubation with 5 µM Rubb12–tri; (I) 
intact tubercles of control worms; (II) withered tubercules of treated worms.  
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2.3.6 Toxicity of Rubb12-tri and Rubb7-tnl  
The toxicity of Rubb12-tri and Rubb7-tnl, two of the ruthenium complexes shown to have high in 
vitro efficacy against all schistosome stages tested, was assessed against human bile duct cells 
and in male BALB/c mice (6-8 weeks) before investigating their in vivo efficacy in a mouse model 
of schistosomiasis. PZQ and DDVP - a metabolite of the anti-schistosome AChE inhibitor 
metrifonate – were included in the study for comparison.  When Rubb12-tri and Rubb7-tnl were 
used at 5 µM, a concentration where they significantly inhibited surface and somatic SmAChE 
activity and glucose uptake in adult worms, cell viability was 42% and 73% for Rubb12-tri and 
Rubb7-tnl, respectively. The EC50 values of Rubb12-tri and Rubb7-tnl were calculated as 3.489 ± 
0.532 µM and 6.829 ± 0.625 µM, respectively.  DDVP was highly toxic to the cells, killing 100% of 
the cells even at 0.1 µM (Fig 2.7).  To determine the MTD in mice, Rubb12-tri or Rubb7-tnl was 
administered to groups of male BALB/c mice (6-8 weeks).  Rubb7-tnl did not show any toxicity 
even after five consecutive daily injections (the proposed dosage frequency of the in vivo drug 
efficacy study) of 10 mg/kg (mice were adversely affected at doses of 20 mg/kg) and so the MTD 
of Rubb7-tnl was considered to be at least 10 mg/kg.  The MTD of Rubb12-tri, using the same 
dosage frequency, was determined to be 2 mg/kg (mice were adversely affected at doses of 4 
mg/kg).  If 100% bioavailability is assumed due to i.v. administration, the host bloodstream 
concentrations of Rubb7-tnl and Rubb12-tri at the MTD can be approximated at 12 µM and 49 µM, 
respectively.  
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Fig 2.7. Cytotoxicity of ruthenium complexes.  
Toxicity against human bile duct cells (H69) after 72 h incubation with Rubb12-tri or Rubb7-tnl, PZQ 
and DDVP – an organophosphate AChE inhibitor - as determined by the MTT cell viability assay. 
Data are the average of six replicate experiments ± SEM. 
 
2.3.7 In vivo efficacy of Rubb12-tri and Rubb7-tnl 
Over two independent trials, a significant reduction in worm burden (42%, P = 0.009) was seen 
in mice treated with Rubb12-tri compared to controls whereas a non-significant trend towards 
decreased worm burden was observed in Rubb7-tnl-treated mice (Fig 2.8A). Surface SmAChE 
activity was decreased in worms collected from mice treated with ruthenium complexes but only 
reached significance for Rubb12-tri-treated animals (Fig 2.8B).  Surface SmNPP5, surface SmAP, 
somatic SmAChE and glucose uptake activity was not significantly different.  
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Although there was no decrease in parasite egg burden (as determined by recovery of ova from 
the liver), the viability of these eggs from trial 1 was examined and highly significant (P < 0.0001) 
reductions in hatching capability (68% and 56%) were observed for the Rubb12-tri- and Rubb7-tnl-
treated mice, respectively (Fig 2.8C). Egg hatching viability was not determined for trial 2.  
Moreover, eggs released from worms recovered from treated mice (trial 2) were significantly 
different (P < 0.0001) in terms of their development (immature, misshapen, eggshell 
malformation) compared to those from parasites recovered from control mice (Fig 2.8D and 
2.8E).  Morphology of eggs released from worms recovered from mice in trial 1 was not 
determined.   
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Fig 2.8. In vivo effect of Rubb12-tri and Rubb7-tnl on S. mansoni-infected mice. 
 (A) Effect of Rubb12-tri and Rubb7-tnl on adult worm burden. Symbols represent data from 
individual mice and are the combination of two independent trials (trial 1 PBS control – n = 8 mice, 
trial 1 Rubb12-tri-treated – n = 8 mice, trial 1 Rubb7-tnl-treated – n = 6 mice, trial 2 PBS control – n 
= 7 mice, trial 2 Rubb12-tri-treated – n = 7 mice, trial 2 Rubb7-tnl-treated – n = 8 mice). (B) Surface 
SmAChE activity of worms recovered from control and treated mice. Data are the average of 
triplicate technical assays ± SEM on extracts made from worms (five pairs) pooled from each group 
of each of the two trials. (C) Hatching viability of eggs obtained from the pooled livers of control 
and treated mice from trial 1 (PBS control – n = 8, Rubb12-tri-treated – n = 8, Rubb7-tnl-treated – n 
= 6). Data are the average of ten replicate counts ± SEM of hatched miracidia. (D) Eggs were 
harvested from triplicate sets of worms (five pairs) from a pool of each group of trial 2 (PBS control 
– n = 7 mice, Rubb12-tri-treated - n = 7 mice, Rubb7-tnl-treated – n = 8 mice) after culturing the 
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parasites for 24 h in Basch media and the percentage of mature, morphologically “normal” eggs 
released from worms recovered from control and treated mice was assessed. Data are the average 
counts ± SEM of eggs released from triplicate sets (five pairs) of worms from trial 2. Differences 
were measured by ANOVA. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, **** P ≤ 0.0001. (E) Auto-
fluorescence images (20×) of eggs released from worms recovered from (I and II) control and (III 
and IV) treated mice.  
 
2.4 Discussion 
Control of schistosomiasis, a neglected tropical disease which affects over 200 million people, 
relies on periodic treatment with single drug, PZQ, a strategy that is unsustainable in its current 
form (Seto et al. 2011; Wang et al. 2012; Vale et al. 2017). As no new anti-schistosome drug (or 
any anti-parasitic) has  been registered in the last decade (Pedrique et al. 2013), the need for 
additional therapeutic compounds has become unquestionable and has driven research efforts 
towards the discovery of alternative anti-schistosome chemotherapies, including those derived 
from natural products (Wangchuk et al. 2016) and metal-based compounds (Kuntz et al. 2007).  
Accordingly, this study has described the anti-schistosome efficacy of a series of mono- and multi-
nucleated metal-based compounds (ruthenium complexes) which exert their action through the 
inhibition of AChE, an enzyme pivotal to the control of worm neuromuscular function and 
implicated in the mediation of host glucose scavenging (Camacho et al. 1995; Arnon et al. 1999). 
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It has been previously shown that mononuclear ruthenium complexes inhibit AChE (E. electricus) 
by a non-competitive or mixed mode of inhibition (Vyas et al. 2014). However, in the present 
study, the trinuclear complex (Rubb12-tri) displayed a competitive mode of inhibition in the 
kinetic experiments. The mononuclear polypyridylruthenium(II) complexes are thought to 
interact with the peripheral anionic site (PAS) of AChE located at the rim of the active-center 
gorge through a combination of electrostatic and hydrophobic interactions (Meggers 2009).  The 
tri- and tetra-nuclear complexes showed greater activity compared to mononuclear complexes, 
presumably due to the presence of the flexibly-linked multiple metal centers which may provide 
more interactions (electrostatic and hydrophobic) with the PAS, or each individual center may 
contribute nonspecific additional points of contact. The activity of the ruthenium complexes 
varied in extracts made from different life stages (adult extracts and SEA) and various species of 
the parasite which is most likely due to differences in enzyme orthologs and the existence of 
multiple paralogs at least in S. mansoni (Chapter 3)  which are present in different life stages and 
species (Arnon et al. 1999).  
 
Encouraged by the activity of ruthenium complexes against parasite extracts, selected 
compounds were tested against all three intra-mammalian stages of the parasite in vitro and 
found similar trends in anti-parasite activity as was seen for extracts; i.e., the tri- and tetra-
nucleated complexes were more effective against each stage of the parasite than the mono- and 
di-nuclear compounds.  Three of the most effective compounds in terms of their combined 
activity against S. mansoni extracts and all intra-mammalian stages were Rubb7-tnl, Rubb12-tri 
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and Rubb16-tnl.  Further, Rubb12-tri was also the most effective at inhibiting AChE activity in S. 
haematobium extracts; availability of material prevented us from doing any experiments on live 
parasites or eggs but I believe that that the similar trends observed between S. mansoni anti-
parasitic activity and extract activity hold true for S. haematobium and ruthenium complexes 
such as Rubb12-tri would display potent anti-schistosome activity against this species. Further, S. 
haematobium has higher levels of tegumental AChE than S. mansoni, which makes the parasite 
more sensitive to AChE inhibitors (Camacho et al. 1994) and might render this species more 
vulnerable to ruthenium drugs.  
 
Any differences observed between the AChE-inhibitory ability and anti-schistosome effect of 
ruthenium complexes could be due to the target of these drugs not solely being AChE. While I 
showed that ruthenium complexes did not have any inhibitory effects on the major tegumental 
enzymes SmNPP5 and SmAP, these drugs have been documented to act as dual inhibitors of 
telomerase and topoisomerase (Liao et al. 2015), thioredoxin reductase (Luo et al. 2014) and 
protein and lipid kinases (Meggers 2009).  There are numerous reports in the literature 
documenting the development of drug resistance in parasites due to mutation (for example, 
benzamidazole resistance in nematodes due to single nucleotide polymorphisms in β-tubulin 
(Von Samson-Himmelstjerna et al. 2007) and mutation of a schistosome sulfotransferase 
resulting in resistance to oxamniquine (Valentim et al. 2013), and so the use of a drug that is 
directed against multiple molecular targets may decrease the chance of resistance evolving.         
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Visually, the effects of the compounds were most pronounced against adult worms, which 
became immobile and coiled when incubated with ruthenium complexes, possibly due to 
paralysis induced by SmAChE inhibition and cholinergic accumulation, effects similarly seen in 
schistosomes treated with other inhibitors of SmAChE (Bueding et al. 1972; Hillman et al. 1975; 
Pax et al. 1981). This observation should be treated with caution, however, as other drugs, such 
as PZQ (which is not a SmAChE inhibitor), induce the same morphological changes. Additional 
evidence of the mechanistic effects of ruthenium complexes on schistosomes manifested in the 
reduced glucose uptake observed in drug-treated worms, potentially a consequence of inhibiting 
the tegumental SmAChE-mediated regulation of host glucose scavenging, a pathway unique to 
schistosomes (Camacho et al. 1995). Further confirmation of this inhibition was evidenced by 
significantly depleted glycogen stores (quantified in parasite extracts and observed by the 
withering of male tubercules – a site of glycogen storage (Bueding et al. 1967)) in these parasites, 
an effect seen in worms recovered from mice treated with carbamate-based AChE inhibitors 
(Bueding et al. 1967). In another example of tegument-mediated glucose regulation, previous 
work by You and colleagues (You et al. 2010) has shown that inhibition of schistosome insulin 
receptor activity significantly decreased glucose uptake by the parasite. It would be interesting 
to explore any relationship that existed between these two regulatory mechanisms, a possibility 
given the alternative is to imagine the evolution of two mechanistically distinct pathways of 
glucose regulation. Additionally, a combination chemotherapeutic strategy could be developed 
using drugs which target different aspects of schistosome glucose uptake.   
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Two of the ruthenium complexes which was considered most effective in vitro (Rubb12-tri and 
Rubb7-tnl) were tested for cytotoxicity before assessment of their in vivo efficacy in a mouse 
model of schistosomiasis. Rubb16-tnl, even though effective in vitro, was not included in the 
cytotoxicity assay or the in vivo study as earlier work by us has shown that ruthenium complexes 
with longer chain lengths are more toxic to eukaryotic cells (Gorle et al. 2016).  Both ruthenium 
complexes tested, Rubb7-tnl and Rubb12-tri, exhibited lower cytotoxicity against eukaryotic cells 
(H69) compared to DDVP, an organophosphorus AChE inhibitor and previously licensed, but now 
withdrawn anti-schistosome drug. Further, studies comparing AChE from schistosomes and 
higher eukaryotes (Jones et al. 2002; Bentley et al. 2003) reveal differences in functionally 
important amino acid residues (human AChE shares 33-36% primary sequence homology across 
all schistosome AChEs) with the active site serine conserved across species. It was previously 
shown that DDVP covalently binds to the active site serine and reduces the AChE activity in 
eukaryotes (e.g., in rat forebrain, erythrocytes and plasma) (Hinz et al. 1996; Jann 1998). By 
contrast, it was considered that the ruthenium complexes might be relatively less toxic to mice 
than DDVP due to the differential binding to AChE. The results of the MTD study, where both the 
ruthenium complexes were well tolerated by mice, supported this argument. 
 
Rubb12-tri and Rubb7-tnl both showed promising in vivo efficacy at doses which were equivalent 
to lethal in vitro concentrations yet well tolerated in mice, with Rubb12-tri-treated mice showing 
a significant reduction in worm burden and recovered worms displaying a small but significant 
decrease in tegumental AChE activity, providing evidence that the anti-schistosome effect may 
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be partially due to AChE inhibition. Studies by us on di-nuclear ruthenium complexes have shown 
the compounds to have a short serum half-life (Li et al. 2017), and the different in vivo efficacies 
of each complex in this study may be attributed to differences in the 
pharmacokinetic/pharmacodynamic (PK/PD) properties of Rubb12-tri and Rubb7-tnl. Although 
these experiments have yet to be performed, the differences exhibited between these two 
compounds in the cytotoxicity assay and tolerability study suggests that their PK/PD are not the 
same. Despite no significant reduction in egg burden in both trials, ova recovered from both 
Rubb12-tri- and Rubb7-tnl-treated mice had significantly reduced hatching ability and were 
morphologically abnormal compared to controls, in agreement with in vitro data. That there was 
no decrease in egg burden in light of a reduced worm load in either treated group was surprising, 
but this did result in an increase in the number of eggs per female in these groups, compared to 
controls. To explain these observations, I postulate that treatment with ruthenium drugs may 
stimulate schistosome reproductive tract motility (AChE inhibitors have been shown to stimulate 
gastrointestinal motility in various organisms (De Giorgio et al. 2004; McNamara et al. 2008)), 
resulting in premature release of under-developed eggs, and have a direct effect on egg 
formation, resulting in abnormally developed eggs (studies in ticks have shown that treatment 
with AChE inhibitors effect ova development (Perez-Gonzalez et al. 2014; Prado-Ochoa et al. 
2014)). Another possible factor contributing to abnormal egg development is that the worms are 
under-nourished due an impaired glucose uptake ability (albeit an effect that could only measure 
in vitro) resulting from ruthenium drug treatment and unable to meet the energetically 
demanding task of producing normally developed ova. There is considerable interest in the use 
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of agents that show ovicidal activity or affect oviposition to control schistosomiasis due to their 
ability to block transmission of the disease. In this regard, ruthenium complexes offer a potential 
advantage over PZQ in that it is only effective against mature worms and so cannot be used to 
interrupt disease transmission, as evidenced by high rates of re-infection in PZQ-treated endemic 
populations (Webster et al. 2013). 
 
So far, this is the first report detailing the anti-parasitic activity of ruthenium complexes and this 
work has identified some lead anti-schistosome compounds. The modular nature of ruthenium 
complexes makes it possible to synthesize these compounds to target specific enzymes, so future 
work will involve tailoring Ru complexes to increase their selectivity and potency. Finally, these 
complexes could be administered in combination with PZQ, overcoming the limitations of current 
monotherapy and augmenting existing schistosomiasis control initiatives.  
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3.1 Introduction 
The functioning of the nervous system is a tightly regulated process controlled through multiple 
catalytic and non-catalytic signaling molecules. Among the catalytic molecules, cholinesterases 
(ChEs) play a pivotal role in regulating the signaling activity of the nervous system. There are two 
major types of ChEs, acetylcholinesterase (AChE) and pseudocholinesterase, or 
butyrylcholinesterase (BChE), and they can be distinguished both kinetically and 
pharmacologically (Girard et al. 2007). AChE selectively hydrolyzes the neurotransmitter 
acetylcholine (ACh) to maintain neurotransmitter homeostasis (You et al. 2017) while the main 
role of BChE is widely accepted to be the detoxification of organophosphorus esters which are 
inhibitors of AChE (Lockridge 2015). ChEs are generally believed to be functionally redundant in 
cholinergic signaling with the main differences between paralogs lying in their spatial and 
temporal expression as well as non-cholinergic functionality (Soreq et al. 2001; Silman et al. 
2005).  
 
While AChE activity has been previously reported in different schistosomes (Arnon et al. 1999), 
“pre-genomic” studies have documented only one AChE-encoding gene in each species (Bentley 
et al. 2003; Bentley et al. 2005). Moreover, to the best of our knowledge, genes encoding proteins 
with BChE activity have not been previously described in schistosomes or any other helminth. 
Interrogation of the now fully annotated S. mansoni genome (Berriman et al. 2009) has revealed 
three different SmChE paralogs; however, their individual contributions to ChE function remain 
unknown.  
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Traditionally, parasite ChEs have been regarded solely as neurotransmitter terminators; 
however, there is increasing data to suggest that these enzymes play a variety of roles within the 
cells that extend beyond this cholinergic function (Soreq et al. 2001; Silman et al. 2005; Paraoanu 
et al. 2008; Zhang et al. 2012). In schistosomes, the most prominent among these is in the uptake 
of glucose by the parasite from the external environment (Camacho et al. 1995). One of the 
proposed mechanisms is by limiting the interaction of host ACh with tegumental nicotinic ACh 
receptors (nAChRs) thus availing surplus glucose (Camacho et al. 1995; Camacho et al. 1995). The 
nAChRs are also associated both spatially and temporally with surface AChE expression and are 
concentrated on the tegument (Camacho et al. 1995), the primary site of glucose uptake (Skelly 
et al. 2014).  
 
Many intestinal nematodes secrete AChE (Rathaur et al. 1987; Lawrence et al. 1993; Hussein et 
al. 2002; Hussein et al. 2002; Selkirk et al. 2005; Selkirk et al. 2005; Hewitson et al. 2013), which 
play a vital role in both cholinergic and non-cholinergic activities. For instance, emerging evidence 
suggests that AChE promote parasite survival not only by inhibiting the host cholinergic signaling 
resulting in inhibition of muscle contraction (Selkirk et al. 2005) but also by altering host cytokine 
profiles which suppress the development of M2 macrophages (Vaux et al. 2016). Despite this 
breadth of literature in nematodes, there has been no documentation of secreted AChE activity 
from schistosomes. 
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In this chapter, two novel ChEs from S. mansoni (SmChEs): SmBChE1 and SmAChE3 have 
been identified and functionally characterized, in addition to further characterizing the only 
previously identified AChE-encoding gene from S. mansoni (Bentley et al. 2003; Bentley et al. 
2005), which I have termed SmAChE1. In a first for schistosomes, SmChE activity in ES (excretory 
and secretory) products of the parasite have also been documented and partially characterized. 
Finally, evidence is provided that the novel SmBChE1 may act as a competitive binder of AChE 
inhibitors to detoxify the effects of these molecules.  
 
3.2 Material and Methods 
3.2.1 Ethics statement  
All experimental procedures reported in the study were approved by the James Cook University 
(JCU) animal ethics committee (ethics approval numbers A2271 and A2391). Mice were 
maintained in cages in the university’s quarantine facility (Q2152) for the duration of the 
experiments. The study protocols were in accordance with the 2007 Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes and the 2001 Queensland Animal Care 
and Protection Act. 
 
3.2.2 Parasite maintenance, culture and ES collection  
Biomphalaria glabrata snails infected with S. mansoni (NMRI strain) were obtained from the 
Biomedical Research Institute (BRI). Cercariae were shed from infected snails through exposure 
to light at 28°C for 1.5 h and were mechanically transformed into schistosomula (Ramalho-Pinto 
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et al. 1974). To obtain adult S. mansoni worms, 6-8 week old male BALB/c mice (Animal Resource 
Centre, WA) were infected with 180 cercariae via tail penetration and adults were harvested by 
vascular perfusion at 7-8 weeks post-infection (Lewis et al. 1986). Both adult worms and 
schistosomula were cultured (10 adult pairs/ml and 2000 schistosomula/ml, respectively, at 37°C  
and 5% CO2 in serum-free modified Basch medium (Basch 1981) supplemented with 4× 
antibiotic/antimycotic (AA - 200 units/ml penicillin, 200 µg/ml streptomycin and 0.5 µg/ml 
amphotericin B) in 6 well plates. Media, containing ES products, was initially collected after 24 h 
(adults) and 3 h (schistosomula) and then harvested and replenished daily and stored at -80°C. 
Media was thawed when needed, pooled if required, concentrated through Amicon centrifugation 
filters (Sigma) with a 3 kDa molecular weight cutoff (MWCO) and buffer exchanged into phosphate 
buffered saline, pH 7.4 (PBS). Concentrated ES products were then quantified using the Pierce 
BCA™ Protein Assay kit (Thermofisher), aliquoted and stored at -80°C. To collect cercarial ES, 
freshly-shed cercariae were incubated in H2O (4000/ml) at 25°C  for 3 h. H2O was filtered through 
Whatman filter paper (11 µm) to remove cercariae and ES products were concentrated, quantified 
and stored as for adult and schistosomula ES.  
 
3.2.3 Parasite extract preparation 
To make PBS-soluble extracts, worms were homogenized in PBS (50 μl/adult worm pair or 50 
μl/1000 schistosomula) at 4°C using a TissueLyser II (Qiagen), homogenates incubated overnight 
with mixing at 4°C and the supernatant collected by centrifugation at 15,000 xg for 1 h at 4°C. 
Triton X-100-soluble extracts were made from the PBS-insoluble pellets by resuspension in 1% 
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Triton X-100, 40 mM Tris-HCl, pH 7.4, mixing overnight at 4°C and the supernatant collected by 
centrifugation at 15,000 xg for 1 h at 4°C. Tegument extraction was achieved using a combination 
of freeze/thaw/vortex technique (Sotillo et al. 2015). In brief, parasites were slowly thawed on 
ice, washed in TBS (10 mM Tris/HCl, 0.84% NaCl, pH 7.4) and incubated for 5 min on ice in 10 mM 
Tris/HCl, pH 7.4 followed by vortexing five times with 1-s bursts. Subsequently, the tegumental 
extract was pelleted at 1000 xg for 30 min and solubilized (3x) in 200 μl of 0.1% (w/v) SDS, 1% 
(v/v) Triton X-100 in 40 mM Tris, pH 7.4 with pelleting at 15,000 xg between each wash. Protein 
concentration was determined using the Pierce BCA Protein Assay kit (Thermofisher), aliquoted 
and stored at -80°C until use. 
 
3.2.4 Bioinformatics studies  
Based on Pfam analysis (search = cholinesterase) of the S. mansoni genome  
(http://www.geneDB.org/Homepage/Smansoni), three SmChE paralogs (SmAChE1 - 
Smp_154600, SmBChE1 - Smp_125350 and SmAChE3 - Smp_136690) were identified. 
Homologous ChE sequences from other species were identified using BLASTP. 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi )  and the resulting sequences were used to generate   a 
multiple sequence alignment using Clustal Omega  
(https://www.ebi.ac.uk/Tools/msa/clustalo/). 
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MEGA 7 was used to generate a neighbor-joining tree with the Poisson correction distance 
method and a bootstrap test of 1000 replicates (Kumar et al. 2016). Structure-homology 3D 
models of SmChEs were generated using the I-TASSER server 
 (http://zhanglab.ccmb.med.umich.edu/I-TASSER/). For structure visualization and catalytic triad 
analyses, the Accelrys Discovery Studio (Accelerys Inc.) and UCSF Chimera MatchMaker ver. 1.4 
(University of California) software packages were utilized. 
 
3.2.5 Developmental expression analysis of SmChE genes by real-time qPCR 
RNA from miracidia, sporocyst, cercariae, adult male worms, adult female worms, and eggs were 
obtained from BRI. Schistosomula were cultured as described in section 3.2.2, harvested (1000 
parasites) after either 3 h, 24 h, 3 or 5 days, washed three times in PBS and stored at -80°C until 
use. Total RNA extraction from schistosomula stages was performed using the Trizol 
(Thermofisher) reagent according to manufacturer’s instructions. After air-drying, RNA pellets 
were re-suspended in 12 µl DEPC water. Concentration and purity of RNA was determined using 
an ND2000 Nanodrop spectrophotometer (Thermofisher). Synthesis of cDNA was carried out 
using 1 µg of total RNA using Superscript-III-Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. Finally, cDNA was quantified, diluted to 50 ng/μl, aliquoted and 
stored at -20°C. 
 
Real-time qPCR primers for each SmChE (Supplementary Table 3.1) were designed using Primer3 
(http://frodo.wi.mit.edu/). SmCOX1 was selected as an internal control to normalize relative 
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SmChE gene expression (Long et al. 2016). Each qPCR (1 μl (50 ng) of cDNA, 5 μl of 2x SYBR green 
master mix (Bioline), 1μl (5 pmol/μl) each of forward and reverse primers and 2 μl of nuclease-
free water) was run in a Rotor-Gene Q thermal cycler (Qiagen) using 40 cycles of 95°C for 10 
seconds, 50-55°C for 15 seconds and 72°C for 20 seconds. Stage-specific SmChE gene expression 
levels were normalized against SmCOX1 gene expression using the comparative 2-ΔΔCT method 
(Schmittgen et al. 2008). All results represent the average of five independent experiments with 
data presented as mean ± SEM. 
 
3.2.6 Cloning and expression of SmChE gene fragments in E. coli 
Complete ORFs for SmAChE1, SmBChE1 and SmAChE3 were synthesized by GENEWIZ, 
(https://www.genewiz.com). Attempts to express full-length sequences in E. coli were 
unsuccessful, so primer sets incorporating NdeI (forward primer) and XhoI restriction enzyme 
sites (reverse primer) were designed (Supplementary Table 3.1) to amplify partial, non-conserved 
regions of each SmChE (pSmChE), which might prove more amenable to expression. Sequences 
for each pSmChE were amplified from each full-length template by PCR, amplicons digested by 
NdeI and XhoI, ligated into the similarly-digested pET41a expression vector (Novagen) and 
transformed into E. coli DH5α (Thermofisher) on LB plates supplemented with 50 μg/ml 
kanamycin (LBkan). Colonies were screened by PCR and positive transformants were cultured in 5 
ml LBkan overnight at 37°C and 200 rpm. Plasmids were extracted from each culture by miniprep 
and recombination confirmed by NdeI/XhoI digestion and sequencing using T7 promoter and T7 
terminator primers. Plasmids selected for expression were transformed into E. coli BL21(DE3) 
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(Thermofisher) and positive colonies seeded into 2x5 ml LBkan and incubated overnight at 37°C 
and 200 rpm. Overnight starter cultures were diluted 1:100 in 1L of 2YTkan broth and cultured at 
37°C and 200 rpm. Cells were induced by 1 mM Isopropyl beta-D-1-thiogalactopyranoside (IPTG) 
when the OD600 of the cultures reached 1 and further incubated at 37°C for 24 h. Finally, cultures 
were harvested by centrifugation (8000 xg for 20 min at 4°C), re-suspended in 50 ml lysis buffer 
(50 mM sodium phosphate, pH 8.0, 300 mM NaCl, and 40 mM imidazole) and stored at -80°C.  
 
3.2.7 Purification of pSmChEs 
Pilot expression experiments showed each pSmChE to be produced in insoluble inclusion bodies 
(IBs). Cell pellets were lysed by three freeze-thaw cycles at -80°C and 42°C followed by sonication 
on ice (10 x 5 s pulses [70% amplitude] with 30 s rest periods in between each pulse) with a 
Qsonica Sonicator. Triton X-100 was added to each lysate at a final concentration of 3% and 
incubated for 1 h at 4°C with end-over-end mixing. Insoluble material (containing pSmChEs) was 
pelleted by centrifugation at 20,000 xg for 20 min at 4°C. The supernatant was discarded, and IBs 
were washed twice by resuspension in 30 ml of lysis buffer followed by centrifugation at 20,000 
xg for 20 min at 4°C. IBs were then solubilized sequentially by resuspension in 25 ml lysis buffers 
containing either 2 M, 4 M or 8 M urea, end-over-end mixing overnight at 4°C and centrifugation 
at 20,000 xg for 20 min at 4°C. Finally, supernatant containing solubilized IBs were diluted 1:4 in 
lysis buffer containing 8M urea and filtered through a 0.22 μm membrane (Millipore). Solubilized 
IBs were purified by immobilized metal affinity chromatography (IMAC) by loading onto a 
prepacked 1 ml His-Trap HP column (GE Healthcare) equilibrated with lysis buffer containing 8M 
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urea at a flow rate of 1 ml/min using an AKTA-pure-25 FPLC (GE Healthcare). After washing with 
20 ml lysis buffer containing 8M urea, bound His-tagged proteins were eluted using the same 
buffer with a stepwise gradient of 50-250 mM imidazole (50 mM steps). Fractions containing 
pSmChEs (as determined by SDS-PAGE) were pooled and concentrated using Amicon Ultra-15 
centrifugal devices with a 3 kDa MWCO (Sigma) and quantified using the Pierce BCA Protein Assay 
kit (Thermofisher). The final concentration of each pSmChE was adjusted to 1 mg/ml) and 
proteins were aliquoted and stored at -80°C. 
 
3.2.8 Generation of anti-SmChE antisera and purification of IgG 
Three groups of five male BALB/c mice (6-week-old) were intraperitoneally immunized with 
either pSmAChE1, pSmBChE1 or pSmAChE3 subunits (50 μg/mouse). Antigens were mixed with 
an equal volume of Imject alum adjuvant (Thermofisher) and administered three times, two 
weeks apart. Two weeks after the final immunization, mice were sacrificed and blood was 
collected via cardiac puncture. Blood from all mice in each group was pooled and serum was 
separated by centrifugation after clotting and stored at −20°C. Polyclonal antibodies were 
purified from mouse sera by using Protein A Sepharose-4B (Thermofisher) according to 
manufacturer’s instructions. Serum from naïve mice was similarly processed. 
 
3.2.9 Immunolocalization using anti-SmChE antisera 
Adult worm sections: Freshly perfused adult S. mansoni and S. haematobium worms were fixed 
in 4% paraformaldehyde, embedded in paraffin and sections (7 μm thick) were cut in a cryostat. 
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Following deparaffinization in xylene and rehydration in an ethanol series, antigen retrieval was 
performed by boiling the slides in 10 mM sodium citrate, pH 6.0, for 40 min followed by a 
solution of 10 mM Tris, 1 mM EDTA, 0.05% Tween, pH 9.0, for 20 min. All sections were then 
blocked with 10% heat-inactivated goat serum for 1 h RT. After washing 3 times with PBST, 
sections were incubated with anti-SmAChE1, anti-SmBChE1, anti-SmAChE3, naïve sera (negative 
control), S. mansoni or S. haematobium infected sera (positive controls) (1:50 in PBST) overnight 
at 4°C and then washed again (3x5 min each). Finally, the sections were incubated with Goat-
anti-mouse IgG-alexafluor647 (Sigma) (1:200 in PBST) for 1 h in the dark at RT. After a final 
washing step, slides were mounted with coverslips in Entellan mounting medium (Millipore). 
Fluorescence and bright-field microscopy were performed with an AxioImager M1 fluorescence 
microscope (Zeiss) using 10x and 20x objectives. 
 
Live schistosomula: In vitro-cultured living cercariae and schistosomula (3 h, 24 h, 3 and 5 days 
old) larvae were harvested and washed with PBS and then blocked with PBST/10% heat-
inactivated goat serum for 30 min at RT. Following three washes, the larvae were incubated with 
anti-SmAChE1, anti-SmBChE1, anti-SmAChE3 or naïve serum (negative control) (1:100 in PBST) 
overnight at 4°C. Parasites were washed again before incubation with Goat-anti-mouse IgG-
alexafluor647 (Sigma) (1: 200 in PBST) for 1 h in the dark at RT, followed by 3 washes. Finally, 
schistosomes were fixed in 4% paraformaldehyde and transferred to a microscopic slide for 
fluorescence microscopy using an AxioImager M1 fluorescence microscope (Zeiss). 
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3.2.10 Cloning and expression of full-length SmChEs in P. pastoris 
Specific primer sets containing flanking EcoRI and XbaI sites were designed to amplify full-length 
sequences (minus the signal peptide) of SmAChE1, SmBChE1 and SmAChE3 (fSmChEs). Amplicons 
were then digested and cloned in-frame with the α-factor secretion signal peptide into the C-
terminal 6XHis tagged pPICZαA expression vector (Invitrogen). The constructs were then 
transformed into E. coli DH5α cells (Thermofisher), plated onto LB agar plates supplemented with 
25 μg/ml of zeocin (LBzeo) and incubated overnight at 37°C. Recombinant colonies were confirmed 
by colony PCR and used to inoculate 5 ml LBzeo which were grown overnight at 37°C and 200 rpm. 
Plasmids were extracted by mini-prep and recombination verified by both restriction digestion 
and sequencing. 
 
Recombinant plasmids (20 μg) were linearized with Pmel (fSmAChE1 & fSmBChE1) and SacI 
(fSmAChE3) for 3 h at 37°C, purified by ethanol precipitation and resuspended in 15 μl of H2O. 
Linearized vectors were electroporated according to manufacturer’s instructions into P. pastoris 
X-33 cells (Thermofisher) in 2 mm cuvettes (2 ms, 2000V, 25 μF, 200 Ω, square wave pulse), using 
a Gene Pulser Xcell (Bio-Rad), plated onto YPDS agar plates containing 100 μg/ml zeocin, covered 
in foil and incubated for 3 days at 30°C. Resultant colonies were then picked and patched onto 
YPDS agar containing 2 mg/ml zeocin and plates incubated at 30°C until colonies were visible. 
Integration of the recombinant cassette into the P. pastoris chromosome was confirmed by 
colony PCR. For each integrated SmChE, ten PCR-positive colonies were selected for pilot 
expression studies and each seeded into 3 ml of BMGY in 50 ml falcon tubes and incubated 
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overnight at 30oC with shaking at 250 rpm. Cells were pelleted (5000 xg for 20 min at RT), re-
suspended in 6 ml BMMY to induce protein expression and incubated at 30oC with shaking at 250 
rpm. Methanol was added to 0.5% at 24, 48 and 72 h after media replacement to maintain 
protein induction. At these timepoints, 500 μl samples of culture media were taken and analyzed 
for protein expression by standard Western blotting techniques using an anti-His antibody and 
SmChE-specific polyclonal antibodies (generated in section 3.2.8).  
 
The highest-expressing P. pastoris culture (determined from the pilot expression experiments) of 
each fSmChE was plated onto YPD agar supplemented with 50 μg/ml zeocin and incubated for 2 
days at 30°C. A single colony was used to inoculate 5 ml BMGY media (supplemented with 50 
ug/ml zeocin) which was grown overnight at 30°C and 250 rpm. The entire culture was then used 
to inoculate 250 ml of BMGY in a 2L baffled flask and incubation was continued for 24 h. Cells 
were pelleted at 5000 xg for 20 min a t  RT, re-suspended in 1L of BMMY and split between 2 
x 2L baffled flasks, which were incubated with shaking (250 rpm) at 30°C for 72 h. Methanol 
was added to a final concentration of 0.5% (2.5 ml/flask) every 24 h. Culture medium containing 
the secreted fSmChE proteins were harvested by centrifugation (5000 xg for 20 min at RT) and 
filtered through a 0.22 µm membrane filter (Millipore). Recombinant proteins were purified by 
IMAC using the AKTA-pure-25 FPLC (GE Healthcare). Briefly, culture medium was loaded onto a 
5 ml His-excel column, pre-equilibrated with binding buffer (50 mM PBS pH 7.4, 300 mM NaCl), 
washed with 20 column volumes of binding buffer and then eluted with binding buffer containing 
a linear imidazole gradient (20 to 500 mM). The purity of fractions within the main peak was 
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analyzed by standard SDS-and fractions of appropriate purity were pooled, concentrated and 
buffer exchanged into PBS using Amicon Ultra-15 centrifugal devices with a 3 kDa MWCO 
(Millipore) and quantified using the Pierce BCA Protein Assay kit (Thermofisher). The final 
concentration of each fSmChE was adjusted to 1 mg/ml) and proteins were aliquoted and stored 
at -80°C. Finally, the recombinant proteins were confirmed by SDS-PAGE and Western blotting 
with anti-His (anti-His-HRP) (Invitrogen) and anti-SmChEs antibodies (generated in section 3.2.8). 
 
3.2.11 SmChE Enzyme Assays 
Activity of fSmChEs, extracts and ES samples was determined by the Ellman method (Ellman et 
al. 1961); modified for use with 96 well microplates. Samples (parasite extracts, ES and fSmChEs) 
were diluted in assay buffer (0.1M sodium phosphate, pH 7.4), and 2 mM acetylthiocholine 
(AcSCh) or butyrylthiocholine (BcSCh) (Sigma) and 0.5 mM 5, 5’-dithio-bis (2-nitrobenzoic acid) 
(DTNB) (Sigma) was added. The absorbance increase was monitored every 5 min at 405 nm in a 
Polarstar Omega microplate reader (BMG Labtech). Specific activity was calculated using the 
initial velocity of the reaction and extinction coefficient of 13260 M−1 cm−1 for TNB. To investigate 
sensitivity of parasite ES products to AChE inhibitors, 25 μg of adult ES was pre-treated with 1 
μM Dichlorvos (DDVP) - active metabolite of the organophosphorus AChE inhibitor metrifonate - 
for 20 min at RT before measuring activity. Kinetic parameters of fSmChEs were characterized by 
measuring enzyme activity at differing substrate concentrations and plotting enzyme activity [V] 
vs. substrate concentration [S]. The Km ([S] at 1/2 Vmax) was calculated using the Michaelis 
Menton equation. Substrate concentration was plotted against reaction rate to check whether 
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the enzymes obeyed Michaelis–Menten kinetics and Km and Vmax were determined from a 
Lineweaver–Burk plot. Enzyme assays with inhibitors were performed as above except that 
fSmChEs in assay buffer were pre-treated with 1 μM DDVP, in the case of fSmAChE1 and 
fSmAChE3, or (1 mM) iso-OMPA – a membrane-impermeable specific BChE inhibitor, in the case 
of fSmBChE1, for another 20 min at RT. Experiments were performed in triplicate with data 
presented as the mean ± SEM. 
  
3.2.12 Purification of secreted SmChEs from adult S. mansoni ES products 
Affinity chromatography using edrophonium chloride-sepharose was used to purify SmAChE 
from S. mansoni based on the method of (Hodgson et al. 1983). Briefly, 1 g of epoxy-activated 
sepharose 6B beads were washed with distilled H2O, the slurry centrifuged at 814 xg for 5 min 
and the pellet gently resuspended in 50 mM sodium phosphate, pH 8.0, containing 200 mM 
edrophonium chloride (1:2 ratio of sepharose:edrophonium chloride). The pH of the solution was 
adjusted to 10.0 and coupling of edrophonium with the sepharose was facilitated by incubating 
the mixture overnight with shaking at 50°C. The gel was then washed sequentially with 10 
volumes each of 100 mM sodium acetate, pH 4.5, 12 mM sodium borate, pH 10.0, and distilled 
H2O and finally resuspended in distilled H2O to generate a 1 ml gel slurry. The gel slurry was 
packed into a chromatography column (10 cm long, 1 cm diameter) and equilibrated by gravity 
flow at 4°C with 10 column volumes (CV) of equilibration buffer (50 mM phosphate buffer, pH 
8.0). Approximately 20 ml of ES from adult S. mansoni (concentrated through a 10Kda MWCO 
centrifugal filter from a starting volume of 500 ml of media, harvested each day for 7 days from 
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100 pairs of adult worms and buffer exchanged into equilibration buffer) was added to the 
column followed by washes with 20 CV of equilibration buffer and 20 CV of equilibration buffer 
containing 500 mM NaCl. Bound SmChE was then eluted with 10 CV of equilibration buffer 
containing 500 mM NaCl and 20 mM edrophonium chloride. The eluate was concentrated and 
buffer exchanged into PBS using a 10Kda MWCO centrifugal filter (edrophonium chloride is an 
AChE inhibitor and would interfere with subsequent activity assays) and resolved by 10% SDS-
PAGE to check purity and facilitate identification by mass spectrometry. 
 
3.2.13 Mass spectrometric analysis of purified, secretory SmChE 
Bands of interest were manually excised from the gel, washed with 50% acetonitrile and dried 
under vacuum at 30°C. Cysteine residues were, then, reduced with 20 mM DTT for 1 h at 65°C 
followed by alkylation with 50 mM iodoacetamide for 40 min at 37°C in the dark. In-gel trypsin 
digestion was performed at 37°C overnight with 0.8 ng of trypsin in trypsin reaction buffer (40 
mM ammonium bicarbonate, 9% acetonitrile). The supernatant was removed to a fresh 
Eppendorf tube and stored at 4°C, and the remaining peptides were further extracted from the 
gel pieces by incubation with 0.1% trifluoracetic acid (TFA) at 37°C for 45 min. The 
newly extracted supernatant was combined with the previously collected supernatant, then 
dried under vacuum. Prior to the matrix-assisted laser desorption/ionization-time-of-flight mass 
spectrometry (MALDI-TOF MS) analysis, peptides were concentrated and desalted using ZipTips 
(Millipore) following manufacturer’s instructions. 
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Tryptic peptides were re-dissolved in 10 μl 5% formic acid and 6 μl was injected onto a 50 mm 
300 µm C18 trap column (Agilent Technologies) followed by initial wash step by Buffer A (5% (v/v) 
ACN, 0.1% (v/v) formic acid) for 5 min at 30 μl/min. Peptides were eluted at a flow rate of 0.3 
μl/min onto an analytical nano HPLC column (15 cm x 75 μm 300SBC18, 3.5 μm, Agilent 
Technologies). The eluted peptides were then separated by a 55-min gradient of buffer B (90/10 
acetonitrile/ 0.1% formic acid) 1-40% followed by a 5 min steeper gradient from 40-80%. The 
mass spectrometer (ABSciex 5600 Triple Tof) operated in data-dependent acquisition mode, in 
which full scan TOF-MS data was acquired over the range of 350-1400 m/z, and over the range 
of 80-1400 m/z for product-ion observed in the TOF-MS scan exceeding a threshold of 100 counts 
and a charge state of +2 to +5. Analyst 1.6.1 (ABSCIEX) software was used for data acquisition 
and analysis. 
 
For protein identification, a database was built using the S. mansoni genome 
v5.0 (http://www.genedb.org/Homepage/Smansoni) with the common repository of 
adventitious proteins (cRAP, http://www.thegpm.org/crap/) appended to it. Mascot v.2.5.1 
(Matrix Science) was used for database search. Carbamidomethylation of Cys was set as a fixed 
modification and oxidation of Met and deamidation of Asn and Gln were set as variable 
modifications. MS and MS/MS tolerance were set at 10 ppm and 0.1 Da, respectively and 
only proteins with at least two unique peptides (each composed of at least seven amino acid 
residues) identified were considered reliably identified and used for analysis. 
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3.2.14 Bio-scavenging of organophosphorus esters by SmBChE1 
To test the hypothesis that SmBChE1 may play a role in the bio-scavenging of AChE-inhibitory 
organophosphates (OPs), I first sought to determine whether inhibition of BChE activity would 
potentiate the AChE-inhibitory and anti-schistosomal effects of OPs. Schistosomula extracts (20 
μg) were diluted in assay buffer, pre-incubated with iso-OMPA (1 or 2 mM) for 20 min at RT and 
then 1 μM (DDVP) for another 20 min at RT (180 μl final volume). ACh (2 mM) and DTNB (0.5 
mM) were then added and the absorbance increase monitored every 5 min at 405 nm in a 
Polarstar Omega microplate reader (BMG Labtech). Extracts untreated with iso-OMPA with or 
without DDVP treatment were used as controls. Experiments were performed in triplicate with 
data presented as the mean ± SEM. 
 
The same experiments were performed on live schistosomula using either an inhibitor- or RNAi-
based approach. For the inhibitor-based experiment, 24 h schistosomula (1000/treatment in 1 
ml serum-free Basch medium supplemented with 4XAA) were pretreated with iso-OMPA at the 
non-lethal concentration of 100 μM and, 1 h after iso-OMPA treatment, schistosomula were 
treated with 1 μM DDVP and cultured for 5 h at 37°C in 5% CO2. Parasites untreated with iso-
OMPA but treated with DDVP were used as controls. For the RNAi-based experiment, 24 h 
schistosomula (1500/100 μl serum-free Basch medium supplemented with 4XAA) were 
electroporated with either 10 μg of a short interfering RNA duplex (siRNA) (Supplementary Table 
4.1) targeting SmBChE1 or firefly luciferase (irrelevant siRNA control) ( (Tran et al. 2010) in 
Genepulser 4 mm electroporation cuvettes (Bio-Rad) using a Bio-Rad Gene Pulser Xcell (single 20 
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ms pulse - 125V, 25 μF capacitance, 200 resistance, square wave electroporation) at RT. Parasites 
were added to 24 well plates containing 1 ml pre-warmed, serum-free Basch medium 
(supplemented with 4XAA) and incubated (37°C, 5% CO2) for 3 days before being treated with 1 
μM DDVP and cultured for a further 5 h. For both inhibitor- and RNAi-based experiments, 
schistosomula viability was determined using Trypan Blue staining and data is presented as the 
mean ± SEM of two biological and three technical replicates. 
 
In a reverse testing of the bio-scavenging hypothesis, I sought to determine whether addition 
ofsCHIcould mitigate the effects of DDVP. Ten micrograms of fSmBChE1 was pre-incubated with 
1 μM DDVP in AChE assay buffer (170 μl final volume) for 20 min at RT. Schistosomula extracts 
(20 μg), ACh (2 mM) and DTNB (0.5 mM) were then added and the absorbance increase 
monitored every 5 min at 405 nm in a Polarstar Omega microplate reader (BMG Labtech). 
Reactions without fSmBChE or without DDVP were used as controls. Experiments were 
performed in triplicate with data presented as the mean ± SEM. Again, the same experiments 
were performed on live schistosomula. After the pre-treatment of different amounts of fSmBChE 
(10, 5, and 2.5 μg) with 1 μM DDVP in 500 μl serum-free Basch medium supplemented with 4XAA, 
twenty-four hour schistosomula (1000/treatment in 500 μl serum-free Basch medium 
supplemented with 4XAA) were added, incubated (37°C , 5% CO2) for 24 hours and then parasite 
viability measured by Trypan Blue Staining. Experiments where a similarly expressed and purified 
but irrelevant protein (SmTSP2) was used instead of fSmBChE, and schistosomula cultured in 
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media alone, were used as controls. Data is presented as the mean ± SEM of two biological and 
three technical replicates. 
 
3.3 Results 
3.3.1 Identification of novel genes encoding ChE proteins in S. mansoni  
Three putative ChE paralogs were identified from interrogation of the S. mansoni genome: 
SmAChE1 (Smp_154600), SmBChE1 (Smp_125350) and SmAhE3 (Smp_136690). The predicted 
SmChEs were then aligned with characterized AChE enzymes from Homo sapiens, the electric eel 
Torpedo californica, and the nematode Caenorhabditis elegans (Fig 3.1A). Homology analysis of 
amino acid sequences revealed that the SmAChE1, SmBChE1, and SmAChE3 share (32-35%) 
sequence identity and (49-52%) sequence similarity. Further, all SmChEs have 36-40% amino acid 
identity with H. sapiens and T. californica AChE. All identified SmChEs had ChE-specific 
characteristics, including a catalytic triad with an active site serine, which is required for ester 
hydrolysis (Dvir et al. 2010). Interestingly, the His residue of the catalytic triad of SmBChE1 
appears to have been substituted for Gln, a change consistent among all the BChE1 homologs 
shown for other Platyhelminthes, but not nematode or model organism BChE1 sequences (Fig 
3.1B). 
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Fig 3.1. The amino acid sequence alignment of ChEs from S. mansoni and other species. (A)   = 
the 14 aromatic rings,     = Oxyanion holes, S= salt bridges, Red box= PAS, Yellow box= Catalytic 
triad, Green box= Acyl Binding Pocket, Numbered Arrow =3 disulphide bonds and Magenta 
box=Anionic site.  H. Sapiens (NP000656), T. Californica (CAA27169), C. elegans (NP510660), 
SmAChE1 (Smp_154600), SmBChE1 (Smp_125350), SmAChE3 (Smp_136690). (B) Sequence 
alignment of the SmBChE1 homologous sequences in other helminths. Accession numbers of 
sequences: Schistosoma mansoni (SmBChE1 – Smp_125350), Schistosoma rodhaini 
(SROB_0000329201), Schistosoma haematobium (KGB33101), Schistosoma japonicum 
(Sjp_0015690), Clonorchis sinensis (csin111679),  Echinostoma caproni (ECPE_0000670801), 
Fasciola hepatica (PIS83327.1), Hymenolepis diminuta (HDID_0000005301), Echinococcus 
granulosus (EGR_07475.1), Taenia solium (TsM_000234300), Taenia saginata 
(TSAs00071g07627m00001), Trichuris muris (TMUE_3000012587), Trichuris trichiura 
(TTRE_0000364501), Trichuris suis (M514_03850), Nippostrongylus brasiliensis 
(NBR_0000102801), Caenorhabditis elegans (Y48B6A.8.1) and Homo sapiens ( P06276). 
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A phylogenetic tree of the alignment (Fig 3.2A) shows that SmChEs were clustered into three 
distinct branches, with SmChE1 being quite phylogenetically distinct from SmBChE1 and 
SmAChE3. In addition, each SmChE was grouped together with closely related flatworms, 
including other Schistosoma species. Importantly, as shown in the sequence alignment, SmChEs 
are divergent from human host homologs. Fig 3.2B shows that reflective of the catalytic triad 
residue differences in Fig.1B, trematode BChEs are phylogenetically divergent from nematode 
and human BChEs. 
 
A 3D model of the three SmChEs was constructed by homology modeling with AChE from model 
organisms (H. sapiens and T. calfornica (Fig 3.3A-C). The overall fold model of all SmChEs 
exhibited folding characteristic of the functional globular enzymes as most of the α-helical and 
β-stranded sheets were tightly aligned. Each predicted SmChE structure consisted of a ChE 
catalytic domain but, although the core architecture of the catalytic gorges was well aligned, 
regions that are associated with substrate specificity and catalytic efficiency were disparate, in 
agreement with the sequence alignment. In particular, the catalytic triad of SmBChE1 was 
predicted to be Ser-Gln-Glu instead of the canonical Ser-His-Glu present in the other two 
paralogs.  
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Fig 3.2. Phylogenetic of AChEs. (A) The three SmChEs are indicated by bold font inside a red box. 
Relationship between SmChEs and other invertebrate and vertebrate species. Evolutionary history 
was inferred using the Neighbor-Joining method and the phylogenetic tree was generated using a 
ClustalW alignment. The evolutionary distances were computed using the Poisson correction 
method and are in the units of the number of amino acid substitutions per site. All positions 
containing gaps and missing data were eliminated, making for a total of 236 positions in the final 
dataset. Evolutionary analyses were conducted in MEGA7 (Kumar et al. 2016). Accession numbers: 
Schistosoma mansoni (Sm_AChE1 - Smp_154600, Sm_BChE1 - Smp_125350, Sm_AChE3 - 
Smp_136690); Schistosoma bovis (Sb_AChE1 - AAQ14323); Schistosoma haematobium (Sh_AChE1 
- AAQ14322, Sh_AChE2 - KGB33101, Sh_AChE3 - KGB33661); Schistosoma japonicum (Sj_AChE1 - 
ANH56887, Sj_AChE2 - Sjp0045440.1); Fasciola hepatica (Fh_AChE - THD22977.1); Clonorchis 
sinensis (Cs_AChE1 - GAA52478, Cs_AChE2 - GAA53463, Cs_AChE3 - GAA27255); Opisthorchis 
viverrini (Ov_AChE - XP009170845, Ov_AChE - XP009168237, Ov_AChE - XP009170760); 
Echinococcus granulosus (Eg_AChE1 - JN662938, Eg_AChE2 - EgG000732400); Hymenolepis 
microstoma (Hm_AChE1 - LK053025); Taenia solium (Ts_AChE1 - TsM000234300, Ts_AChE - 
TsM001220100, Ts_AChE - TsM000001700); Anopheles gambiae (Ag_AChE1 - AGM16375); Aedes 
aegypti (Ae_AChE - AAB35001); Culex tritaeniorhynchus (Ct_AChE - BAD06210); Caenorhabditis 
elegans (Ce_AChE1 - NP510660, Ce_AChE2 - NP491141, Ce_AChE3 - NP496963); Trichuris muris 
(Tm_AChE1 - TMUEs0033000600); Nippostrongylus brasiliensis (Nb_AChE1 - AAK44221, Nb_AChE2 
- AAC05785, Nb_AChE3 - AAK44221); Homo sapiens (Hs_AChE - NP000656); Torpedo californica 
(Tc_AChE - CAA27169); Danio rerio (Dr_AChE - NP571921); Mus musculus (Mm_AChE - CAA39867); 
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Rattus norvegicus (Rn_AChE - NP742006). (B) Phylogenetic analysis of SmBChE1 and its human and 
other helminth homologs. The phylogenetic tree was built using the maximum likelihood method 
with SmBChE1 and the top 16 similar helminths cholinesterase protein sequences identified from 
the BLASTp search, as well as one known Human BChE protein. Accession numbers of sequences: 
Schistosoma mansoni (SmBChE1 – Smp_125350), Schistosoma rodhaini (SROB_0000329201), 
Schistosoma haematobium (KGB33101), Schistosoma japonicum (Sjp_0015690), Clonorchis 
sinensis (csin111679),  Echinostoma caproni (ECPE_0000670801), Fasciola hepatica (PIS83327.1), 
Hymenolepis diminuta (HDID_0000005301), Echinococcus granulosus (EGR_07475.1), Taenia 
solium (TsM_000234300), Taenia saginata (TSAs00071g07627m00001), Trichuris muris 
(TMUE_3000012587), Trichuris trichiura (TTRE_0000364501), Trichuris suis (M514_03850), 
Nippostrongylus brasiliensis (NBR_0000102801), Caenorhabditis elegans (Y48B6A.8.1) and Homo 
sapiens ( P06276). 
 
 
Chapter 3. Characterization of novel cholinesterases 
 
98 
 
 
Fig 3.3. Magnified view of 3D models showing the catalytic triads of SmAChE1, SmBChE1, and 
SmAChE3. The amino acid residues of the catalytic triad of each paralog are magnified and their 
position number is given according to Torpedo AChE numbering: SmAChE1 (Ser277, Gln538, 
Glu406), SmBChE1 (Ser244, Gln538, Glu406), and SmAChE3 (Ser239, His514, Glu375).  
 
3.3.2 Developmental expression analysis of SmChE genes 
Gene expression patterns of the three SmChE paralogs across different developmental stages 
were measured using semi-quantitative qPCR (Fig 3.4A-C) and this data was used to generate a 
comparative expression heat map of all three genes (Fig 3.4D). While all SmChE developmental 
expression patterns were variable, the transcript levels of all the three genes were relatively 
lower in cercariae compared to the other developmental stages. Overall, the transcript levels of 
SmAChE1 and SmAChE3 genes in most life stages were higher as compared to the SmBChE1 
transcript. In adult worms, SmAChE1 was expressed at higher levels, specifically in male parasites 
(A) (C)(B)
SmAChE3SmAChE1 SmBChE1
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followed by sporocysts. Eggs and sporocysts exhibited ubiquitous expression of SmBChE1 and 
SmAChE3, respectively.  
 
Fig 3.4. Expression profiles of SmAChE1, SmBChE1, and SmAChE3.  
The expression of SmAChE1 (A), SmABChE1 (B), and SmAChE3 (C) genes at different developmental 
stages of S. mansoni as quantified by qPCR analysis. (D) The heat map shows the comparative 
expression pattern of the paralogs in each developmental stage. Data are presented as mean ± SEM 
of five independent experiments and are normalized to the SmCOX1 housekeeping gene. 
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3.3.3 Cloning and protein expression of SmChEs in bacteria  
Partial ORFs selected from highly polymorphic regions of each paralog were cloned and 
expressed in E. coli BL21 (DE3) cells. Recombinant proteins of expected size were purified from 
inclusion bodies using IMAC under denaturing conditions. Final yields were: pSmAChE1 (25 kDa) 
– 6.0 mg/L, pSmBChE1 (23 kDa) - 16 mg/L and pSmAChE3 (25 kDa) – 3.5 mg/L. 
 
3.3.4 Immunolocalization of SmChEs 
To gain insight into the anatomical sites of expression of ChE proteins in S. mansoni, SmChEs were 
immunolocalized in whole juvenile and sectioned adult parasites. In adults, and consistent with 
their predicted cholinergic function, all SmChEs were expressed throughout the worms’ internal 
structures (presumably localizing to the neuromusculature) and on their surface. SmAChE1 was 
the least uniformly distributed of all SmChEs, localizing mostly to the tegument (Fig 3.5A). 
Additionally, anti-SmChE antibodies were able to detect homologous ChEs in adult S. 
haematobium sections. SmChE proteins were detected in all stages of larval development tested 
and, as was the case with adult worms, localized to the tegument.  
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Fig 3.5. Immunofluorescent localization of SmChEs. 
Fluorescence and brightfield images of (A) Male (M) and female (F) S. mansoni and S. haematobium 
adult worm sections. (B) Live, fixed cercariae, and schistosomula at 3 h, 24 h, 3 days and 5 days 
after transformation. Both adult sections and juvenile parasites were labeled with either anti-
SmAChE1, anti-SmBChE1 or anti-SmAChE3 primary antibody (1:100 in PBST) followed by goat-anti-
mouse IgG-alexafluor647) (1:200 in PBST). Naive mouse sera was used as a negative control. 
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3.3.5 Expression and ChE activity of fSmChEs 
Soluble, functionally active proteins were expressed in P. pastoris purified via IMAC. Both 
fSmAChE1 and fSmAChE3 demonstrated significantly stronger hydrolase activity when AcSCh was 
used as a substrate, compared to fSmBChE1. Conversely, fSmBChE1 hydrolyzed BcSCh to 
significantly higher levels compared to fSmAChE1 and fSmAChE3. Both classes of fSmChEs 
showed significantly higher activity against their preferred substrate (Fig 3.6B). All paralogs 
exhibited Michaelis–Menten kinetics (Table 3.1) when hydrolyzing their designated substrate. In 
addition, preferred substrate activity of both fSmAChE1 and fSmAChE3 were inhibited by DDVP 
(Fig 3.6C), an AChE inhibitor that forms an irreversible covalent bond with the catalytic serine, 
but iso-OMPA, a specific inhibitor of BChE, only inhibited SmBChE1 activity (Fig 3.6D). 
 
Table 3. 1. Km and Vmax fSmChEs as estimated by Michaelis-Menten equation  
SmChE paralog Vmax 
(nmol/min/mg) 
Km 
(mM) 
fSmAChE1 5.57 ± 0.54 5.83 ± 1.62 
fSmAChE3 5.59 ± 1.37 10.87 ± 6.17 
fSmBChE1 1.7 ± 0.09 34.38 ± 12.71 
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Fig 3.6. Enzymatic activity of fSmChEs. (A) Western Blot analysis of purified recombinant 
fSmAChE1, fSmBChE1, and fSmAChE3 expressed in P. pastoris. Each fSmChE was probed with its 
cognate pSmChE antibody (I) fSmAChE1 probed with anti-SmAChE1 mice antisera, (II) fSmBChE1 
probed with anti-SmBChE1 (III) fSmAChE3 probed with anti-SmAChE3. Multiple bands observed 
are due to protein degradation during the purification process. (B) Cholinergic substrate 
preference (AcSCh or BcSCh) of each fSmChE. (C) Inhibition of fSmAChE1 and fSmAChE3 with DDVP 
(AcSCh used as a substrate) and inhibition of fSmBChE1 with iso-OMPA (BcSCh used as a substrate). 
Data are presented as mean ± SEM of triplicate experiments and differences between groups 
were measured by the student’s t test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.  
Chapter 3. Characterization of novel cholinesterases 
 
104 
 
 
3.3.6 BChE and secretory AChE activity in schistosomes 
Although the presence of nonspecific ChE activity has long been known in schistosomes (Bueding 
1952), the gene identity and its function remain unknown. Prompted by the identification of 
SmBChE1 as a BChE based on its substrate preference and inhibition by iso-OMPA, I sought to 
investigate the distribution of BChE activity in juvenile and adult schistosomes. Assay of BChE 
activity revealed that extracts from S. mansoni schistosomula had higher BChE activity compared 
to S. mansoni adult worms (Fig 3.7A) and that activity was significantly greater in S. mansoni 
compared with S. haematobium adults (Fig 3.7B). Varied amounts of AChE activity was detected 
in ES from all developmental stages tested. ES products from adult males had double the AChE 
activity compared to adult female ES products (P < 0.001) while cercarial ES exhibited the highest 
activity (at least ten-fold more than male ES products (P < 0.0001) and egg ES had the lowest (Fig 
3.7C). Availability of ES precluded the measurement of secretory BChE activity from the same 
developmental stages but, of those tested, the BChE activity in schistosomula ES products was 
the highest - twice as high as that of adult (P < 0.01) and cercarial (P < 0.01) ES (Fig 3.7D). SmChEs 
were purified from ES products of S. mansoni adult worms using edrophonium–sepharose affinity 
chromatography. Purification resulted in an activity increase of more than 200-fold relative to 
crude ES (Fig 3.7E). Resolution of the purified sample by SDS-PAGE resulted in a doublet with an 
estimated molecular weight of 70 kDa (Fig 3.7F). The identity of purified, secretory SmChEs was 
substantiated by in-gel LC-MS/MS spectrometry analysis with the peptide data generated used 
to interrogate the S. mansoni proteome (predicted from the S. mansoni genome 
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(http://www.genedb.org/Homepage/Smanson)). The false discovery rate was set at <1% and 
only proteins with at least two unique peptides having significant Mascot identification scores 
(P < 0.05) were considered. The top protein hits were identified as SmAChE1 (Smp_154600) and 
SmBChE1 (Smp_125350) with SmAChE1 having a relative abundance more than 40 fold that of 
SmBChE1 (Supplementary Table 3.2). 
 
Fig 3.7. BChE and secretory AChE activity in schistosomes. (A) BChE activity in S. mansoni adults 
and schistosomula Tx-100 extracts. (B) BChE activity in Tx-100 extracts from S. mansoni and S. 
haematobium.  (C) AChE and (D) BChE activity of ES products from different developmental stages 
of S. mansoni.  (E) AChE activity and (F) SDS-PAGE analysis of purified, secretory SmChEs. Data are 
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presented as mean ± SEM of triplicate experiments and differences between groups 
were measured by the student’s t test. *P ≤ 0.05, **P ≤ 0.01. 
 
3.3.7 Bio-scavenging of organophosphorus esters by SmBChE1 
The hypothesis that SmBChE may act as a molecular decoy in schistosomes and detoxify the 
effects of organophosphorus AChE inhibitors was examined by testing whether (a) inhibition of 
parasite-derived BChE potentiated the effects of DDVP (an organophosphorus AChE inhibitor) 
and (b) addition of exogenous BChE (fSmBChE1) mitigated the effects of DDVP. Inhibition of AChE 
in extracts by DDVP significantly increased in the presence of increasing amounts of the BChE 
inhibitor, iso-OMPA (Fig 3.8A) and DDVP-mediated killing of schistosomula was significantly 
increased in the presence of iso-OMPA (60.9% compared with 21.8%; P < 0.0001) (Fig 3.8B) and 
in SmBChE-silenced parasites (83.44% compared with 22.95%; P < 0.0001) (Fig 3.8C). Conversely, 
DDVP-induced inhibition of AChE in extracts was completely ablated in the presence of fSmBChE 
(Fig 3.8D) and schistosomula were increasingly resistant to DDVP-mediated killing with the 
addition of increasing amounts of recombinant protein to the culture media (Fig 3.8E).  
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Fig 3.8. SmBChE1 bio-scavenges DDVP and protects parasites against DDVP-induced effects.(A) 
Schistosomula extracts were treated with DDVP (1 μM), or pretreated with iso-OMPA (1 and 2 mM) 
and then DDVP, before assaying AChE activity. (B) Schistosomula were treated with DDVP (1 μM) 
or pretreated with iso-OMPA (100 μM) and then DDVP, and parasite viability measured 5 h after 
treatment. (C) SmBChE1-silenced or luciferase siRNA-treated schistosomula were treated with 
DDVP (1 μM) and parasite viability measured 5 h after treatment. (D) Schistosomula extracts were 
pre-incubated with fSmBChE1 (10 μg) then treated with DDVP (1 μM), or treated with DDVP alone, 
before assaying AChE activity. (E) DDVP was pre-incubated with fSmBChE1 (10, 5 and 2.5 μg) or 10 
μg of SmTSP2 for 1 h before being used to treat schistosomula. Parasite viability was measured 24 
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h post-treatment. For all assays, data are the average of triplicate biological and technical 
experiments ± SEM and differences were measured by the student’s t test. *P ≤ 0.05, ***P ≤ 0.001, 
****P ≤ 0.0001. 
 
3.4 Discussion  
Cholinesterase (ChE) activity in S. mansoni was first described by Bueding in 1952 (Bueding 1952) 
and was well characterized biochemically in the four decades succeeding this discovery. The 
technological limitations of this time period meant that most of the evidence for SmChEs came 
from whole worm studies and analyses of crude parasite extracts (reviewed in (Arnon et al. 
1999)), which could not ascribe ChE activity to any particular protein. Several studies in the early 
2000’s characterized a single AChE from S. mansoni (Smp_154600 in the current gene annotation 
nomenclature) and its direct homolog in other species of schistosomes (Jones et al. 2002; Bentley 
et al. 2003; Bentley et al. 2005) but lack of a comprehensive schistosome genome annotation 
precluded identification of more ChE family members. Interrogation of the most recent iteration 
of the S. mansoni genome assembly has identified two additional ChE-encoding genes that are 
paralogs to Smp_154600 (termed SmAChE1); Smp_125350 (SmBChE1) and Smp_136690 
(SmAChE3). In this current study, I have provided a more in-depth characterization of the 
previously documented SmAChE1 and described two novel ChEs from S. mansoni: SmAChE3 – an 
AChE not reported before – and SmBChE1 – a BChE which, to the best of our knowledge, has 
never been documented in the helminth literature. 
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All SmChEs share a modest level of identity which is consistent with their divergence over 
evolutionary time, an occurrence possibly due to a series of gene duplications as each paralog’s 
clade is distant from one other. This divergence between SmChEs and, also, ChEs of other 
organisms, provides evidence for the increasing reports of non-cholinergic functions appearing 
for ChEs in the literature. Additionally, the relative lack of sequence identity between SmChEs 
and human ChEs suggests potential scope for the development of intervention strategies 
targeting schistosome ChEs that will not affect the host. Despite the diversity between ChEs, all 
enzymes analyzed would appear to be enzymatically active as they possessed a catalytic triad 
with an active site serine, the amino acid responsible for ester hydrolysis (Dvir et al. 2010). It is 
interesting to note, however, the catalytic triad His – Gln substitution in SmBChE1 (and the other 
platyhelminth BChE1 homologs); while this change is not a hallmark of model BChEs, that it 
occurs within an entire parasite lineage is remarkable and will be investigated further. 
 
The transcript levels of SmChEs varied among parasite developmental stages and this is likely a 
response to the differing cholinergic and cholinesterase-independent needs of the parasite 
throughout its lifecycle.  For example, SmAChE1 is expressed at a relatively higher level in adult 
males compared to females, probably due to the more “muscular” roles of attachment and 
movement orchestrated by the male compared to the female, which remains sedentary once 
inside gyancophoric groove of the male (Basch 1990). SmBChE1 expression was the highest in 
eggs; there is evidence for BChE involvement in chicken embryo neurogenesis and development, 
independent of its enzymatic function (Mack et al. 2000), which suggests that SmBChE1 could 
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play a role in parasite embryogenesis. The miracidia and sporocyst stages had the highest levels 
of SmAChE3 expression, in agreement with Parker-Manuel et al (Parker-Manuel et al. 2011).  
 
Immunolocalization of the SmChEs revealed expression in the neuromusculature and tegument 
to varying degrees, depending on the paralog, and is consistent with early localization 
experiments (Espinoza et al. 1991), although the antibodies used in those studies were raised 
against AChEs purified from parasite extracts and so the localization could not be attributed to a 
specific family member. Localization to the neuromusculature relates to the proteins’ traditional 
cholinergic functions whereas tegumental distribution is suggestive of more non-neuronal 
cholinergic and/or non-cholinergic roles. Indeed, surface-expressed SmAChE has been implicated 
in mediating glucose scavenging by the parasite as this process can be ablated by membrane-
impermeable AChE inhibitors (Camacho et al. 1995; Sundaraneedi et al. 2017). Tegumental 
SmAChE may also act to hydrolyze exogenous ACh, neutralizing its immune-mediating function 
to create an environment more conducive to parasite establishment (Vaux et al. 2016). The 
localization of these antigens to the tegument of schistosomula should also be noted since early 
developing schistosomula are considered most vulnerable to immune attack (Gobert et al. 2007) 
and so SmAChE-targeted immunotherapeutics could be used effectively to vaccinate against 
schistosomiasis. Indeed, antibodies against SmAChEs have been shown to interact with the 
molecules on the surface of schistosomula, resulting in complement-dependent killing of the 
parasite (Arnon et al. 1987). 
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Full-length and functional SmChEs were expressed in P. pastoris. SmAChE1 had preferred 
substrate specificity for AcSCh over BcSCh, albeit at a three-fold less affinity than previously 
reported for SmAChE1 expressed in Xenopus laevis oocytes (Bentley et al. 2005). SmAChE3 also 
had a substrate preference for AcSCh and an affinity twice that of SmAChE1. Extremely low 
enzyme activity was observed with SmBChE1 when AcSCh was used as a substrate, which 
significantly increased with the use of BcSCh. Although sequence alignment of SmBChE1 with the 
other two SmChEs revealed a single amino acid substitution in the PAS (Glu – Trp), acyl binding 
pocket (Val – Leu) and catalytic triad (His – Gln), it was unclear whether these changes alone were 
enough to classify SmBChE1 as a BChE. Based on the significant difference in substrate 
preference, however, this classification would appear valid. Cloning of a recombinant BChE from 
S. mansoni is consistent with our observations of BChE activity in parasite extracts. S. mansoni 
schistosomula exhibited significantly more activity than adults, as did S. mansoni compared to S. 
haematobium adults. It has been reported that S. mansoni is more sensitive to the BChE inhibitor, 
iso-OMPA, than S. haematobium (Camacho et al. 1994) and it may be because there is an 
increased BChE activity in S. mansoni. Indeed, this relationship has been documented between 
AChE and metrifonate (precursor of DDVP used in this study); S. haematobium is more sensitive 
to the inhibitor than S. mansoni because of the greater amount of AChE on the worm’s surface 
(Camacho et al. 1994). 
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For the first time, I document the presence of secretory SmChE activity in schistosomes and AChE 
activity was highest in cercarial ES products. Of the intra-mammalian stages tested, AChE activity 
was highest in schistosomula and adults and may be acting to bind and neutralize exogenous 
AChE inhibitors (Mackintosh 2004) (thus protecting tegumental and somatic AChE) or host-
derived ACh to mitigate the immunomodulatory effects of this molecule. Extending this 
hypothesis, ES products from cultured females had lower AChE activity than males and could be 
due to females’ worm having less of a requirement for this defensive mechanism as they reside 
in relative shelter of the gynaecophoric canal. BChE activity was present in the ES products of 
adults, schistosomula and cercariae and was significantly higher in the intra-mammalian larval 
stage than the other two stages. The SmChE molecules present in ES were isolated by purification 
on edrophonium (a ChE inhibitor) sepharose and, consistent with the class of activity observed 
in ES, identified by mass spectrometry as SmAChE1 and SmBChE1; the former being forty-fold 
more abundant than the latter.  
 
It is generally accepted that vertebrate BChE has a predominant role in the detoxification of 
ingested or inhaled drugs and poisons such as the AChE-inhibitory organophosphorus esters that 
constitute nerve agents and pesticides due to the binding of the enzyme to these molecules 
[reviewed in (Lockridge 2015)]. Inactivation of SmBChE1 in parasite extracts and live 
schistosomula by the BChE inhibitor iso-OMPA or through RNAi-mediated silencing potentiated 
the effects of DDVP whereas addition of exogenous SmBChE1 mitigated the effects, suggesting a 
similar detoxification role exists for schistosome BChE as for the vertebrate enzyme. The 
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localization of SmBChE1 to the tegument and its presence in ES products may further support 
this hypothesis as the enzyme would be spatially available to interact with toxins present in the 
host environment and safeguarding parasite AChE against AChE inhibitors. Moreover, BChE 
activity is higher in S. mansoni than S. haematobium, which is more sensitive to the effects of the 
organophosphorus AChE inhibitor metrifonate; it has been reported that this sensitivity is due to 
the larger amount of tegumental AChE present in S. haematobium (Camacho et al. 1994), but it 
may also be due to the reduced amount of BChE available to detoxify the inhibitor as a similar 
relationship has been reported in studies which use human BChE to counter organophosphate 
toxicity (Saxena et al. 2006).  Plasma-derived human BChE is currently in phase I clinical trial to 
as a nerve agent detoxifier and a recombinant human BChE mutant is being used to prevent 
relapse in cocaine addicts due to the enzyme’s ability to hydrolyze the drug into inactive by-
products (Lockridge 2015). One of the major limitations of these approaches, however, is the 
catalytic turnover of human BChE (Lockridge 2015) and so there is a research focus into the 
identification of BChE homologs from other organisms, such as SmBChE1, that might act better 
as detoxification agents in this regard. 
 
Inhibition of BChE in the absence of DDVP results in parasite death so a bio-scavenging role is 
possibly not the only function of this enzyme. Indeed, vertebrate BChE has also been shown to 
have roles in (1) ACh hydrolysis in situations of AChE deficiency (Boudinot et al. 2005), (2) fat 
metabolism by hydrolyzing the feeding stimulant peptide octanoyl ghrelin (De Vriese et al. 2004)  
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and (3) scavenging polyproline-rich peptides to regulate protein-protein and protein-DNA 
interactions (Adzhubei et al. 2013).  
 
In summary, the work herein has identified multiple ChE paralogs in the genome of S. mansoni 
where previous studies, making use of the technology available at the time, attributed ChE 
activity to a single AChE, which I have termed SmAChE1. Consistent with previous observations 
that ChEs are multi-faceted enzymes, I posit that the three ChE paralogs described herein may 
fulfil distinct neuronal and non-neuronal functions based on their anatomical and temporal 
expression in the parasite and its ES products and the enzymatic activity of recombinant 
molecules. The function of SmBChE1 has been partially addressed by RNAi studies and a more 
comprehensive RNAi-based study of all three paralogs is described in chapter 4, which may 
further elucidate the function of these molecules.  
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CHAPTER 4 
 
 
 RNAi-mediated silencing of SmChEs affects parasite cholinergic signaling and 
development 
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4.1 Introduction 
The nervous system of helminths has been long known to be a potential target for therapeutic 
agents (Ribeiro et al. 2012; Ribeiro et al. 2013) as it plays several crucial roles in parasite biology 
that are fundamental to survival, including coordinating motility within and outside of the host, 
feeding and reproduction (Kimber et al. 2005; McVeigh et al. 2005; Ribeiro et al. 2005; Sangster 
et al. 2005; Vermeire et al. 2005). Further, the Schistosoma nervous system is particularly 
important as this parasite lacks a body cavity and circulating body fluid (Halton et al. 1996; Ribeiro 
et al. 2010) and, as a result, its signaling functions are chiefly achieved via neurotransmission. 
The primary neurotransmitter that schistosomes utilize is acetylcholine (ACh), which allows 
muscle contraction. The physiological concentration of ACh, however, must be maintained 
otherwise it triggers paralysis (Kimber et al. 2005; McVeigh et al. 2005; Ribeiro et al. 2005).  
 
Acetylcholinesterase (AChE) hydrolyzes excess ACh at the neuromuscular junction between the 
nervous system and muscles of both vertebrates and invertebrates (Soreq et al. 2001). Without 
the action of AChEs, uncontrolled influx of ACh causes paralysis and eventually death (Kimber et 
al. 2005; McVeigh et al. 2005; Ribeiro et al. 2005). Three cholinesterase (ChE) paralogs have been 
identified from the S. mansoni genome (SmAChE1, SmBChE1, and SmAChE3 – described in 
Chapter 3). Yet, it is not clear whether the three SmChE genes have distinct and/or overlapping 
functions and it remains to be determined which one of the three paralogs is an ideal therapeutic 
target in Schistosoma. The ability to inhibit the SmAChE paralogs separately with gene silencing 
techniques may thus be valuable for understanding the distinctive functions of these molecules. 
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Successful application of RNA interference (RNAi) in various schistosome life stages (reviewed in 
(Bhardwaj et al. 2011; Da’dara et al. 2015)) highlights the potential of this tool to study the 
nervous system of this parasite. Indeed, in schistosomes, RNAi has been successfully used to 
disrupt neurotransmitter transporters (Patocka et al. 2013) as well as neuronal receptors and 
channels (Patocka et al. 2014; MacDonald et al. 2015).  In this chapter, I describe the use of RNAi 
to knockdown each SmChE paralog, in isolation and combination, and examine the impact of this 
silencing on SmChE activity and parasite survival to assess the suitability of each SmChE as an 
intervention target against schistosomiasis.  
 
4.2 Materials and Methods 
4.2.1 Ethics statement  
All experimental procedures reported in the study were approved by the James Cook University 
(JCU) animal ethics committee (ethics approval numbers A2391 and A2432). Snails and mice were 
maintained in the university’s quarantine facilities (Q2713 and Q2152, respectively) for the 
duration of the experiments.  The study protocols were in accordance with the 2007 Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes and the 2001 Queensland 
Animal Care and Protection Act.  
 
4.2.2 Parasite maintenance  
Biomphalaria glabrata snails infected with S. mansoni (NMRI strain) were obtained from the 
Biomedical Research Institute (BRI) and were used as a source of S. mansoni cercariae for this 
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experiment. To obtain cercariae stages, 7-8 weeks old infected snails were set to shed cercariae 
by exposure to light at 28°C for 1.5 h (Lewis et al. 1986) and were mechanically transformed into 
schistosomula (Ramalho-Pinto et al. 1974), the developmental stage used for RNAi experiments. 
 
4.2.3 siRNA Design and Synthesis 
Three short interfering RNA duplexes (siRNAs) targeting each of the three identified SmChE 
paralogs (SmAChE1 - Smp-15460, SmBChE1 - Smp-125350 and SmAChE3 - Smp-
136690), were designed for gene-specific silencing experiments (Supplementary Table 4.1).  
Each siRNA was checked to avoid off-target silencing by BLAST searching the S. mansoni 
genome with each sequence. An irrelevant siRNA from firefly luciferase was selected as 
a negative control (Tran et al. 2010). All selected siRNAs were commercially synthesized (IDT) and 
oligos were suspended (1 μg/μl) using diethylpyrocarbonate (DEPC) treated water.  
 
4.2.4 Electroporation of schistosomula with siRNA 
Prior to electroporation, mechanically transformed schistosomula were cultured for 24 h (2000 
schistosomula/ml, at 37°C and 5% CO2 in modified Basch medium (Basch 1981) supplemented 
with 4× AA in 6 well plates.  After 3 washes with PBS, schistosomula were re-suspended in 
modified Basch medium (3000 schistosomula/100 μl) and 3000 schistosomula were transferred 
into Genepulser 4 mm electroporation cuvettes (Bio-Rad) per siRNA treatment (four) and 
timepoints (four for each treatment – 1, 3, 5 and 7 days). Schistosomula were electroporated 
with 10 μg of either luciferase, SmAChE1, SmBChE1 or SmAChE3 siRNA or a combination of all 
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three SmChE siRNAs (30 μg total) using a Bio-Rad Gene Pulser Xcell (single 20 ms pulse – 125 V, 
25 μF capacitance, 200 Ω resistance, square wave electroporation) at RT, added to 24 well plates 
containing 1 ml fresh pre-warmed modified Basch medium and incubated (37°C, 5% CO2) for 7 
days. Schistosomula were harvested at each timepoint and used for either qPCR analysis (to 
assess transcript knockdown), protein extract preparation (to examine phenotypic knockdown) 
or Trypan Blue exclusion assays (to determine parasite viability). All parasite material was 
generated from two independent experiments. 
 
4.2.5 Total RNA isolation, cDNA synthesis, and real-time qPCR 
Schistosomula (1000 parasites) were harvested after day 1, day 3, day 5 and day 7, washed three 
times in PBS and stored at -80°C until use. Total RNA extraction, cDNA synthesis and RT-qPCR 
(triplicate assays) were performed as described in section 3.2.5.  
 
4.2.6  Parasite extract preparation 
Schistosomula (2000 parasites) were harvested from each timepoint into 300 μl 0.1% Triton X-
100 and stored at -80°C until use.  Parasites were homogenized on ice and mixed overnight at 
4°C. Homogenates were centrifuged at 15,000 xg for 1 h at 4°C, supernatants collected and 
protein concentration determined using the Pierce BCA Protein Assay kit (Thermofisher), 
aliquoted and stored at -80°C until use. 
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4.2.7 AChE and BChE activity assay 
Activity assays were performed as previously described (section 3.2.11) with 15 μg of 
schistosomula extract. Reactions were carried out in triplicate. 
 
4.2.8 Determination of schistosomula viability  
Schistosomula (100 parasites/replicate) were harvested at each timepoint and viability 
determined by Trypan Blue exclusion staining (Wangchuk et al. 2016). Briefly, schistosomula 
were stained with 0.16% Trypan Blue in PBS with gentle shaking for 30 min at RT and then excess 
stain removed by multiple washes in PBS before fixing in 10% formalin.  Parasites were counted 
under 10x objective and the live parasites (which had not taken up stain) expressed as a 
percentage of total worms. Each assay was performed in triplicate.  
 
4.2.9 Evaluation of protein expression 
Western blots were performed with day 7 parasite extracts (20 μg) following standard 
procedures. The blots were probed with polyclonal SmChE antibodies (generated in section 
3.2.8). A polyclonal anti-Sm-paramyosin antibody (Tran et al. 2010) was used as a loading control. 
 
4.2.10 Glucose uptake of schistosomula treated with siRNA 
Newly transformed schistosomula (5000/treatment) were incubated in complete Basch media 
for 5 days. Parasites were then washed several times with PBS and transferred to serum-free 
DMEM. At day 5, all parasites were electroporated with SmChE siRNAs (as in section 4.2.4) and 
transferred into fresh DMEM (1 mg/ml glucose). Media (50 μl) from each experiment was 
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collected 48 h post-treatment and the amount of glucose was quantified using a colorimetric 
glucose assay kit (Sigma) following the manufacturer’s instructions. Parasite viability at this 
timepoint was determined by Trypan Blue exclusion and transcript levels of SmChEs, as well as 
the glucose transporters SGTP1 and SGTP4, were also measured. Glucose levels were normalized 
according to the number of parasites and expressed relative to the luciferase group. Data is the 
average of 2 biological and three technical replicates ± SEM. 
 
4.2.11 Infection of mice with SmChE siRNA-treated schistosomula 
One-day-old cultured schistosomula (10,000) were electroporated in 500 µl of modified basch 
medium with 50 μg of either luciferase, SmAChE1, SmBChE1 or SmAChE3 siRNA or a combination 
of all three SmChE siRNAs (150 μg total) (as in section 4.2.4). Parasites were injected 
intramuscularly (1,000 each thigh) into male, 6-8 week BALB/c mouse (5 mice per group) using a 
23-gauge needle. A control group of mice were similarly injected with non-electroporated 
schistosomula. Adult worms were perfused 20 days later to assess the number of worms that 
had matured and reached the mesenteries.  
 
4.2.12 Statistical analyses 
Data were reported as the means ± standard error of the mean (SEM). Statistical differences 
were assessed using the student’s t test. P values less than 0.05 were considered statistically 
significant. 
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4.3 Results  
4.2.13 SmChE transcript reduction and protein suppression  
Schistosomula electroporated with SmAChE1 siRNA showed respective decreases in SmAChE1 
mRNA levels of 55.4% (P ≤ 0.05) and 81.3% (P ≤ 0.001) at 1 and 7 days post-treatment, 
respectively, compared to the luciferase control (Fig 4.1A), while treating parasites with SmBChE1 
siRNA caused 32.0% (P ≤ 0.001) and 84.5% (P ≤ 0.001) SmBChE1 mRNA suppression at day 3 and 
7 after electroporation, respectively, compared to the luciferase control (Fig 4.1B).  Treatment of 
schistosomula with SmAChE3 siRNA resulted in respective decreases in SmAChE3 mRNA levels of 
average 27.4% (P ≤ 0.001) and 47.2% (P ≤ 0.01) 3 and 7 days after electroporation, compared to 
the luciferase control (Fig 4.1C).  Schistosomula electroporated with a cocktail of all three SmChE 
siRNAs showed decreases of all three transcript levels over time, with SmAChE3 mRNA levels 
decreasing by an average of 90% (P ≤ 0.001) by day 3 after treatment, compared to the luciferase 
control (Fig 4.1D).  
 
Seven days after treatment with SmAChE1, SmBChE1 or SmAChE3 siRNAs, parasites showed 
decreases in SmAChE1, SmBChE1 or SmAChE3 protein expression of 73%, 59% and 46%, 
respectively, compared to luciferase controls (Fig 4.1E).      
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Fig 4.1. Suppression of SmChE mRNA transcript and protein expression in schistosomula by RNAi. 
(A) SmAChE1, (B) SmBChE1, (C) SmAChE3 individual siRNA treatment (D) treatment with cocktail 
of SmAChE1, SmBChE1, and SmAChE3 siRNAs. SmChE transcript levels in parasites treated with 
SmChE siRNAs are shown relative to SmChE transcript expression in schistosomula treated with the 
luciferase control (mean ± SEM of triplicate assays from 2 biological replicates of each treatment). 
Transcript expression in all parasites was normalized with the housekeeping gene, SmCOX1. 
Differences in transcript levels were measured by the student’s t test. *P ≤ 0.05, **P ≤ 0.01, ***P 
≤ 0.001. (E) Western blot of day 7 schistosomula extracts following treatment with SmChE or 
luciferase siRNAs. Extracts were immunoblotted with the corresponding anti-SmAChE1, anti-
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SmBChE or anti-SmAChE3 polyclonal antibody. An antibody against SmPmy was used as a loading 
control.  
 
4.2.14 Suppression of SmChE activity 
Suppression of AChE activity was seen in SmAChE1 and SmAChE3 siRNA-treated parasites at 5 
and 3 days after electroporation, respectively (Fig 4.2A), compared to the luciferase control, 
while schistosomula treated with SmBChE1 siRNA did not show any significant reduction in BChE 
activity, even 7 days after electroporation (Fig 4.2B).  Parasites electroporated with a cocktail of 
all 3 SmChE siRNAs showed significant decreases in AChE activity at 3 days (62% reduction, P ≤ 
0.001), 5 days (67% reduction, P ≤ 0.001) and 7 day (71% reduction, P ≤ 0.001) after treatment 
(Fig 4.2C). BChE activity was not measured in the cocktail siRNA treatment group. 
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Fig 4.2. Effects of SmChE knockdown on cholinesterase activity. (A) AChE activity of parasites 
treated with SmAChE1, SmAChE3 or luciferase siRNA (dashed line). (B) The BChE activity of 
parasites treated with SmBChE1 or luciferase siRNA (dashed line). (C) AChE activity of parasites 
treated with all 3 siRNAs or luciferase siRNA (dashed line). Data represents mean ± SEM of 
duplicate assays from 2 biological replicates of each treatment. Differences were measured by 
the student’s t test. ***P ≤ 0.001. 
 
4.2.15  Suppression of parasite viability 
Parasites treated with SmAChE1, SmBChE1 or SmAChE3 siRNA showed significant decreases in 
viability at day 3, 5 and 1 after treatment, respectively, compared to luciferase controls. At day 5 
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and 7 post-treatment, the most significant decreases in parasite viability was seen in the group 
which received the cocktail siRNA treatment, compared to luciferase controls. Further, viability 
in this group was also significantly lower than any individual treatment at these two time periods.  
Fig 4.3. Effects of SmChE silencing on schistosomula viability. Schistosomula treated with (A) 
individual or (B) all 3 siRNAs were cultured for 7 days in complete Basch medium with viability 
determined at day 1, 3, 5 and 7 after treatment by Trypan Blue exclusion (mean ± SEM of 
duplicate assays from 2 biological replicates of each treatment. Differences in viability between 
SmChE and luciferase treated groups and individual and cocktail treated groups were measured 
by the student’s t test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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4.2.16 RNAi-mediated suppression of glucose uptake 
Individual silencing of SmAChE1 or SmAChE3 and combined silencing of all three SmChEs reduced 
glucose uptake in schistosomula by 24.9% (P ≤ 0.001), 32.34% (P ≤ 0.001) and 38.61% (P ≤ 0.001) 
at 48 h post-treatment, respectively, relative to the luciferase control. However, SmBChE1-
silenced parasites showed no significant changes in glucose uptake at the same timepoint. There 
was no difference in the glucose consumed by the SmAChE1 or SmAChE3 siRNA-treated groups 
compared with the cocktail siRNA-treated group (Fig 4.4A).  Transcript levels of the glucose 
transporters, SGTP1 and SGTP4, were neither decreased nor significantly increased in individual 
or cocktail SmChE-silenced parasites (Fig 4.4B). 
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Fig 4.4.  Schistosome glucose uptake is affected by SmChE suppression. (A) Glucose uptake by S. 
mansoni schistosomula 48 h after treatment with SmChE siRNAs. Schistosomula (5 days old - 
5000/treatment) were electroporated with either luciferase or SmChE siRNA and glucose 
consumption normalized by parasite viability was measured 48 h after treatment. (B) Transcript 
levels of glucose transporters SGTP1 and SGTP4 and SmChEs in individual and cocktail SmChE-siRNA 
treatment parasites, relative to luciferase-treated controls (dashed line). Data are representative of 
the mean ± SEM of two independent experiments. P values were calculated using the student’s t 
test. *p value ≤ 0.05, **p value ≤ 0.01, ***p value ≤ 0.001. 
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4.2.17 SmChEs are essential for parasite development and survival in mammalian hosts 
To examine whether RNAi-mediated SmChE suppression reduced parasite viability in vivo, mice 
were infected with SmChE-silenced parasites and worm burdens measured after three weeks. 
From two independent experiments, there was an average 88.15%, 55.15%, 75.95% and 88.35% 
decrease in worm burden from mice infected with SmAChE1-, SmBChE1-, SmAChE3- and SmChE 
cocktail-silenced parasites, respectively, compared to mice infected with luciferase-treated 
parasites.   All worm burden decreases were significant and there was no significant difference 
between mice infected with luciferase-treated and non-electroporated control parasites. 
There was no longer any difference in SmChE transcript levels from recovered parasites (data not 
shown) and all mice had been successfully infected with parasites, as serum from necropsied 
mice contained parasite-specific antibodies (data not shown).   
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Fig 4.5. Silencing of SmChEs suppresses parasite establishment in vivo.  
One-day-old schistosomula were treated with SmAChE1, SmBChE1 or SmAChE3 siRNA, a cocktail of 
all three SmChE siRNAs, or luciferase siRNA and then intramuscularly injected (2,000 parasites) into 
mice. Non-electroporated parasites were similarly used as controls After 3 weeks, adult worms 
were recovered and counted. Data from two independent experiments (A and B) are shown.  
Significant differences were determined using the student’s t test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. 
 
4.4 Discussion 
RNA interference (RNAi) is a mechanism employed by most eukaryotic cells to control coding 
transcript levels of targeted genes which, in turn, results in downregulation of targeted protein 
expression (Ndegwa et al. 2007; Da'dara et al. 2015). Schistosomes have the cellular machinery 
to carry out this gene-specific targeting of protein expression (Krautz-Peterson et al. 2008) and 
so RNAi has been used to characterize schistosome proteins through loss of function studies 
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(Krautz-Peterson et al. 2008; Krautz-Peterson et al. 2010; Patocka et al. 2014). Further, and 
relevant to this study, RNAi has been used to disrupt schistosome neurotransmitter transporters 
(Patocka et al. 2013) and neuronal receptors and channels (Patocka et al. 2014; MacDonald et al. 
2015). Accordingly, this gene-silencing method was used to determine the functionality and 
essentiality of SmAChE1, SmBChE1 and SmAChE3 through targeted knockdown, either 
individually or in combination, with a view to validating these proteins as therapeutic targets 
against schistosomiasis.  
Treatment of schistosomula with SmChE siRNAs, either individually or in combination, resulted 
in transcriptional suppression of each target by at least 50% three days after electroporation.  
Knockdown had increased at each timepoint until termination of the experiment at day 7 post-
treatment, and there was a comparable reduction in protein expression of each paralog at this 
time, indicating that silencing of SmChE genes can be achieved effectively by siRNA-mediated 
RNAi and demonstrating the feasibility of simultaneous transcript suppression in schistosomes.  
 
SmAChE1- and SmAChE3-silenced parasites showed decreases in AChE activity, consistent with 
reductions in transcript and protein expression levels. Moreover, inhibition of this biochemical 
activity was greater in schistosomula treated with the SmChE siRNA cocktail than parasites 
receiving any of the individual treatments, further evidence suggestive of simultaneous silencing 
of SmAChEs. AChE activity inhibition in SmAChE3-silenced parasites was more pronounced than 
in SmAChE1-silenced parasites, which was inconsistent with protein level reductions and this may 
be due to the increased AChE activity reported for SmAChE1 (Vmax = 5.57 nmol/min/mg, Km = 
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5.83 mM) compared to SmAChE3 (Vmax = 5.59 nmol/min/mg, Km = 10.87 mM) (section 3.3.5). It 
is also possible that there may not be a direct correlation between AChE activity and protein 
expression, given that additional, non-cholinergic functions have been ascribed to ChEs 
(Camacho et al. 1995; Lee 1996; Soreq et al. 2001). This may also be the reason why no significant 
decrease in BChE activity was observed in SmBChE1-silenced parasites, despite significant 
reductions in transcript and protein expression levels. 
 
Individual SmChE silencing each resulted in significant decreases in parasite viability at various 
timepoints after treatment with SmAChE3-silenced parasites showing the most significant 
decrease in viability most quickly after treatment. SmAChE3 is the only one of the SmChE paralogs 
studied whose expression is remarkably upregulated between S. mansoni cercariae and 
schistosomula (Parker-Manuel et al. 2011), an observation consistent with qPCR data (section 
3.3.2), and so silencing this relatively highly expressed gene may have the most profound effects 
of all SmChE silencing on parasite viability. The viability of parasites treated with all three SmChE 
siRNAs was significantly decreased compared to parasites treated with an individual siRNA, 
suggestive of the fact that functional overlap exists between the paralogs.  This redundancy has 
been documented in AChE-knockout mice where BChE has the ability to hydrolyze ACh in the 
absence of AChE (Li et al. 2000; Mesulam et al. 2002). Moreover, AChE deletion is found to be 
lethal in Drosophila only because there is no alternative BChE paralog to compensate for the lack 
of ACh hydrolysis (Greenspan et al. 1980; Xie et al. 2000). Similar to the observations in this study, 
simultaneous knockdown of multiple ChE genes have been reported to have deleterious effects 
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on their target organisms including the insects Plutella xylostella (Smith et al. 2012), Chilo suppressalis 
(X.-M. et al. 2011) and Tribolium castaneum (Lu et al. 2012) and the nematodes  Nippostrongylus 
brasiliensis (Hussein et al. 2002) and Caenorhabditis elegans (Johnson et al. 1988). Similarly, 
chemotherapy with “broad spectrum” ChE inhibitors has shown to be effective against a range 
of organisms, including pest insects (Lang et al. 2012), schistosomes (Davis et al. 1969; Bueding 
et al. 1972; Feldmeier et al. 1982; Sundaraneedi et al. 2017) and Trichuris muis parasites 
(Sundaraneedi et al. 2018). It is likely that the simultaneous silencing of the SmChE genes in this 
study has a profound effect on parasite viability due to the knockdown of cholinergic signaling, a 
process to which all paralogs contribute, as they have all been shown to hydrolyze ChE substrates 
(section 3.3.5). Also possible is that knockdown of these three genes might have also resulted in 
the ablation of multiple other functions that have been suggested for these molecules (Pritchard 
1993; Soreq et al. 2001; Lu et al. 2012). Whatever the reason, it is evident that the targeting of 
all these paralogs may be necessary in the development of an intervention strategy against 
schistosomiasis. 
 
Previous studies have documented the involvement of SmChEs in the uptake of exogenous 
glucose by schistosomes through the ablation of the glucose uptake pathway by 
organophosphorus (Camacho et al. 1994) and large molecule (Sundaraneedi et al. 2017) AChE 
inhibitors so I sought to identify the SmChE paralog(s) responsible for this mediation through the 
use of RNAi targeting SmChE genes.  Individual SmChE gene knockdown of SmAChE1 and 
SmAChE3 suppressed glucose uptake in schistosomula, implying that both genes were involved 
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in regulation of this mechanism. Tegumental AChE is speculated to mediate glucose uptake by 
limiting the interaction of ACh with tegumental nicotinic ACh receptors which is thought to 
decrease the amount of glucose uptake through surface glucose transporters and so the fact that 
both molecules are localized to the tegument (section 3.3.4) and can hydrolyze ACh (section 
3.3.5) provide evidence for their role in this pathway. SmBChE1-silenced parasites did not show 
any difference in glucose uptake and is probably reflective of the molecule’s limited role in ACh 
hydrolysis (section 3.3.5).    Transcript levels of SGTP1 and SGTP4 were not significantly increased 
in SmAChE1- and SmAChE3-silenced parasites, suggesting that SmAChEs may facilitate glucose 
uptake in a manner which does not directly involve glucose transporters. Indeed, at least in 
nematodes, AChEs have been proposed to be involved in altering the permeability of 
surrounding host cells, allowing nutrients (such as glucose) to leak into the parasite niche and be 
uptaken (Lee 1970).  
 
Given that suppression of SmChEs affected parasite viability and inhibited biochemical activity in 
vitro, it was decided to examine whether the establishment of SmChE-silenced schistosomula 
would be impaired in vivo.  Worm recovery from mice infected with all groups of SmChE-silenced 
parasites was significantly less than controls, indicating that suppression of SmAChE1, SmBChE1 
or SmAChE3 could inhibit schistosome establishment and/or development in the host.  Viability 
of silenced parasites was decreased in in vivo compared to in vitro experiments. It may be that in 
vitro killing of parasites silenced for individual SmChEs could have been achieved had the 
experiment been conducted for longer than 7 days. Another possible explanation is that SmChE 
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silencing may be more “effective” in vivo as knockdown is inhibiting processes that are influenced 
by host biology and not evident in an in vitro system. For example, it has been indirectly shown 
that the nematode N. brasiliensis employs parasite-derived AChE to alter the host cytokine 
environment so as to be more favorable to worm survival (Vaux et al. 2016); the consequence of 
silencing this interaction could only be observed in vivo and not through the use of an in vitro 
RNAi experiment. This contrast between in vitro and in vivo RNAi experimental results has been 
observed previously in schistosomes; Krautz-Peterson et al (Krautz-Peterson et al. 2010) have 
shown that, while the mortality of schistosomula silenced for the glucose transporters SGTP1 and 
SGTP4 was unaffected in vitro, similarly silenced parasites displayed an impaired ability to 
establish infection when introduced into mice.   Further, and consistent with in vitro data, 
schistosomula silenced for all three SmChEs exhibited the highest mortality in vivo when worm 
recovery was averaged across the two independent trials, suggesting that, not only is 
simultaneous knockdown of SmChEs required to overcome any functional redundancy between 
the molecules, this treatment has the largest impact on parasite pathogenesis due to the 
inhibition of multiple biological functions collectively orchestrated by these proteins. 
 
SmChE transcript levels of silenced worms recovered from mice were no different from control 
parasites and it is likely that the surviving worms were parasites which received less siRNA than 
others in the population, resulting in less gene suppression, and/or recovered from the effects of 
RNAi, which is a transient treatment. CRISPR/Cas9 technology offers an advantage over RNAi in 
that it permanently “knocks out” the targeted gene by introducing mutations in the genome of 
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an organism and the recent application of this procedure to schistosomes (Ittiprasert et al. 2018) 
means that the functions of biologically important molecules such as SmChEs can be 
comprehensively deciphered using in vivo models of schistosomiasis due to the permanent 
silencing effects of this technology. 
 
Taken together, these results confirm that SmChEs are essential for parasite survival, a claim 
reinforced by numerous studies in a variety of organism where suppression of AChE genes 
affected survivability (Kumar et al. 2009; X.-M. et al. 2011; He et al. 2012; Gong et al. 2013; Malik 
et al. 2016; Kishk et al. 2017; Ye et al. 2017). While ChEs have previously been validated as lethal 
chemotherapeutic target in Schistosoma spp (Davis et al. 1969; Bueding et al. 1972; Hillman et 
al. 1975; Feldmeier et al. 1982; Sundaraneedi et al. 2017), this study is the first report on the 
effect of ChE gene silencing on the in vivo development of any Schistosoma spp. Given the 
essentiality of SmChEs, determined by the RNAi studies in this chapter, the vaccine efficacy of 
recombinant SmChEs will be explored in Chapter 5. 
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CHAPTER 5 
 
 
 
Vaccine efficacy of recombinant S. mansoni cholinesterases in a mouse model of 
schistosomiasis 
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5.1. Introduction  
Despite decades of concentrated research, there is still no effective and practical vaccine against 
schistosomiasis (Egesa et al. 2017). Further, mass chemotherapy using praziquantel (PZQ), the 
only effective anti-schistosomal drug, is complicated by rapid and frequent re-infection (Mduluza 
et al. 2001). There is also evidence that resistance to PZQ is emerging (Crellen et al. 2016). So far, 
a considerable number of schistosome antigens have been identified and tested as vaccines and, 
although a number of these vaccine candidates (for example SmTSP-2, Sm14, Sm29, SmCB1 and 
Smp80) have shown promising efficacy in animals models and are in various stages of pre-clinical 
or clinical development, none has been approved for licensure [reviewed in (Tebeje et al. 2016)].  
 
Due to the fundamental roles they play in parasite biology (reviewed in  (Arnon et al. 1999), 
schistosome cholinesterases (SmChEs) have been posited as intervention targets against 
schistosomiasis and there are several indications to support the feasibility of their use as 
vaccines. Firstly, SmChEs have been localized to the tegument of schistosomula and adult worms 
(Espinoza et al. 1991) (Chapter 3) and anti-SmChE antibodies have been shown to bind to and kill 
schistosomula (Arnon et al. 1987), suggesting that the enzymes are accessible to immune attack. 
Anti-SmChE antibodies also showed no cross-reactivity against human AChE (Espinoza et al. 
1991), indicating that a vaccine safe for human use could be designed. Thirdly, protein array 
studies have detected significantly high levels of antibodies to SmChEs in humans exhibiting 
resistance and low pathology to schistosomiasis, suggesting an involvement of these antibodies 
in a protective anti-schistosomal response (Pearson et al. 2015; Driguez et al. 2016). 
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Lastly, RNAi-mediated suppression of ChEs in both S. mansoni (Chapter 4) and S. japonicum (You 
et al. 2018) revealed that the enzymes are essential for parasite survival. However, it remains to 
be determined which SmChE paralogs are effective vaccine targets in S. mansoni, particularly as 
there appears to be some functional redundancy between the enzymes (Chapter 3).  
 
Herein, I have demonstrated that purified IgG against each of the three SmChE paralogs identified 
in chapter 3 inhibit ChE activity in both larval and adult worms in vitro, which results in eventual 
parasite death. Further, I document the efficacy of these SmChEs, when administered as 
recombinant vaccines in isolation or as a triple combination, in reducing parasite burden, stunting 
worm growth and decreasing egg viability. 
 
5.2. Material and Methods 
5.2.1. Ethics statement  
All experimental procedures reported in the study was approved by the James Cook University 
(JCU) animal ethics (Ethics approval numbers A2391). Mice were maintained in cages in the 
university’s quarantine facility (Q2152) for the duration of the experiments.  The study protocols 
were in accordance with the 2007 Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes and the 2001 Queensland Animal Care and Protection Act. 
 
5.2.2. Parasites  
Biomphalaria glabrata snails infected with S. mansoni (NMRI strain) were obtained from the 
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Biomedical Research Institute (BRI) and cercariae were shed by exposure to light at 28°C for 1.5 
h (Ramalho-Pinto et al. 1974). Cercariae were mechanically transformed to obtain schistosomula 
(Ramalho-Pinto et al. 1974). To obtain adult worms, 6-8 week old male BALB/c mice (Animal 
Resource Centre, WA) were infected with 180 cercariae via tail penetration and parasites 
harvested by vascular perfusion at 7-8 weeks post-infection (Lewis et al. 1986).  
 
5.2.3. Recombinant protein expression and purification  
Recombinant SmChE subunit proteins (pSmChEs) were expressed in E. coli BL21 (DE3) and 
purified by IMAC, as described in Section 3.2.6-3.2.7.  
 
5.2.4. Effect of polyclonal anti-SmChE IgG on larval worms  
Newly transformed schistosomula (1000/ml) were cultured in DMEM (supplemented with 4x AA) 
at 37°C and 5% CO2 in the presence of 50 µg of either anti-SmAChE1, SmBChE1 or SmAChE3 
polyclonal IgG (section 3.2.8) or a combination of all three antibodies (equal amounts - 50 µg 
total). Separate sets of parasites were similarly incubated with 50 µg of naïve mouse IgG, which 
served as a control.  After 2 and 14 h (separate experiments were conducted for each timepoint), 
surface and secreted ChE activity was measured by Ellmann assay (section 3.2.11) by incubating 
the parasites in assay buffer for 1h and schistosomula viability determined by Trypan Blue 
exclusion (section 2.x). Enzyme activities of IgG-treated parasites were expressed relative to 
parasites cultured with naïve IgG (negative control). Data are presented as the average of two 
biological and three technical replicates ± SEM. 
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5.2.5. Effect of polyclonal anti-SmChE IgG on adult worms  
Enzyme inhibitory effects 24 h after addition of IgG were measured as for schistosomula using 5 
pairs of freshly perfused adult worms in 1 ml of media. Data are presented as the average of two 
biological and two technical (four total) replicates ± SEM. To investigate the effects of polyclonal 
anti-SmChE IgG on worm viability, ten pairs of worms were similarly incubated with antibodies 
for 10 days, monitored every 24 h for motility by microscopic examination and considered dead 
if no movement was seen. Glucose uptake was also measured calorimetrically using a glucose 
assay kit (Sigma) as described earlier (section 2.17), 24 h after antibody addition. Glucose levels 
were expressed relative to media collected from worms which received naïve IgG (negative 
control). Data are presented as the average of two biological replicates ± SEM.  
 
5.2.6. Anti-SmChE IgG responses in S. mansoni-infected mice during infection and before and 
after PZQ treatment  
Sera from S. mansoni infected male BALB/c mice (6-8 weeks) (n=5) was collected at day 3, 14, 28, 
42 and 56 post infection (p.i.) to assess anti-SmChE responses during the course of parasite 
infection. In a separate experiment, sera from S. mansoni infected male BALB/c mice (6-8 weeks) 
(n=11) was collected at 5 weeks p.i. and then mice were treated orally with PZQ (100 mg/kg) at 
35, 37 and 39 days p.i. Sera was again collected at day 49 p.i. (2 weeks post-PZQ treatment). Anti-
SmChE responses during infection and before and after PZQ treatment were screened by ELISA 
with plated pSmChEs (100 ng/well) using standard methods. The cutoff value for each dilution 
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was established as three times the mean OD of the naïve sera for that dilution and the endpoint 
was defined as the highest dilution above the cutoff value.  
 
5.2.7. Vaccine trials 
Five groups of 10 male BALB/c mice (6-8 weeks) were immunized intraperitoneally on day 1 (50 
μg/mouse) with either pSmAChE1, pSmBChE1, pSmAChE3, a combination of all three pSmChEs 
(17 μg each - 50 μg total) or PBS, each formulated with an equal volume of Imject alum adjuvant 
(Thermofisher) and 5 μg of CpG ODN1826 (InvivoGen). Immunizations were repeated on day 
15 and 29 and each mouse was challenged (abdominal penetration) with 120 S. 
mansoni cercariae on day 43. Two independent trials were performed to ensure reproducibility. 
Blood was sampled at day 28 and 42 and on the day of a necropsy to determine pre- and post-
challenge antibody titers.  
 
5.2.7.1 Mouse necropsy and estimation of worm and egg burden: 
Mice were necropsied at day 91 (7 weeks post-infection) and worms harvested by vascular 
perfusion and counted. Livers were removed and halved, with one half weighed and digested for 
5 h with 5% KOH at 370C with shaking. Schistosome eggs from digested livers were concentrated 
by centrifugation at 1,000 g for 10 minutes and re-suspended in 1 ml of 10% formalin. The 
number of eggs in a 5 μl aliquot was counted in triplicate and the number of eggs per gram 
(EPG) of t h e  liver was calculated. Small intestines were removed and cleaned of debris before 
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being weighed and digested as per the liver halves. Eggs were also similarly concentrated and 
counted to calculate intestinal EPG. 
 
5.2.7.2 Egg viability assays 
The other half of each liver was pooled according to the group, homogenized in H2O and placed 
in identical foil-covered volumetric flasks under bright light to hatch eggs released from the livers. 
After 1 h, the number of miracidia in 10 x 50 μl aliquots of H2O (sampled from the extreme top 
of each flask) were counted.  The number of eggs in each flask at the start of the hatching 
experiment was determined by liver EPG calculations, allowing the egg hatching index of each 
group to be calculated by expressing the hatched eggs (miracidia) as a percentage of the total 
eggs. 
 
5.2.7.3 Glucose consumption and glycogen storage assays 
Five pairs of freshly perfused worms from each vaccinated group were cultured in DMEM (1000 
mg/l glucose). Media (50 µl) from each experiment was collected after 24 h, and the amount of 
glucose was quantified using a colorimetric glucose assay kit (Sigma) according to the 
manufacturer’s instructions. Glucose levels were expressed relative to media collected from 
worms, recovered from PBS treated mice (negative control).  To measure the glycogen content 
of the same worms used for glucose uptake assay were used for Triton X-100-soluble extraction 
and assayed for glycogen in a modified procedure described by Gomez- Lechon et al. (Gómez-
Lechón et al. 1996). Briefly, 0.2 M sodium acetate, pH 4.8, was added to 30 μg parasite extract 
Chapter 5. Vaccine efficacy of recombinant S. mansoni cholinesterases 
 
144 
 
and 50 μl glucoamylase (10 U/ml) to make a reaction volume of 150 μl. The mixture was 
incubated at 40°C for 2 h with shaking at 100 rpm, 40 μl added to a new microplate with 10 μl 
0.25 M NaOH and the amount of glucose quantified using the colorimetric glucose assay kit. 
Extracts were made from triplicate sets of parasites (five pairs of worms) and assays were 
performed three times.  Data are presented as the average of each triplicate biological and 
technical experiment ± SEM.   
 
5.2.7.4 Immune responses in vaccinated mice 
Sera were collected from all mice in each group before cercarial challenge and at necropsy. 
Serum anti-SmChE IgG antibodies were measured by ELISA using standard methods. 
 
5.2.8. Statistical analyses 
Statistical differences for all experiments in this chapter were calculated by the Student’s t test 
using GraphPad Prism 7 software. Results are expressed as the mean ± standard error of the 
mean (SEM). 
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5.3. Results  
5.3.1. Anti-SmChE polyclonal antibodies block enzyme activity and decrease viability of larval 
S. mansoni in vitro 
To determine the ability of anti-SmChE specific polyclonal antibodies to inhibit ChE activity in S. 
mansoni, and the effect this had on parasite viability, I studied the effects of paralog-specific 
antibodies on at two different timepoints. Treating schistosomula with anti-SmAChE1 IgG, anti-
SmAChE3 IgG, or a cocktail of all three anti-SmChE IgGs caused significant inhibition (P ≤ 0.01) 
of AChE activity by 56.2%, 57.1% and 59.74%, respectively, 2 h after treatment, in comparison 
with the naïve IgG control (Fig 5.1A). When schistosomula were incubated with anti-SmBChE1 
IgG or a cocktail of all three anti-SmChE IgGs for 2 h, BChE activity was inhibited by 37.4% (P ≤ 
0.01) and 49.3% (P ≤ 0.001), respectively, compared to the control (Fig 1B). Schistosomula 
viability was not significantly affected at this timepoint (Fig 1C). Extending the treatment with 
anti-SmAChE1 IgG, anti-SmAChE3 IgG, or a cocktail of all three anti-SmChE IgGs for 14 h 
significantly decreased (P ≤ 0.001) AChE activity by 66.9%, 70.5% and 72.6%, respectively, 
compared to the control (Fig 5.1D). Similarly, when schistosomula were incubated with anti-
SmBChE1 IgG or a cocktail of all three anti-SmChE IgGs for 14 h, BChE activity decreased 
significantly (P ≤ 0.01) by 26.5% and 35.6%, respectively, compared to the control (Fig 5.1E). 
Schistosomula viability was significantly decreased (P ≤ 0.01) by all treatments at this 
timepoint, with the biggest decrease seen in the anti-SmChE cocktail IgG-treated group (Fig 
5.1F).  
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Fig 5.1. Anti-SmChE antibodies inhibit ChE activity in schistosomula which leads to decreased 
parasite viability. Newly transformed schistosomula (1000/treatment) were incubated in DMEM in 
the presence of anti-SmChE IgG and incubated at 37 °C in 5% CO2. Naïve IgG served as a negative 
control. (A) AChE activity 2 h after treatment, (B) BChE activity 2 h after treatment, (C) 
schistosomula viability 2 h after treatment, (D) AChE activity 14 h after treatment. Data represents 
the mean ± SEM of two biological and three technical replicates. Significance (relative to the naïve 
IgG control) determined by the student’s t test ** P ≤ 0.01, *** P ≤ 0.001.  
 
5.3.2. Effects of anti-SmChE antibodies on adult worms 
The effects of anti-SmChE antibodies on S. mansoni adult worms was also tested in vitro. Freshly 
perfused worms cultured in the presence of anti-SmAChE1, anti-SmAChE3, or a cocktail of all 
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three anti-SmChEs, showed no significant inhibition of AChE or BChE (data not shown) activity at 
2 h post-treatment, compared to controls. After 24 h treatment, however, all anti-SmChE IgG-
treated groups showed significant inhibition of AChE and BChE activity with the anti-SmChE 
cocktail IgG-treated group displaying the greatest inhibition of AChE activity (Fig 5.2A and 5.2B). 
The rate of glucose uptake over 24 h was also measured at this timepiont and all antibody 
treatments significantly reduced glucose uptake in adult worms, compared with naïve IgG-
treated controls, again with the anti-SmChE cocktail IgG-treated group displaying the greatest 
inhibition (Fig 5.2C). To determine if anti-SmChE antibodies can play a role in killing adult worms, 
the antibody experiment was repeated with 5 pairs of adult worms per treatment and worm 
viability post-treatment was assessed. Consistent with inhibition of AChE activity and glucose 
uptake, the cocktail of anti-SmChE antibodies were the most effective in killing (all worms dead 
at day 7 post-treatment), compared to controls (Fig 5.2D).  
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Fig 5.2.  Effects of anti-SmChE antibodies on adult S. mansoni worms.  
Five pairs of freshly perfused worms were incubated in the presence of anti-SmChE purified IgG in 
DMEM at 37 °C in 5% CO2. Naïve IgG served as a negative control. (A) AChE activity 24 h after 
treatment, (B) BChE activity 24 h after treatment, (C) glucose uptake over 24 h, one day after 
treatment (D) survivability up to 10 days after treatment. The results are the mean ± SEM of two 
biological and three technical replicates (A-C) or two biological replicates (D). Significance (relative 
to the naïve IgG control) determined by the student’s t test *P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.  
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5.3.3. Antibody responses to SmChEs during the course of infection and following PZQ 
treatment in mice 
Antibody responses to all SmChEs were significantly higher in infected mice than before infection, 
even at just 3 days post-challenge (P ≤ 0.05), and increased as infection progressed (Fig 5.3A). In 
a separate experiment, all anti-SmChE IgG responses were shown to significantly increase (P ≤ 
0.001) after PZQ treatment (Fig 5.3B). 
Fig 5.3. Antibody responses to SmChEs during the course of infection and following PZQ 
treatment in mice. Anti-SmChE IgG responses in mice (A) from 3 days to 8 weeks post-infection 
(n=5) and (B) before (5 weeks post-infection) and 2 weeks after PZQ treatment. Data represents 
the mean of 2 technical replicates and significance determined by the student’s t test *P ≤ 0.05. 
 
5.3.4. Vaccine efficacy of recombinant SmChEs in a mouse model of schistosomiasis 
In both vaccine trials, all four groups of mice immunized with SmChEs, either in isolation or as 
a combination, showed a significant decrease in worm burden (28% - 38%), compared to 
controls, with the SmChE cocktail-vaccinated group displaying the highest reduction in trial 1 
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and 2 of 38% (P ≤ 0.001) (Fig 5.4A and 5.4B). Compared to controls, significant decreases in 
liver egg burdens (expressed as eggs per gram – EPG) were observed for all groups across both 
trials (13% - 46%), except for the SmAChE1-vaccinated group in trial 1. When averaged over 
both trials, liver egg burdens in the cocktail-vaccinated group showed the greatest reduction 
(Fig 5.4C and D). Intestinal egg burdens (expressed as EPG - only determined for trial 2) were 
significantly reduced for all vaccinated groups, compared to controls, with the greatest reduction 
seen in the group vaccinated with the SmChE cocktail (33%, P ≤ 0.001). (Fig 5.4E). Egg viability 
(only assessed for trial 2), as determined by egg hatching from liver homogenates, was 
significantly reduced in the groups vaccinated with the SmChE cocktail (40%, P ≤ 0.01) and 
SmAChE3 (46%, P ≤ 0.01) (Fig 5.4F). While there was no significant reduction in glucose uptake 
for worms from any of the vaccinated groups, compared to controls (data not shown), the 
glycogen content of worms from all vaccinated groups in trial 1 was significantly lower (24% - 
52%, P ≤ 0.001) than worms from the control group (Fig 5.5A). A significant reduction in worm 
length (30%-50%) was also observed between worms from all vaccinated groups compared to 
worms from the control group (Fig 5.5B). As with the parasitology burden data, worms from the 
cocktail-vaccinated group showed the greatest decrease in glycogen content and body length. 
Glucose uptake, glycogen content and worm size was not significantly different between control 
and vaccinated worms in trial 2 (data not shown).   
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Fig 5.4. Vaccine efficacy of recombinant SmChEs in a mouse model of schistosomiasis.  
Graphs show parasitology burdens from vaccinated and control mice (A) trial 1 adult worms, (B) 
trial 2 adult worms, (C) trial 1 liver EPG, (D) trial 2 liver EPG, (E) trial 2 intestinal EPG. (F) Hatching 
viability of eggs obtained from the pooled livers of control and vaccinated mice from trial 2. Data 
are the average of ten replicate counts ± SEM of hatched miracidia. Significance and percent 
reductions (if any) for all parameters are measured relative to the control group. Significance 
determined by the student’s t test *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001. 
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Fig 5.5. Effect of pSmChEs vaccination on glycogen storage in, and size of, S. mansoni adults.  
(A) Triton-X-100 extracts were made from 5 pairs of worms freshly perfused from each vaccinated 
or control group and the glycogen content in these extracts was measured. Plotted data are the 
average of triplicate biological and technical experiments ± SEM. (B) Worm sizes (mm) were 
assessed by randomly selecting and measuring (ImageJ) at least 20 worms from each group. 
Significance and percent reductions (if any) for both parameters are measured relative to the 
control group. Differences for both experiments were measured by the student’s t test *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001. 
 
5.4. Discussion 
Surface-exposed proteins, such as tegumental proteins, are effective targets for vaccine 
development in schistosomes (Mulvenna et al. 2010; Sotillo et al. 2015). In this regard, SmChEs 
are promising candidates as immunolocalization studies in S. mansoni has shown SmAChE1, 
SmBChE1 and SmAChE3 to be expressed in the tegument of adult worms and schistosomula 
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(chapter 3), and proteomic analysis of ES products has confirmed the presence of SmAChE1, 
SmBChE1 (chapter 3),  suggesting that these molecules are accessible to immune attack.  Further, 
RNAi-mediated silencing of all 3 SmChE genes, both individually and in combination, significantly 
decrease schistosomula viability in vitro and parasite survival in vivo (Chapter 4), implying that 
these genes are essential for proper worm development and function.  Moreover, recent protein 
array studies have demonstrated high levels of circulating antibodies to SmBChE1 in individuals 
exhibiting drug-induced resistance and low pathology to schistosomiasis, implicating these 
antibodies in a protective anti-schistosomal  response (Pearson et al. 2015; Driguez et al. 2016).  
 
Given SmChEs are accessible to antibody attack, and are enzymatically functional (chapter 3), 
catalytic activity can be used to measure the effectiveness of antibody binding as the interaction 
between enzymes and their corresponding antibodies generally leads to a complete or partial 
reduction in their enzymatic activity (Cinader et al. 1971; Arnon 1973; Arnon 1975). The data 
presented here show that antibodies against recombinant SmChEs are capable of inhibiting 
surface (and, in the case of SmAChE1 and SmBChE1, secreted)  enzymatic activities in both 
schistosomula and adult worms, which is similar to previous studies that have used antibodies 
raised against parasite-derived AChE to inhibit AChE activity on intact S. mansoni (Espinoza et al. 
1995), Necator americanus (Pritchard et al. 1991), Dictyocaulus viviparus (McKeand et al. 1994) 
and Electrophorus electricus (Williams 1969). The inhibitory effect of antibodies is likely to be due 
to steric hindrance, potentially blocking substrate access to the peripheral anionic sites or 
catalytic gorge of AChE. Indeed, previous studies on rabbit (Brimijoin et al. 1985), human 
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(Sorensen et al. 1987) and bovine (Wolfe 1989) AChE have documented the AChE-inhibitory 
ability of antibodies raised against epitopes other than AChE-active sites.  
 
Consistent with the effects of RNAi-mediated SmChE gene silencing, antibody-mediated SmChE 
inhibition resulted in a significant decrease in parasite viability. I posit that this mode of enzyme 
inhibition was the cause of eventual parasite death as schistosomula were still viable, compared 
to controls, at 2 hours after antibody treatment, despite a significant decrease in ChE activity; it 
was not until after a much longer exposure (14 h) to anti-SmChE antibodies that parasite viability 
was significantly lower. It should be noted that, while more effective in vitro killing experiments 
have been performed (Arnon et al. 1987), these studies were conducted with the addition of 
guinea pig complement to facilitate complement-dependent killing and so may not truly 
represent the amount of parasite death due to enzyme inactivation appeared to have a similar 
effect on adult worms in that a significant reduction in ChE activity was evident in treated 
parasites before death started to occur. Glucose uptake in adult worms (not tested in 
schistosomula) was also significantly reduced by anti-SmChE antibody treatment. The cholinergic 
action of surface AChE has been implicated in mediation of the glucose scavenging mechanism 
in schistosomes (Camacho et al. 1995) and I have shown that AChE-inhibitory, anti-schistosomal  
drugs reduce glucose import in parasites (Sundaraneedi et al. 2017) so it is likely that antibody-
mediated impairment of glucose uptake contributed to a decrease in parasite viability. As seen 
in our RNAi studies, simultaneous inhibition of multiple SmChEs by the treatment with a cocktail 
of SmChE antibodies resulted in the greatest reduction in parasite viability, both adult and 
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juvenile. It may be that there is some redundancy in the cholinergic functioning of these 
molecules (even BChEs, like SmBChE1, can perform a cholinergic role in situations of AChE 
deficiency (Boudinot et al. 2005) and so collective inhibition of the molecules is required to 
produce a functional deficit. Also, given the multiple proposed functions for parasite ChEs (Day 
et al. 1996; Arnon et al. 1999), it is possible is that the neutralization of multiple enzymatic targets 
more profoundly interrupts varied processes of parasite biology than just cholinergic 
transmission.  
 
Given the relative cytotoxic potential of antibodies against all three SmChEs as opposed to 
anyone SmChE, I decided to test the efficacy of this antigen cocktail as a vaccine in a mouse model 
of schistosomiasis. The vaccine efficacy of each individual SmChE was also tested to investigate 
the relative anti-parasitic effects of anyone SmChE over the cocktail or one another.  
 
Mice vaccinated with the cocktail of SmChE antigens displayed the highest level of protection 
against experimental schistosomiasis, showing the greatest reductions in every parameter 
tested. An additive protective effect was not readily apparent, however, as protection levels were 
not significantly different from groups vaccinated with single antigens. Of the groups vaccinated 
with individual SmAChEs, the SmAChE3 vaccinated group engendered the highest levels of 
protection. Similar results were reported in a test of the vaccine efficacy of a recombinant AChE 
from S. japonicum (You et al. 2018). Further, vaccine trials using purified secretory AChE from the 
nematodes Trichostrongylus colubriformis and Dictyocaulus viviparous have resulted in 
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significant protection in animal models (Griffiths et al. 1994; McKeand et al. 1995). 
 
Egg burdens did not concomitantly decrease with worm burdens, but there were significant 
reductions in egg viability in all but the SmAChE1-vaccinated group, an observation I have 
previously reported when testing the in vivo anti-schistosomal  efficacy of AChE-inhibitory drugs 
(Sundaraneedi et al. 2017). Studies in rats and honey bees have observed abdominal spasms and 
involuntary muscle contractions when AChE inhibitors have been administered to these 
organisms (Jarvie et al. 2008; Williamson et al. 2013) so a possible explanation for this less than 
expected decrease in egg number but significant reduction in viability could be that ova are being 
prematurely released as a result of AChE inhibition affecting reproductive tract motility. It could 
also be that the significant stunting of worms recovered from vaccinated groups affected 
fecundity and egg maturity. Indeed, previous studies on insects demonstrated that suppression 
of AChE considerably reduced the weight and length of surviving organisms (Kumar et al. 2009; 
Hui et al. 2011; Ye et al. 2017) and severely affected the hatching ability of the eggs laid (Kumar 
et al. 2009; Xiao et al. 2015). These researches have suggested that dysregulated cell 
proliferation and apoptosis during larval growth may be reasons for such phenotypic effects 
attributed to the absence of AChE, although such a link in trematodes remains to be established. 
Finally, parasites recovered from vaccinated mice had significantly depleted glycogen stores. 
Reduced glycogen content and glucose uptake in worms treated with AChE-inhibitory drugs have 
been previously observed in vitro (Sundaraneedi et al. 2017) and be attributed to interference 
with the tegumental AChE-mediated glucose scavenging pathway (Camacho et al. 1995) through 
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the inhibition of this enzyme. It could be that the same effect is being orchestrated by antibody-
mediated inhibition of AChE (which would be consistent with the results of in vitro antibody-
based experiments and RNAi studies - chapter 4, forcing the parasite to rely on its glycogen 
stores, rather than the scavenging of exogenous glucose, for nutrition. 
 
Even though immunization with SmChEs induced high titers, these antibody levels were not 
sustained during the course of infection, with titers at necropsy dropping between four- and ten-
fold from pre-challenge levels. This would seem to indicate that the specific antibody response 
induced by immunization was not augmented by natural infection, a hypothesis corroborated by 
the generation of modest anti-SmChE titers during the course of parasite infection in a separate 
experiment. That being said, the SmChEs used in this study were still capable of inducing 
moderate levels of protection in the face of modest antibody titers. Treatment with PZQ has been 
shown to induce antibody-mediated resistance to schistosomiasis in humans through the 
exposure of parasite antigens to the immune system (and subsequent generation of an antibody 
response) as a result of tegument damage (Harder et al. 1987)  and protein array studies by us 
have shown that antibodies to SmBChE1 are significantly upregulated in resistant individuals 
(Pearson et al. 2015). The upregulation of SmChE immune responses following PZQ treatment 
has been verified in this study. Given that an effective anti-schistosomal  vaccine strategy would 
ideally be linked with chemotherapy (Pearson et al. 2015), it is possible that the vaccine efficacy 
of antigens such as the ones described here could be increased by vaccination after PZQ 
treatment due to the augmentation of an already upregulated immune response.
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Schistosomiasis affects over 200 million people in the developing tropics. There is no approved 
vaccine for the infection and current treatment and disease control relies on chemotherapy with 
a single drug, praziquantel (PZQ) (Trainor-Moss et al. 2016), which is a concern due to the 
inevitable development of drug resistance (Cioli 2000). There is a strong imperative, therefore, 
to identify novel vaccine and drug targets which can form the basis of anti-schistosomal  
intervention strategies. In this respect, we need to increase our understanding of the biology of 
this parasite to identify essential facets of schistosome physiology that could be disrupted 
through immuno- or chemotherapy. 
 
The vital biological processes of schistosomes are solely regulated and controlled by the 
parasite’s nervous system (Halton et al. 1996), emphasizing the importance of targeting its 
neuromusculature and associated proteins for therapeutic development. In the present work, I 
show that acetylcholinesterases (AChE)s - a class of neuronal and tegumental enzymes 
responsible for the regulation of neurotransmission through hydrolysis of the neurotransmitter 
acetylcholine (ACh) – can be inhibited by inorganic metal complexes, causing death of the 
parasite. I then provide a comprehensive molecular characterization of three cholinesterase 
enzymes from Schistosoma mansoni (SmChEs) and give evidence that they are vital for the 
normal functioning of the parasite through the use of RNAi- and vaccine-based approaches that 
target these molecules.  
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The work presented in chapter two of this thesis documents the use of polypyridylruthenium (II) 
(Ru) complexes in the successful treatment of schistosomiasis through the inhibition of parasite 
AChE. Various classes of synthetic Ru complexes, including the panel screened in this study, have 
been shown to possess antimicrobial properties (Gorle et al. 2016), but this current work is the 
first documentation of the anthelmintic activity of these compounds. The AChE activity in 
schistosome extracts was inhibited significantly (low micromolar concentration) by a range of 
panel members. Further studies on live S. mansoni parasites also revealed that the complexes 
displayed efficacy against eggs and juvenile worms in vitro. They were also active against adult 
worms, which became immobile and coiled upon treatment, possibly due to the paralyzing 
effects of AChE inhibition (Bueding et al. 1972; Hillman et al. 1975; Pax et al. 1981). Treated 
parasites showed significant decreases in surface and somatic AChE activity, implying the 
complexes exerted their effects, at least partially, through the inhibition of the activity of these 
enzymes. Worms treated with Ru complexes had a significantly reduced ability to uptake 
glucose, an observation likely explained by the inhibition of tegumental AChE, which is a 
mediator of exogenous glucose scavenging by the parasite (Camacho et al. 1995). Two of the 
compounds were tested for their efficacy in a mouse model of schistosomiasis and were shown 
to have a significant impact on egg viability and development. This effect may be due to 
compounds stimulating reproductive tract motility (De Giorgio et al. 2004; McNamara et al. 
2008), resulting in the premature release of under-developed eggs, a hypothesis supported by 
AChE inhibitor studies in ticks (Perez-Gonzalez et al. 2014; Prado-Ochoa et al. 2014).  
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In addition to highlighting the potential of Ru compounds as effective drug leads for the 
treatment of schistosomiasis, the experiments in chapter two stimulated research efforts into 
determining the specific molecules responsible for ChE functioning in S. mansoni (chapter three). 
In contrast to previous studies, interrogation of the now comprehensively annotated S. mansoni 
genome, revealed the presence of three ChE-encoding genes: two acetylcholinesterases (AChE)s 
- SmAChE1 (Smp_154600) and SmAChE3 (Smp_136690) – and one butyrylcholinesterase (BChE) 
– SmBChE1 (Smp_125350). Functional expression of the three paralogs verified their ChE class 
based on hydrolysis of AcSCh or BcSCh. Antibodies to recombinant molecules localized the 
proteins to the tegument and neuromusculature of adults and schistosomula and developmental 
expression profiling differed among the molecules, suggestive of functions extending beyond 
traditional cholinergic signaling for each of them. SmAChE1 and SmBChE1 were also found in 
parasite ES products. Evidence was provided for the role of SmBChE1 as a bio-scavenger of 
carboxylic esters, using the anti-schistosomal  AChE inhibitor, DDVP, as an example. It was 
postulated that SmBChE1 might protect parasite AChE against the effects of naturally occurring 
AChE inhibitors by performing this function, given the role of human BChE in the detoxification 
of similar molecules (Lockridge 2015). 
 
RNA interference was used to further investigate the functions of SmChEs (chapter four). 
Silencing of SmChEs, either individually or in a combination of all three paralogs, reduced 
transcript and protein expression levels significantly. For SmAChE1 and SmAChE3, knockdown 
resulted in decreased AChE activity in parasite extracts and suppressed uptake of glucose by live 
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schistosomula, reflective of the neuronal and non-neuronal cholinergic functions suggested from 
immunolocalization results. Silencing of SmBChE1 did not suppress BChE activity or impair 
glucose uptake, implying a different function for this molecule. All SmChEs were regarded as 
essential for parasite development and function, however as SmChE-silenced schistosomula 
failed to survive both in vitro and in vivo. Further, simultaneous silencing of all three paralogs had 
a more profound impact on parasite survivability than each individual treatment, implying some 
degree of functional redundancy between the molecules but also highlighting the effectiveness 
in targeting numerous molecular functions in the development of a parasite intervention strategy 
 
The tegumental localization (chapter three) and essentiality (chapter four) of SmChEs attested to 
the feasibility of targeting these molecules with antibodies to develop an effective vaccine 
against schistosomiasis, the objective of the experiments in chapter five of this thesis. Indeed, 
both adult worms and schistosomula treated in vitro with anti-SmChE IgG (either individually or 
in combination) showed significant decreases in ChE activity and glucose uptake ability, reflective 
of RNAi results. Further, when administered as vaccines, either individually or in combination, in 
a mouse model of schistosomiasis, recombinant SmChEs protected against parasite challenge as 
adult worm burdens were significantly reduced and surviving worms were stunted and 
nutritionally depleted. Egg loads were not as decreased as worm numbers but egg viability was 
affected by SmChE vaccination, reflective of results observed in the drug in vivo efficacy trials 
(chapter two). 
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In conclusion, the data generated in this thesis has resulted in a detailed characterization of a 
family of ChE molecules from S. mansoni and has highlighted the anti-schistosomal efficacy of a 
novel class of AChE-inhibitory Ru complexes. Further, it offers new approaches for targeting 
aspects of schistosome neurobiology as a method of controlling the debilitating disease caused 
by these parasites.   
 
Future directions 
In chapter two of this thesis, I have described the anti-schistosomal activity of a family of Ru 
complexes and, while some members showed promising efficacy in vivo, the maximum tolerated 
dose was relatively low. The modular nature of Ru complexes makes it possible to synthesize 
these compounds to target specific enzymes and even regions within molecules, so future work 
will involve tailoring Ru complexes to increase their selectivity and potency. Further, given their 
potency against PZQ-refractory schistosomula, these complexes could be administered in 
combination with PZQ, overcoming the limitations of current monotherapy and augmenting 
existing schistosomiasis control initiatives. 
 
In a first for schistosomiasis research, I have documented the presence of catalytically active 
SmChEs (SmAChE1 and SmBChE1) in parasite ES products (chapter three). Secretory AChEs have 
extensively characterized in N. brasiliensis (Selkirk et al. 2005; Selkirk et al. 2005) and recent 
studies have suggested an immunomodulatory function for these molecules through the 
hydrolysis of host ACh (Vaux et al. 2016). It is tempting to speculate that secreted (and even 
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tegumental) SmAChE1 may perform a similar function in schistosomes, given its accessibility to 
the host environment. Co-culture experiments with RNAi-silenced schistosomula and immune 
effector cells could be designed to explore this hypothesis. 
 
The isolation of a BChE (SmBChE1) from schistosomes (chapter three) is a novel finding, and one 
with potential translational application, given its perceived role in the detoxification of AChE-
inhibitory compounds. Human BChE is currently being developed as a treatment for cocaine 
addicts due to its ability to rapidly inactivate the drug and there is considerable research effort 
focused on producing structural mutants of BChE, from humans and other organisms, to increase 
the catalytic turnover (and, therefore, detoxification potential)  of the enzyme (Lockridge 2015). 
SmBChE1 could be studied for this, and similar, purposes and be added to the growing arsenal of 
helminth molecules being exploited for therapeutic use. 
 
The SmChEs characterized in this study have been shown to provide modest protection against 
schistosomiasis when administered as vaccines (chapter five). I have documented the ability of 
anti-SmChEs to impact parasite viability in vitro, thus providing evidence for the role of humoral 
immunity in protection, so it may be possible that the generation of only modest antibody titers 
in vaccinated animals may be the reason for the protection levels observed, although the role. 
Future studies to maximize the vaccine potential of these molecules will include the use of full-
length proteins as vaccine antigens (to potentially increase immunogenicity. The role of T-cell 
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mediated immunity in protection cannot be ignored so additional experiments will involve the 
use of different adjuvant formulations to stimulate a range of immune responses.    
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Appendices 
Supplementary Table 3.1.  
Oligonucleotides used in this project 
Gene Direction Sequence 
fSmAChE1  Fwd GAATTCGCGGCCGCGAATTC 
Rev TCTAGAGGTCTAGAGCTCGAG 
fSmBChE1  Fwd GAATTCGCGGCCGCGAATTC 
Rev TCTAGAGGTCTAGAGCTCGAG 
fSmAChE3  Fwd GAATTCGCGGCCGCGAATTC 
Rev TCTAGAGGTCTAGAGCTCGAG 
pSmAChE1  Fwd GACAGAAACCACATGATGTTGGAA 
Rev TTCCAACATCATGTGGTTTCTGTC 
pSmBChE1  Fwd TCCAGGAAGCACATGGTCTTCACT 
Rev AGTGAAGACCATGTGCTTCCTGGA 
pSmAChE3  Fwd CGCCATATGCTCTCCAAAGCGTGGTTACT 
Rev CGCCTCGAGCGGATCCCAACTTAGTCTCATC 
  
SmAChE1 qPCR Fwd ATGGATATGAGATTGAGTATG 
Rev CTGGAAGGATGTTAGGAT 
Appendices 
 
205 
 
SmBChE1 qPCR Fwd CTACTCGTAATGATGACT 
Rev GGCTGAATTATACAAGATT 
SmAChE3 qPCR Fwd ATGCGACCACACTATCACCA 
Rev CCTGATGTAAATCCACCACCA 
SGTP1 qPCR Fwd CTGCAGCTTATTCACTGAGTCAATC 
Rev CCACCGATGTTTTTCTGTATAACAGGAT 
SGTP4 qPCR Fwd AGCCAAGGAGTTAACTTATTATGCAATTTATTG 
Rev TCCAACAGATAATAACGATAACTAAAAATGGTAAGAA 
SmCOX1 qPCR Fwd TAGGGTTGGTGGTGTCACAG 
Rev ACGGCCATCACCATACTAGC 
 
 
 
Gene Target sequence for siRNA duplex 
SmAChE1 CAGGAGCTTTAATGTTTGGCA 
SmBChE1 GTATCATCTTGTACAAAGTTTAAGA 
SmAChE3 CATCAAAACCAATTGGTAAATTACGT 
Luciferase ACTGAGACTACATCAGCTATTCTGAT 
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Supplementary Table 3.2 
 
Identification of secreted form of SmChE by MALDI-TOF/TOF mass spectrometry purified by Edrophonium chloride 
 
 
 
 
 
 
 
 
 
a Protein identification is from Uniport database 
b number of significant distinct sequences  
c Exponentially Modified Protein Abundance Index 
Accession 
numbera 
Protein 
name 
Molecular function  Score Seq(Sig)b emPAIc Peptide sequences 
Smp_154600.1 Carboxylic 
ester 
hydrolase 
carboxylic ester 
hydrolase activity 
15457 19 4.64 SFKCPTINMATAVTNDYR 
CPTINMATAVTNDYR 
RAHTLPVYFYEFQHR 
AHTLPVYFYEFQHR 
TVSLPMPK 
QLSDIMMTYWANFAR 
TGDPNILPDGR 
HVTDNLNPDDPDEITEDQLK 
NPFIGWPEFR 
NPFIGWPEFRNSTK 
SAPANLLVSTRPR 
RWYPALLQQVER 
 
Smp_125350.1 protein 
(S09 family) 
acetylcholinesterase 
activity 
89 2 0.13 ALGTGSWTSLEVVK 
YETYSPHSVATR 
Smp_034840.1 14-3-3 
epsilon 
protein domain specific 
binding 
53 2 0.38 VFSAVEQTEGNR 
DILELIDK 
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Supplementary Table 4.1.  
siRNAs used for gene silencing 
Gene Target sequence for siRNA duplex 
SmAChE1 CAGGAGCTTTAATGTTTGGCA 
SmBChE1 GTATCATCTTGTACAAAGTTTAAGA 
SmAChE3 CATCAAAACCAATTGGTAAATTACGT 
Luciferase ACTGAGACTACATCAGCTATTCTGAT 
